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ABSTRACT  
 
RENE STERLING: “Not Ready for Prime Time”: The Commercialization of         
Nutrigenomic Services 
 
(Under the direction of Felicia E. Mebane) 
 
Nutrigenomic researchers hope to improve health through study of relationships among diet, 
genes, and disease, but many consider the sale of nutrigenomic services to be premature. Gaps in the 
oversight of genetic services increase the potential for harm to consumers who may use services 
without a full understanding of their benefits, risks, and limitations. Using nutrigenomic services as a 
case study, the goal of this dissertation was to inform policy development to improve oversight of 
genetic services. Research aims included: 1) identify and describe websites that sell or promote the 
use of nutrigenomic services, 2) identify what genetic professionals think consumers should know 
about nutrigenomic services, and 3) assess the adequacy of US FDA guidelines for the classification, 
pre-market review, and labeling of nutrigenomic services.  
In October 2006, diverse organizations (N=64) hosting nutrigenomic websites were identified 
in a comprehensive search. Few websites presented information about important caveats associated 
with genetic testing. The vast majority of genetic professionals completing an on-line opinion survey 
(N=300), found the following attributes of nutrigenomic services very important to share with 
consumers: if consumer information or specimens would be shared with third parties; use and utility 
of recommended supplements; non-genetic factors impacting test accuracy; and laboratory 
compliance with government standards. Few attributes were considered unimportant to share raising 
 iv 
concerns about information overload. Using definitions established in FDA guidelines, three 
companies presented information on their websites classifying nutrigenomic tests as moderate risk 
medical devices in need of FDA review. Websites rarely presented warnings or precautions 
associated with test use, as recommended for the proper labeling of medical devices. 
Nutrigenomic services may be particularly appealing to consumers given their relatively low 
cost, ease of access, and association with more common and less severe conditions. Organizations 
promoting nutrigenomic services on-line can use various Web-based tools and recommendations from 
researchers, professional societies, and policy makers to improve website content. Such efforts in the 
absence of regulation can help industry regain or maintain public trust. In the absence of good faith 
efforts, policy makers will continue to struggle to keep pace with innovation and minimize threats to 
consumer health and safety. 
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PREFACE 
 
(Written by Felicia E. Mebane, Dissertation Committee Chair) 
 
In order to best prepare Ms. Sterling for a career of publishing in academic journals, her 
dissertation committee set a high standard for the approval of her dissertation. In addition to the 
“three-paper option” format allowed by the university (and described below), we asked her to choose 
specific journals and write her each of her papers according to the publication requirements for the 
target journal. This additional constraint encouraged Ms. Sterling to balance the literature reviews and 
in-depth explanations required to establish that she meets the qualifications of a doctoral degree with 
the parsimony demanded of actual journals. This dissertation is evidence that Ms. Sterling has the 
judgment, analytical and communications skills required to earn this degree and succeed in her 
research career. This dissertation is divided into six chapters and eight appendices: 
 
• Chapter 1 provides a brief introduction to the evolving genetic research and policy environment 
under which this dissertation was written.  
• Chapter 2 provides background on the federal agencies involved in the oversight of genetic 
services and the science behind nutrigenomic services. Basic premises guiding this research and 
this dissertation’s three research aims also are presented.  
• Chapters 3, 4, and 5 are manuscripts for submission to peer-reviewed journals. Each manuscript 
is written as a standalone document, including some redundancies with other chapters.  
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• Key findings and implications across the three manuscripts are reviewed in Chapter 6. This 
chapter also offers a critique of premises guiding this research and reviews the strengths and 
weaknesses of this study. 
• Appendices include additional detail on study methods and descriptive data not presented in the 
three manuscripts and useful for a complete understanding of this study. 
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CHAPTER 1 
 
INFORMING POLICY DEVELOPMENT TO IMPROVE OVERSIGHT OF GENETIC 
SERVICES: THE CASE OF NUTRIGENOMIC SERVICES PROMOTED ON THE WEB 
 
Nutrigenomic services 
 
Nutrigenomic (NG) services include genetic tests for variants in multiple genes associated 
with diet-related disease or other health conditions that have multiple causes, such as heart disease, 
diabetes, and osteoporosis. NG tests also focus on more nebulous health-related traits, such as 
detoxification, aging, or athleticism. Test results often include genotype-customized or personalized 
recommendations for diet or lifestyle changes to reduce risk of disease or improve overall health and 
wellness. Some companies also offer “nutraceuticals” or supplements whose formulations are 
designed to address identified predispositions.  
NG services are largely marketed on the World Wide Web and have been sold directly to 
consumers on and off-line since early 2002. While there is growing evidence to support the influence 
of diet on gene expression and diet-related disease, NG researchers and policy makers have expressed 
substantial concern about the premature availability and use of NG services.  An investigation by the 
US Government Accountability Office (GAO) in 2006 found the NG services offered by four 
companies to be “meaningless and potentially harmful to consumers” (US GAO 2006). Findings from 
  2 
this report increased the salience of all health-related genetic services sold directly to consumers as a 
key policy issue.  
 
Genomic innovation and policy development 
 
Over the last two years, a growing body of gene-disease association research has encouraged 
the commercialization of new genetic services, including whole genome profiles (Feero et al 2008). 
These direct-to-consumer (DTC) “personal genomic services” provide results from the analysis of 
hundreds of thousands of gene variants associated with disease and other health conditions for which 
there may or may not be clinical intervention. Some companies offering personal genomic services 
tout their non-clinical benefits, such as establishing social networks with others of similar genotype, 
learning more about a family’s history of migration across continents, and understanding genetic 
contributors to non-health related traits such as baldness or bitter taste perception. Furthermore, 
companies argue that although the information they provide may not have established clinical utility, 
it is supported by findings in the peer-reviewed literature.  
Proponents of DTC genomic services argue that consumers have a right to access information 
about their personal genome and industry offers a way for consumers to access this information and 
keep it out of their medical record (Wolfberg 2006, DeNoon 2008). Furthermore, consumers are 
savvier than popular opinion might suggest and capable of understanding the nuances involved in 
interpreting genomic information (Jones 2008). Proponents also argue that the commercialization of 
genomics will help advance genomic research and the integration of genomics into medicine. 
Opponents express concerns over how consumers might use the information they receive and argue 
that genetic experts should be involved in any genetic testing process to help consumers interpret 
results (ACMG 2008). Furthermore, opponents argue that the science and mystique surrounding 
genetics lend false legitimacy to test results that have unproven validity and utility. The use and 
promotion of unvalidated tests may lead to poor health care decision-making, economic loss, 
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unwarranted stress or anxiety about future health, and a mistrust of genetic and genomic science 
(Hudson et al 2007, SACGHS 2008, Hunter et al 2008). Balancing an interest advancing genomic 
medicine with the need to ensure consumer safety has been cited as an important goal (Jones 2008). 
In April 2008, the Department of Health and Human Services Secretary’s Advisory 
Committee on Genetics, Health and Society released a report identifying 29 gaps in the oversight of 
genetic services (SACGHS 2008). The lack of evidence to demonstrate the validity and utility of 
DTC genetic services was considered of paramount importance. In the absence of adequate federal 
regulation, the health departments of New York and California called for a moratorium on the sale of 
DTC genetic services to state residents in June 2008 (Pollack 2008). Several professional societies 
have released position statements over the last year offering standards, guidelines, and other 
recommendations regarding the DTC marketing and sale of genetic services. Federal and state 
agencies have released statements as well, advising consumers and health care providers to view DTC 
genetic services with a “healthy dose of skepticism” (US FTC 2006). 
 
Dissertation overview 
 
 It is in this flurry of scientific discovery, technological innovation, stakeholder debate, and 
policy development that this dissertation was undertaken. The overarching goal of this dissertation 
was to inform genetic policy development through the collection of empirical data and the analysis of 
new guidelines regarding the marketing, sale, and labeling of NG services. Mixed methods were used 
to fulfill the three specific aims listed below and described further in Chapter 2.  
1. Describe organizations involved in the promotion and sale of nutrigenomic services on-line. 
2. Identify what genetic professionals think consumers should know when deciding whether or 
not to purchase a nutrigenomic test on-line. 
3. Assess the adequacy of draft recommendations by the US Food and Drug Administration 
(FDA) for the classification and labeling of health-related genetic services.  
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This dissertation is divided into six chapters, including this introduction. Chapter 2 provides 
additional background on the federal agencies involved in the oversight of genetic services and the 
science behind nutrigenomic services. Basic premises guiding this research also are discussed 
including the following: 1) marketing impacts consumer thought and behavior, 2) the lack of federal 
oversight increases the need for consumer education, and 3) genetic services have unique 
characteristics that increase the potential for harm to consumers. The chapter ends with an overview 
of the three research aims.  
Chapters 3, 4, and 5 present manuscripts for submission to peer-reviewed journals reporting 
study findings from each aim. Key findings from this dissertation are reviewed in Chapter 6 and the 
implications of these findings for consumers, health professionals, industry, and federal agencies are 
discussed. Chapter 6 also offers a critique of premises guiding this research and reviews the strengths 
and weaknesses of this dissertation. Appendices include additional detail on study methods and 
descriptive data not presented in the three manuscripts. References appear at the end of each chapter, 
followed by tables and figures in order of mention (including tables for submission as on-line 
supplements to manuscripts, where applicable).  
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CHAPTER 2 
 
BACKGROUND AND SIGNIFICANCE 
 
Growth in the visibility and accessibility of genetic services 
 
New discoveries about relationships among genes, human characteristics, the environment, 
illness, and disease are common given success of the Human Genome Project. Over 1200 health-
related genetic tests are now commercially available, with almost 300 additional tests under 
investigation (GeneTests 2008). Genetic tests and services marketed to consumers as providing 
health-related information (entirely or in part) include: 1) whole genome profiling; 2) genetic (single 
gene) and genomic (multiple gene) tests for disease or illness; 3) genetic tests to inform prescription 
drug use (pharmacogenetic); and 4) genomic tests to inform nutritional (nutrigenomic), cosmetic 
(dermagenomic), or other lifestyle improvements. Examples of services marketed to consumers as 
non-health-related include the more familiar tests for paternity and other familial relationships to the 
more novel ancestry profiling (Bolnick et al 2007), at-home DNA collection and storage to uncover 
infidelity and help find missing children (Associated Press 2006, Kesner 2006), and custom DNA 
artwork (Butler 2007).  
The most extensive advertising of genetic services currently occurs on the World Wide Web 
(here forward the Web). Previous studies have identified 13 to 24 laboratories or biotechnology 
companies (here forward companies) marketing a wide variety of genetic services directly to 
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consumers on the Web (Gollust 2003, Williams-Jones 2003, Berg and Fryer-Edwards 2008, Geransar 
and Einsiedel 2008). Genetic services are becoming easier to access (among those who can afford 
them) through both on-line direct-to-consumer (DTC) sale (i.e., no requirement for clinician 
involvement) and the diversification of US vendors. Sorenson Genomics introduced an over-the-
counter paternity test kit in drug and retail stores in 2007 (Mui 2008), which may be used by some 
consumers to inform reproductive decisions and seek medical treatment or intervention (ACOG 
2008).  
Sciona, Inc., one of the first companies offering on-line DTC sale of nutrigenomic (NG) 
services, began selling its testing kits in mid-West drug stores in 2005 (Sciona 2005). More recently, 
the company established two new agreements for national distribution through fitness centers and 
health spas (Business Wire [1] 2008, Business Wire [2] 2008). In 2007, Interleukin Genetics, Inc. 
expanded its partnership with Alticor, Inc.—a holding company operating Amway (direct-sales), 
Quixtar (Web-based sales), and Access Business Group (manufacturing and logistics services)—for 
the development and distribution of genetic services for heart disease, general nutrition, and 
osteoporosis (Biotech Business Week 2007). Through this partnership, Interleukin’s genetic services 
are being sold on-line alongside supplements, cosmetics, and a variety of non-health-related products 
including electronics, business supplies, apparel, and jewelry.  
 
 “As is often the case, science is running ahead of public policy.”  
—Dr. Francis Collins, Former Director, National Human Genome Research Institute (Associated 
Press 2005)  
 
Rapid growth in genetic services has stimulated substantial debate about the risks and 
benefits associated with the collection, analysis, use and availability of genetic information (Wallace 
1998, Caulfield 2000, Murphy and Maynard 2000, Parens and Asch 2003, Gray and Olopade 2003). 
Current oversight of genetic services, described as a loose web of government regulations and 
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professional guidelines, do not adequately address raised concerns. The Department of Health and 
Human Services Secretary’s Advisory Committee for Genetics, Health, and Society (SACGHS) 
recently issued a report identifying 29 gaps in the oversight of genetic testing (SACGHS 2008). 
Federal agencies with jurisdiction over genetic services and a summary of major gaps in their 
oversight (noted by SACGHS) are listed in Table 2.1.  
The majority of genetic services are sold as laboratory services or “in-house tests”, where by 
the laboratory uses an in-house, often proprietary, protocol to analyze specimens and report results. 
According to the Food, Drug, and Cosmetic Act, in-house tests are medical devices falling under the 
regulatory authority of the US Food and Drug Administration (FDA) (21 USC 321h).  Most medical 
devices require FDA review and approval prior to commercial availability (i.e., pre-market review). 
The scientific and regulatory process of pre-market review is an important tool for ensuring the safety 
and effectiveness of medical devices, including their analytic validity (correct identification of the 
target when it is present and no identification of the target when it is absent), clinical validity (correct 
detection or prediction of disease or health condition), and clinical utility (effective use of test results 
in routine health care). However, fewer than 15 of the over 1000 genetic tests commercially available 
have been reviewed and approved by the FDA. The lack of pre-market review contributes to the 
availability of health-related genetic tests with inadequate evidence to demonstrate their clinical 
validity and clinical utility.  
To date, the FDA has used enforcement discretion in its regulation of in-house genetic tests. 
Pre-market review has not been consistently required as test components have included commercially 
available ingredients (analyte specific reagents or ASRs). Furthermore, tests have been performed by 
specialized laboratories whose competence in the use of ASRs has been demonstrated through 
certification as a high-complexity laboratory by the Clinical Laboratory Improvement Amendments 
(CLIA) (US FDA 2007). In 2006, the FDA first expressed its intent to increase enforcement of the 
pre-market approval process for in-house genetic tests due to the use of new inputs, procedures, and 
technologies that render discretionary enforcement inadequate (US FDA 2007).  The non-binding 
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(i.e., not legally enforceable) recommendations proposed by the FDA in its draft guidance to industry 
include requirements for the classification, review, labeling and surveillance of in-house tests, but 
they have yet to be finalized (Huang and Javitt 2008). 
The Center for Medicaid and Medicare Services (CMS) administers CLIA (with advisement 
from the Centers for Disease Control and Prevention), which requires all laboratories performing tests 
for health-related purposes (i.e., clinical laboratories) to meet quality standards (CMS 2004). Specific 
requirements for proficiency in the analysis of genetic tests are not delineated (e.g., performance 
measures for sensitivity and specificity, requirements for genetic counseling or informed consent). 
New York is the only state to issue genetic-test-specific laboratory requirements and a few other 
states are considering similar regulations (Sternesky 2002). In addition, several professional 
organizations issue best practices and offer non-compulsory certifications for laboratory services, 
such as the American Association of Blood Banks, College of American Pathologists, and American 
College of Medical Genetics.  
Finally, the Federal Trade Commission (FTC) does have authority over the marketing and 
business practices for all commercial products, including genetic services (Daynard 2003). Among 
FTC’s designated areas of focus are health fraud on the Web and claims about product performance. 
The FDA and FTC have worked in collaboration on various efforts to address fraudulent and 
misleading claims in promotional material for other diagnostic tests, dietary supplements, and other 
health products. In addition, the two agencies and the National Institutes of Health announced a joint 
effort to identify companies offering genetic services with false marketing (Javitt and Hudson 2006). 
Both the FDA and the FTC have reported limited active oversight and resources to monitor the 
promotion and sale of genetic services (Deen 2004). Furthermore, in pursuing violations, the Federal 
Trade Commission Act may challenge “‘unfair’ practices [that] are defined as those that ‘cause or 
[are] likely to cause substantial injury to consumers which is not reasonably avoidable by consumers 
themselves and not outweighed by countervailing benefits to consumers or to competition” (emphasis 
in original) (US FTC 2008). Recent restrictions on the DTC marketing and sale of genetic services in 
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New York and California have raised public debate about whether or not the potential for harm 
(actual or perceived) outweighs the potential for restrictions on DTC sale to curtail advancements in 
genomic research and medicine (Editorial Nature Biotechnology 2008, Jones 2008, Pollack 2008, 
O’Rielly 2008). 
 
The science behind personalized nutrition  
 
Among the various health-related genetic tests sold directly to consumers, NG tests and 
related services (here forward NG services) have a relatively long history of DTC sale (beginning 
early 2000).  NG services include tests for variants in multiple genes associated with diet-related 
disease or other health conditions that have multiple causes (i.e., complex traits), such as heart 
disease, diabetes, and osteoporosis. NG tests also focus on more nebulous health-related traits, such 
as detoxification, aging, or athleticism. Test results often include genotype-customized or 
personalized recommendations for dietary and lifestyle changes to reduce disease risk or improve 
overall health and wellness. Some companies also offer recommendations for the use of NG 
supplements or “nutraceuticals.” Companies offering NG services base their claims on findings from 
the legitimate and growing field of NG research. 
Nutrition research has been used to formulate dietary guidelines for the general public and to 
improve health for populations with special needs. While existing guidelines may be useful for 
determining population-level health outcomes in response to diet, they are less useful for predicting 
individual outcomes, in part due to genetic variability. NG research is “the study of how foods affect 
the expression of genetic information in an individual and how an individual's genetic makeup affects 
the metabolism and response to nutrients and other bioactive components in food” (Kaput and 
Dawson 2007).  
As a scientific approach, NG research integrates the fields of nutrition, systems biology (the 
study of interconnected structures and dynamics within an organism in its entirety), epigenetics (the 
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study of inherited modifications to the genome), and several genomic technologies, including 
transcriptomics (the study of gene expression under specific conditions using microarrays and other 
technologies), proteomics (the study of all proteins in an organism and their expression under specific 
conditions using mass spectrometric techniques), and metabolomics or metabonomics (the study of 
metabolites in an organism after specific dietary exposures using chemometric analysis) (Kitano 
2002, Mutch et al 2005, Burton and Stewart 2005). Included among the aims of NG research are to: 
1) identify genes and gene variants that may be significant to understanding genetic responses to diet, 
2) identify genotypes associated with diet-related disease, 3) modify diet for the treatment or 
prevention of disease, and 4) improve dietary guidelines at group and individual levels (Muller and 
Kersten 2003, Ordovas and Mooser 2004, Kauwell 2005, Strover 2006). Two examples of NG gene-
disease associations are presented in Table 2.2. Listed conditions include a monogenic condition or 
single gene contribution condition (i.e., lactose tolerance) and a polygenic condition where multiple 
genes, behavior, and environment impact the risk and manifestation of disease. 
 
 
 “Right now, no one in their right mind would offer genetic testing.”  
—Dr. Muin Khoury, Director, Office of Genomics and Disease Prevention, Centers for Disease 
Control and Prevention (Grierson 2003) 
 
While there has been little scientific review of specific NG tests, researchers report several 
methodological challenges to the field which must be addressed before the goal of personalized 
nutrition can be achieved. These challenges contribute to inconsistent findings across gene-disease 
association studies and complicate the development of NG interventions to improve individual health 
(Hirschhorn et al 2002). 
Defining and measuring diet. The complex and varied composition of food complicates NG 
research. While specific nutrients are often interest to researchers, there are other food components 
not characterized as nutrients which also may be of significance to biological processes (Ordovas and 
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Mooser 2004). Any particular diet will contain a wide range of nutrients and other dietary chemicals, 
each with unique effects at different loci within an organism (Mutch et al 2005). Furthermore, 
organism nutrient levels are not always easily detectable and must be considered “in the context of 
chronic exposure” (Muller and Kersten 2002). Quantifying (or qualifying) dietary exposure is subject 
to considerable measurement error and inconsistency. In review of 26 studies regarding diet, genes 
and cardiovascular disease (CVD), Ordovas and Mooser found measurements of dietary exposure to 
vary widely across studies involving apolipoprotein E (APOE) gene, including one-time oral fat and 
glucose tolerance tests, dietary and behavioral interventions, controlled diets, and food frequency 
recall questionnaires (from up to 40 years into the past).  
Integrating technologies. Unlike the “one drug and one target” paradigm often used in 
pharmacogenomics (the study of how genes affect drug response), NGs requires consideration of 
multiple nutrients and other food components at various levels of concentration, and their differing 
effects on a number of biological processes within an organism (Mutch et al 2005 Chadwick 2004, 
Muller and Kersten 2003). Thereby, NG research requires an “unprecedented amount” of genetic, 
molecular, clinical, phenotypic, and dietary data posing substantial challenges to data analysis 
(Burton and Stewart 2005). The integration of various genome-related technologies is required for 
meaningful results; however, the majority of studies use only one approach and thereby fail to 
account for the full effects of food (Mutch et al 2005). In addition, genomic and related technologies 
currently are very expensive (although anticipated to decrease with wider use, Ordovas and Mooser 
2004), and investments in NGs are unlikely to reach levels achieved in pharmacogenomics (Muller 
and Kersten 2003). The financial cost of NG research has lead to questions regarding its cost-
effectiveness in reducing diet-related disease (Chadwick 2003).  
Designing studies and establishing quality standards. Prospective study designs with large 
samples are essential to the success of NG research but are not generally employed (Ordovas and 
Mooser 2004, Burton and Stewart 2005). Large longitudinal studies allow for greater consideration of 
genetic or phenotypic covariates along with changes in phenotype in response to diet overtime 
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(Ordovas Mooser 2004). The dependent variables used in NG research also have been subject to 
scrutiny. Ordovas and Mooser (2004) found in the previously mentioned review of diet, gene and 
CVD studies that researchers often use risk factors for CVD as opposed to actual disease or related 
events for dependent variables. Actual disease has been suggested as the more appropriate endpoint 
for NG studies. In addition, universal standards for quality in the processing and analysis of biological 
specimens in research laboratories have yet to be established and have a direct impact on study 
replication, comparability of findings, and specimen and data pooling (Burton and Stewart 2005). 
Disseminating findings. Lack of consistency in “keyword” assignment and publication bias 
also have been mentioned as challenges to the field in that pertinent information is hard to locate and 
negative findings (failure to reject the null hypothesis) are not published (Ordovas Mooser 2004). The 
bias toward positive findings is problematic across fields as published studies have a direct impact on 
the nature and direction of research (Hojat et al 2003). Publication bias also poses problems for 
literature reviews and meta-analyses (Misakian and Bero 1998). Researchers have noted publication 
bias as problematic in meta-analyses of gene-disease association studies (Sudlow et al 2006, Lewis et 
al 2005, Masson et al 2003). 
The translation of NG research into personalized nutrition and the commercialization of NG 
services has been referred to as “bad science and a bad idea” (Wallace 2005), producing products 
“that are far from being complete and useful” (Ordovas and Mooser 2004). Dr. Muin Khoury, director 
of the CDC Office of Genomics and Disease Prevention, stated that very little is known about the 
value of most health-related genetic tests and in many cases “family history is a better indicator of 
future disease” (Sample 2006).  Despite the lack of evidence to demonstrate the validity and utility of 
NG services, companies report expanding their services, establishing new agreements for their 
distribution, and tailoring advertising to new consumer markets on-line (Business Wire 2006, PR 
Newswire January 2008, PR Newswire February 2008, Business Wire [2] 2008). 
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Marketing matters 
 
Advertisements and other promotional material for genetic services have appeared in various 
media. Gollust, Hull and Wilfond (2002) describe several examples of print advertisements for 
genetic services (i.e., paternity, cancer) appearing in community newspapers and popular magazines. 
Myriad Genetics, Inc., the company holding patents for BRCA1/BRCA2 gene sequencing for 
inherited breast and ovarian cancer risk, was the first company to launch a traditional DTC marketing 
campaign for a genetic test (Myers et al 2006). During the five month pilot campaign (September 
2002 to February 2003), BRACAnalysis® advertisements appeared in television, radio, and print in 
Atlanta, GA and Denver, CO.  The campaign raised substantial concerns over the inappropriate wide-
scale marketing of the test beyond groups for whom testing is considered appropriate (Myers et al 
2006). Five years later, Myriad launched a second multi-media campaign for BRACAnalysis® in the 
Northeast US to “raise public awareness so [that women] will have a conversation with their health 
care providers” about their potential risk for cancer (Pollack 2007).  
Relative to advertisements appearing in other media, the promotion of genetic services on the 
Web has been substantial. The on-line marketing of genetic services may have a greater impact on 
consumer attitudes than marketing via other media as the Web provides a “rich” product experience 
(Evans and Wurster 1999, Coyle and Thorson 2001). Furthermore, Internet users frequent the Web to 
obtain health and genetics-related information (Taylor et al 2001, Bernhardt et al 2002, Case et al 
2004, Fox 2005, Saukko et al 2007), and have reported using on-line information to make decisions 
about specific treatments, when to visit a doctor, and when to get a second opinion (Fox and Rainie 
2000).  
As a largely unregulated forum, credible and unreliable or even harmful information are 
presented side by side on the Web. The accuracy of information is of growing concern as chat rooms, 
blogs, discussion lists, and electronic bulletin boards are used to communicate health-related 
information (Culver et al 1997, ADA 2006). The Genetics Home Reference (GHR), a consumer-
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friendly website for information about genetics and health (http://www.ghr.nlm.nih.gov), is a recent 
example by the National Library of Medicine (NLM) of an effort to provide credible information and 
alleviate information overload through the Web (Mitchell et al 2006). While this and other 
government efforts to establish reliable sources of information about genetics on-line are growing in 
number (Mitchell et al 2003), findings from a national survey suggest that when seeking health 
information on-line, Internet users visit private websites more than twice as often as government-
sponsored websites (Miller and West 2007).  
This dissertation focuses on the on-line marketing and promotion of NG services given the 
popularity of the Web among marketers of NG services and among Internet users seeking genetic and 
health-related information increases the importance of examining on-line promotional material for 
NG. While there are differences in length and format, the primary goal of advertisements and other 
promotional material is to sell—whether it is a particular product, service, image, or idea. By design, 
advertisements are informative, persuasive, and appealing to targeted audiences (Pollay 1986). 
Advertisements have direct and indirect benefits for consumers, such as saving consumers the cost of 
searching for information, and encouraging competitive pricing and innovation (Abernathy and 
Franke 1998). They also have an effect on consumers beyond, and regardless of, a purchase or “buy 
in.” As noted by Schudson (1984), advertising “surrounds us and enters into us, so that when we 
speak we may speak in or with reference to the language of advertising and when we see we may see 
through the schemata that advertising has made salient for us.” Where there is increased uncertainty, 
bewilderment, and confusion in the public (arguably characteristic of genomics and nutrition), 
advertising can have a stronger role in creating social meaning (Pollay 1986).  
Advertising scholars have debated whether advertisements reflect social values and norms, or 
create them; whether or not advertising unethically coerces viewers into thoughts and behaviors they 
would otherwise evade; and whether or not advertising has deleterious or unintended effects 
(Kirkpatrick 1986, Holbrook 1987, Grove and Kilbourne 1994). Grove and Kilbourne (1994) suggest 
a Mertonian framework as a means by which to understand the role of advertising in society. The 
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framework acknowledges that advertising may have both manifest (i.e., intended) and latent (i.e., 
unintended) effects that can be functional or dysfunctional in nature. Table 2.3 shows the Mertonian 
framework adapted to include both potentially beneficial and harmful outcomes relevant to 
promotional materials for NG and other genetic services. Grove and Kilbourne (1994) argue that 
“primary among the manifest dysfunctions are intentionally deceptive advertisements and 
advertisements knowingly promoting the use of products that are dangerous to consumer’s health or 
safety” (Table 2.3, cell 3).  
While acknowledging the potential of DTC marketing to improve education and awareness 
about genetic services, the SACGHS report discussed the potential for harm to consumers, health care 
providers, and the general public. The potential for harm has been reiterated in position statements by 
several professional societies and in consumer fact sheets issued by government agencies. These 
harms include: 1) economic loss from the purchase of invalid tests or unnecessary care and health 
products (e.g., supplements, skin care), 2) adverse health outcomes due to inappropriate health care 
decision-making by consumers and health practitioners (i.e., ignoring family history when test results 
suggest no genetic predisposition for disease), 3) increased and unwarranted anxiety about the future 
health, and 4) decreased genetic literacy and public trust in genetics and genomics (Oehlke 2005, 
ACMG 2004, ACMG 2008, FTC 2006, NSGC 2007, Hudson et al 2007, NSGC 2007, SACGHS 
2008, ACOG 2008).  
 
Informing consumer decisions 
 
The DTC sale of NG services represents a substantial shift toward individual responsibility in 
health care decision making and suggests a reliance on market forces to ensure that genetic services 
of high quality are available and that useless or fraudulent services are not sold. However, consumer 
decisions about the purchase and use of NG services will only be as good as the information available 
to inform their choices. The overwhelming amount of complex and novel information available about 
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NG and other genetic services may lead to “information overload,” a phenomenon whereby an 
individual receives more information than is useful to effective decision-making. Information 
overload is more likely to occur when information is “uncertain, ambiguous, novel, complex, or 
intense” (Herbig and Karmer 1994) as is the case with the ever evolving nature of genomic medicine 
and nutrition sciences. Marketing literature suggests that measuring information overload requires 
attention to the number of individual products available or being compared, the number of different 
attributes described for a product or a group of products, the importance of different product attributes 
to the decision-maker (information quality), and the complexity of provided information (Schneider 
1987, Keller and Staelin 1987, Lee and Lee 2004).  
Researchers argue that the general public can be quite sophisticated in their thinking about 
genetics (Kerr et al 1998) and can process substantial amounts of information when making choices. 
However, consumer capacity to process information is not unlimited (Malhotra 1984, Elias and Annas 
1994). Despite this limitation, consumers often report wanting more information when making 
decisions (Hibbard et al 1997). Overloaded consumers and experts may experience stress, confusion, 
difficulty establishing priorities, reduced confidence, and poor judgment (Hibbard et al 1997, Eppler 
and Mengis 2004, Hall and Walton 2004, Lee and Lee 2004). Overloaded consumers also are likely to 
ignore information or employ heuristics to simplify their decision making. Selective information 
processing or heuristics (i.e., informal strategy used to simplify decision-making, such as speculation, 
intuition, assumption, etc.) may reduce cognitive strain at the sacrifice of informed choices or optimal 
decisions (Hibbard et al 1997, Lee and Lee 2004). Therefore, two key challenges consumers are 
likely to face when gathering information about NG services include, “the inability to locate what is 
relevant due to sheer volume and overlooking what is most critical among relevant data” (Herbig and 
Kramer 1994).  The sale of NG services in non-clinical environments, on the Web, and alongside 
other over-the-counter and non-health related products may minimize consumer attention to or 
awareness of the unique risks, limitations, and complexities associated with NG services and NG 
research.  
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Consumer preferences for information may differ in type and quantity; however, Ormond et 
al (2007) argue that a minimum amount of genetic testing information should be established and 
provided to all patients or consumers.  Authors considered the use of standards in provided 
information especially important as consumers may not have the same opportunity, personal 
empowerment, or skill set to ask questions of interest. Furthermore, consumers may not always know 
what additional information is relevant to their situation. 
 
Exploration of commercial websites for nutrigenomic services is needed  
 
As discussed previously, DTC marketing of NG services has largely been on the Web and 
many companies also allow consumers to purchase NG services on-line. The DTC sale of genetic 
services represents a shift toward individual responsibility in health care decision making. However, 
consumer decisions about the purchase and use of genetic services will only be as good as the 
information available to inform their choices. In the absence of pre-market review, proficiency 
standards for laboratories, labeling requirements for laboratory services, and ongoing monitoring for 
fraudulent and misleading advertising, genetic services and on-line promotional materials are likely to 
cover the quality spectrum.  
Relative to other diagnostic devices, genetic or genomic tests have several unique 
characteristics that increase the need for improved oversight. These characteristics include: 1) the 
provision of a test result that does not determine the occurrence, severity, or duration of disease, but 
provides “highly nuanced” information about disease risk; 2) the provision of a test result that may 
impact family members with varying levels of interest in the information generated by the test; and 3) 
the potential for genetic information to be viewed deterministically (i.e., “my genes are my destiny”). 
In addition, new findings in gene-disease association research may change the interpretation of test 
results over time. Companies that do not destroy residual specimens post-testing may advance 
research in directions that are objectionable to consumers.  
  19 
In the case of NG services, attention should be paid to both genomic tests and recommended 
supplements or dietary modifications. Similar to genetic services, rapid growth in supplements and 
functional foods (manipulation or modification of one or more components to enhance health benefit) 
has outpaced government regulation and scientific review. Lack of oversight contributes to the 
dissemination of misinformation about nutrition and nutrition-related products, which over time may 
reduce consumer self-efficacy, trust in traditional providers of nutrition information, and attention to 
new findings in nutrition research (Wansink 2006). While NG services are marketed to simplify 
consumer decision-making around nutrition, health and overall wellness, integrating genetic services 
into the already overgrown field of non-genetic diagnostic tests, drugs, supplements, teas, diets, 
exercise regimens, and other lifestyle enhancements creates only an illusion of simplicity for those 
seeking to improve their health.  
The DTC sale of NG services began early 2000, despite their unproven validity and utility. At 
the request of the US Senate Special Committee on Aging, the US Government Accountability Office 
(GAO) investigated the legitimacy of claims made by laboratories with DTC marketing of NG 
services. In June 2006, the GAO reported that the NG services provided by four companies were 
“meaningless and potentially harmful to consumers” (US GAO 2006). More information is needed 
about the marketing and sales practices of laboratories and other organizations that may serve as 
intermediaries between laboratories and consumers, or promote the use of NG services. The 
increasing visibility and accessibility of NG services underscores the importance of identifying 
information critical to informed decision-making by consumers about their use. As federal agencies 
work to ensure consumer health and safety in the diffusion of genetic services, the collection of 
baseline data can support the evaluation of industry responsiveness to new regulations and guidelines.  
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Purpose of this dissertation 
 
The overarching goal of this dissertation was to inform genetic policy development through 
the collection of empirical data and the analysis of new guidelines regarding the marketing, sale, and 
labeling of NG services. The commercialization of NGs is an important case study for exploring how 
to improve the oversight of genetic services for several reasons. First, NG services have been on the 
market for almost a decade despite their unproven validity. Unlike other health-related genetic 
services, companies provide personalized recommendations for health improvement with test results, 
and often bundle NG tests with personalized supplements. The reporting of genotypic information 
and the subsequent use of genotypic data to issue personalized recommendations for health 
improvement raise interesting questions about what constitutes the “test system” in need of review 
and approval by the FDA.  In addition, Internet users are likely to come across websites promoting 
NG services when searching for genetic services in particular or other health information such as diet, 
nutrition, supplements, or fitness. These topics are included among the most popular health topics 
searched for on-line.  
As outlined above, this dissertation is guided by three main premises, including the belief 
that: 1) advertising for NG services can impact consumer thought and behavior regardless of 
purchase, 2) the lack of federal oversight increases the need for informed-decision making by 
consumers about the purchase and use of NG services, and 3) unique aspects of NG and other genetic 
services increases the potential for harm to consumers and thereby warrants further analysis and 
policy development. The specific aims of this dissertation are described below. 
Research Aim #1: Describe organizations involved in the promotion and sale of 
nutrigenomic services on-line.  NG services are largely marketed on the Web. Four studies have been 
published to date that report results from searches for websites selling or marketing genetic services 
directly to consumers (Williams-Jones 2003, Gollust et al 2003, Berg and Fryer-Edwards 2008, 
Geransar and Einsiedel 2008). These studies focused on the on-line DTC sale of health-related 
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genetic tests by biotechnology companies and laboratories (here forward companies), some of which 
include NG services. Relatively less attention has been paid to the marketing and sales practices of 
other types of organizations that serve as intermediaries between consumers and companies or 
promote the use of NG services. In addition, previous studies have not focused on describing the 
types of NGs services promoted on-line (e.g., conditions and traits, genes profiled, recommendations 
provided) and the frequency of their promotion. To address these gaps, this aim answered the 
following questions: Who is involved in the on-line promotion and sale of NG services? What types 
of NG services are promoted? To what extent do websites provide information addressing important 
caveats about at-home genetic testing identified by the FTC?  
Multiple search engines and pilot-tested keywords were used to capture the population of 
websites that sold or promoted NG services in October 2006. Relevant websites were archived 
establishing a cross-section of websites for analysis. Standard methods for the content analysis of 
media messages were followed. To capture variation in the promotion and sale of NG services, the 
unit of analysis was a NG test mentioned on a particular website. To assess health claims in test 
descriptions the following steps were taken: 1) health conditions were searched in the International 
Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007 
(ICD-10); 2) gene names or symbols were searched in the National Center for Biotechnology 
Information (NCBI) Entrez Gene database; and 3) published studies regarding claimed associations 
between health conditions and genes were searched for in the National Institute on Aging and the 
National Institutes of Health Center for Informational Technology Genetic Association Database 
(GAD). Study results will be published in the November 2008 issue of Genetics in Medicine, the 
official peer-reviewed journal of the American College of Medical Genetics focusing on the 
integration of genetics into the practice of medicine. 
Research Aim #2: Identify what genetic professionals think consumers should know when 
deciding whether or not to purchase a nutrigenomic test on-line.  As a health-related genetic service 
with a relatively long history of DTC sale, NG services are an important case study for understanding 
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how to improve promotional and educational materials for genetic services. Government agencies and 
professional societies have identified several issues consumers should be aware of when thinking 
about purchasing genetic services. However, NG services are somewhat unique relative to other 
health-related genetic services in that they claim to provide personalized recommendations for the 
purchase and use of other products to improve health. The unproven validity and utility of NG 
services and their increasing visibility and accessibility underscores the importance of identifying 
information critical to informed decision-making by consumers about their use.  
To identify what consumers need to know about the purchase and use of NG services, an on-
line opinion survey was disseminated March through August 2007. A multi-phase process was used 
to develop this survey, including review of peer-reviewed literature and government reports to 
identify survey items, assessment of draft items by an interdisciplinary group of experts, and 
cognitive think-aloud pilot-testing of the on-line survey. Convenience sampling was used to recruit 
genetic professionals through three professional listservs and the CRISP (Computer Retrieval of 
Information on Scientific Projects) database of biomedical research. Respondents ranked the 
importance of 10 broad topics and rated the importance of 55 attributes pertaining to genetic services 
in general and NG services in particular. Descriptive statistics, content analysis, chi-square tests, and 
Krusal-Wallis one-way analysis of variance tests were used to analyze survey responses. Study results 
were drafted for publication in Genetic Testing, a peer-reviewed journal publishing on all aspects of 
genetic testing, to include the clinical consequences of molecular genetics, and ethical and legal 
issues.  
Research Aim #3: Assess the adequacy of FDA draft guidance on classification and 
labeling of in-house genetic tests for improving the oversight of nutrigenomic services.  The lack of 
evidence to demonstrate the clinical validity and clinical utility of DTC health-related genetic services 
was highlighted as a concern of “paramount” importance to the SACGHS. An important tool for 
improving the safety and effectiveness of genetic services is the FDA process of pre-market review; 
however, the FDA has used enforcement discretion in its review of genetic services. Recently, the 
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FDA issued a draft guidance stating its intent to classify genetic services offered by laboratories as In 
Vitro Diagnostic Multivariate Index Assays (IVDMIA) in need of pre-market review, labeling, and 
post-market surveillance.  
This research aim assessed the adequacy of the FDA draft guidance on IVDMIAs for 
improving the oversight of NG services and ensuring consumers have access to quality information 
about their use. Commercial websites archived shortly following release of the guidance were 
reviewed to determine the extent to which: 1) NG services classified as IVDMIAs in need of pre-
market review, and 2) websites promoting NG services provided information recommended for the 
proper labeling of IVDMIAs. Finally, recommendations for the improvement of future drafts of the 
guidance were proposed. Study results were drafted for publication in Food and Drug Law Journal, a 
peer-reviewed journal covering original research and commentary from multiple disciplines on a wide 
variety of health policy issues. 
These research aims allow for a comprehensive assessment of the promotion and sales 
practices of companies and other organizations involved in NG service delivery. As NG researchers 
work to realize the promise of personalized nutrition, policy makers must ensure that efforts to 
commercialize NG services do not jeopardize consumer health and safety. Findings from these 
research aims can be used to inform policy development in the area of DTC marketing, consumer and 
health provider education, and the pre-market review, labeling, post-market surveillance of NG 
services.  Manuscripts as described above are presented in the next three chapters.  
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Table 2.1.  Summary of US federal agency involvement in the oversight of genetic services, 
April 2008 a 
 
Agency Legislation/Programs Major Gaps b 
Food and Drug 
Administration 
(FDA) 
Administers the Food, Drug, and 
Cosmetic Act 
Regulates medical devices for 
diagnosis, cure, treatment, and 
prevention of disease or health 
condition. Assesses accuracy, 
sensitivity, specificity, and 
complexity of test. Requires pre-
market review and approval for 
medical devices sold as “testing 
kits” (in-vitro diagnostic devices) for 
use by multiple laboratories. 
o Of the over 1000 genetic tests 
commercially available, less than 15 
have received pre-market approval. 
o Most genetic tests are not testing kits 
but “in-house” laboratory services over 
which FDA has jurisdiction, but has 
used “enforcement discretion”. 
o Recent guidance to industry regarding 
pre-market review of laboratory 
services contains non-binding 
recommendations. 
o No clear jurisdiction over laboratory 
communications regarding genetic tests, 
the sale of tests, or the provision of test 
results. 
Centers for 
Medicare and 
Medicaid 
Services 
(CMS) 
Administers the Clinical Laboratory 
Improvement Amendments of 1988 
(CLIA) 
Regulates clinical laboratories, 
including personnel qualifications, 
quality control procedures, and 
proficiency testing programs 
o No genetic testing specific proficiency 
standards or requirements for clinical 
validity or clinical utility, informed 
consent, or genetic counseling. 
o No advertising standards (i.e., what labs 
can say in advertisements, to whom 
advertisements can be directed) 
o No obligatory communications 
regarding genetic tests (i.e., meaning of 
test results, test limitations) 
Centers for 
Disease 
Control and 
Prevention 
(CDC) 
Coordinates the Evaluation of 
Genomic Applications in Practice 
and Prevention (EGAPP) Program  
Evaluates evidence base for 
translating genetic tests and genomic 
technologies into practice. Advises 
CMS on CLIA implementation. 
o Recommendations issued regarding 
genetic test validity and utility are not 
legally binding. 
Federal Trade 
Commission 
(FTC)  
Authorized by the Federal Trade 
Commission Act 
Protects consumers against “unfair 
or deceptive acts or practices in or 
affecting commerce.” Prohibits false 
advertising or misleading material, 
including misrepresentations and 
omissions. Considers whether 
practice: 1) injures consumers, 2) 
violates established policy, or 3) is 
unethical or unscrupulous.  
o Few resources available for monitoring 
of genetic services. 
o Little evidence to demonstrate genetic 
testing or advertising has caused 
“substantial” injury. 
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a  Sources: Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS). US System 
of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human 
Services. April 2008. Available at http://www4.od.nih.gov/oba/sacghs/reports/ SACGHS_oversight 
_report.pdf Accessed: June 2, 2008.  Javitt GH, Hudson K. Federal Neglect: Regulation of Genetic 
Testing. Issues Sci Technol On-Line. Spring 2006. Available at http://www.issues.org/22.3/javitt.html 
Accessed: July 26, 2008      
b Gaps in oversight not a comprehensive list.  
 
  
  33 
Table 2.2.  Examples of health conditions for which diet-gene interactions have been established 
or are under exploration in the peer reviewed literature a  
 
Condition Susceptible Gene(s) Manifestation 
Monogenic  
Lactose Tolerance 
Several variants on LCH 
(lactase-phlorizin 
hydrolase) gene involved 
in lactose metabolism.  
With less common variants: Persistent 
lactose tolerance. High prevalence among 
Caucasians of North European and 
Scandinavian decent.  
Polygenic 
Heart Disease & Blood 
Lipids  
Seven candidate genes 
involved in lipid 
metabolism. Several  
susceptible to dietary 
intervention, e.g., APOA1 
(apolipoprotein A1), LPL 
(lipoprotein lipase) 
With less common APOA1 gene variant: 
Increased intake of poly-unsaturated fatty 
acids (PUFA) leads to higher HDL levels.  
 
With less common LPL gene variant: 
Physical exercise and low calorie diets 
attenuate lipid levels.   
 
a
 Source: Mutch DM, Wahli W, Williamson G. Nutrigenomics and nutrigenetics: the emerging faces of 
nutrition. FASEB J 2005;19(12):1602-16.  
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Table 2.3.  Adaption of Grove and Kilbourne’s (1994) Mertonian framework for analysis of 
promotional materials for genetic services a 
 
 Consequences of phenomenon 
Character of 
phenomenon 
Functional 
Beneficial 
Dysfunctional 
Detrimental 
Manifest 
Intended (by advertiser), 
objective consequences 
 1   Facilitate flow of critical 
information and products to 
consumers. Integration of 
clinically useful services into 
health care settings. 
 3   Generate demand, sale, or use 
beyond what is appropriate or 
recommended by research. Fail to 
provide full information to 
consumers and health care 
providers. 
Latent  
Unintended (by 
advertiser), generally 
unrecognized 
consequences 
 2   Reduce morbidity, mortality 
and health care costs. Increase 
consumer genetic literacy. 
Improve quality of services 
through increased competition. 
 4   Engender preoccupation with 
disease, ability, appearance. 
Increase in anxiety, stress, 
stigmatization, discrimination. 
Reduce public trust in genomics 
and genetic science. 
 
a Source: Grove SJ, Kilbourne WE. A Mertonian framework for the analysis of the debate over advertising’s 
role in society. Journal of Current Issues and Research in Advertising 1994;16(2):19-27. 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
THE ON-LINE PROMOTION AND SALE OF NUTRIGENOMIC SERVICES 
 
ABSTRACT  
 
Purpose: Nutrigenomic researchers hope to improve health through personalized nutrition, 
but many consider the sale of nutrigenomic services to be premature. Few studies have evaluated the 
promotion and sales practices of organizations hosting nutrigenomic websites.  
Methods:  Systematic search and analysis of websites promoting nutrigenomic services in October 
2006.  
Results: Of the 64 organizations hosting websites, 29 organizations offered (24/29) or 
promoted (5/29) at-home testing and 26 organizations sold services on-line (17/26) or provided a 
direct link to on-line sales (9/26). A lack of transparency made it difficult to identify unique tests; 
however, three organizations were linked to 56% of all test mentions. Most organizations were 
healthcare/wellness service providers (50%) or laboratories/biotech companies (27%). Few 
organizations provided on-line information about laboratory certifications (20%), nutrigenomic test or 
research limitations (13%), test validity or utility (11%), or genetic counseling (9%). Affiliation 
opportunities were offered by 15 organizations. 
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Conclusions: Organizations did not provide adequate information about nutrigenomic 
services and at-home genetic testing. Affiliation opportunities and distribution agreements suggest the 
promotion and sale of nutrigenomic services will continue, increasing the importance of consumer 
and provider education. In absence of federal regulation, organizations promoting nutrigenomic 
services should equate websites to product labels and include information to facilitate informed 
decision-making.  
 
KEYWORDS 
nutrigenomic services; at-home genetic testing; direct-to-consumer marketing; Internet; policy  
 
INTRODUCTION 
 
Nutrigenomics (NG) examines relationships among genes, diet, and health. Specifically, NG 
research is “the study of how foods affect the expression of genetic information in an individual and 
how an individual's genetic makeup affects the metabolism and response to nutrients and other 
bioactive components in food” (Kaput and Dawson 2007). Included among the aims of NG research 
are to: 1) identify genes and gene variants that may be significant to understanding genetic responses 
to diet, 2) identify genotypes associated with diet-related disease, 3) modify diet for the treatment or 
prevention of disease, and 4) improve dietary guidelines at group and individual levels (Ordovas and 
Mooser 2004, Muller and Kersten 2003, Kauwell 2005, Stover 2006).  
Although there is growing expectation that NG research will improve individual and group 
health through personalized nutrition (Lampe 2006, Kaput 2007), the field faces several 
methodological challenges. Some of these challenges include: 1) defining and measuring dietary 
intake; 2) shifting outcomes of interest from actual disease to biomarkers indicating early stages of 
disease; 3) simultaneously analyzing genetic, molecular, clinical, phenotypic, and dietary data to 
account for the full effects of food; 4) conducting longitudinal studies with large, diverse populations 
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for adequate statistical power; and 5) addressing bias toward positive findings in the publication of 
NG research (Elliot et al 2007, Mutch et al 2005, Martinez-Gonzalez and Sudlow 2006, Kaput et al 
2005). These and other challenges contribute to inconsistent findings across genetic association 
studies and complicate the development of NG interventions to improve individual health 
(Hirschhorn et al 2002). 
Despite these challenges, biotechnology companies and laboratories (here forward 
companies) are offering genetic services based on findings from NG research. These services include 
NG tests for variants in several genes associated with diet-related disease or other health conditions 
that have multiple causes, such as heart disease, diabetes, and osteoporosis. Companies also offer 
supplement, diet, and lifestyle recommendations based on NG test results and other health-related 
information (e.g., smoking status, exercise habits, family history of disease). Like the majority of 
commercially available genetic services, NG services are sold as laboratory services, where by the 
laboratory uses an in-house protocol to analyze patient or consumer specimens and prepare a report of 
test results. Unlike in-vitro diagnostic “test kits” that are manufactured and labeled with instructions 
for a specific clinical use by multiple laboratories, laboratory services are not currently regulated by 
the US Food and Drug Administration (FDA), including their validity, utility, branding, and 
marketing (Javitt 2007). Furthermore, regulations and policies pertaining to laboratory and testing 
standards, informed consent, and direct-to-consumer sale in the delivery of genetic services vary by 
state (Javitt and Hudson 2006, NCSL 2008) 
The US Government Accountability Office (GAO) investigated the legitimacy of claims 
made by companies with direct-to-consumer (DTC) marketing of NG services in June 2006. The 
GAO reported that the NG services provided by four companies were “meaningless and potentially 
harmful to consumers” (US GAO 2006). This investigation prompted the US Federal Trade 
Commission (FTC) to release a fact sheet advising consumers and health practitioners to review 
advertisements for at-home genetic tests with “a healthy dose of skepticism” (US FTC 2006). The 
fact sheet noted that no at-home genetic tests have been reviewed by the FDA and discussed several 
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important caveats to genetic testing as follows: 1) some genetic tests lack scientific validity, 2) 
genetic testing should be performed by specialized laboratories, 3) genetic test results are complex 
and require expert interpretation, and 4) genetic test results are meaningful only in the context of a 
complete medical evaluation. In addition, consumers were advised to review company privacy 
policies.  
NG services are largely marketed on the Internet. Results from 4 Internet searches for 
websites selling health-related genetic services directly to consumers have been published to date 
(Williams-Jones 2003, Gollust et al 2003, Berg and Fryer-Edwards 2008, Geransar and Einsiedel 
2008). These studies found websites to provide inadequate levels of information regarding the 
diseases tested, risks associated with genetic testing, efforts to protect consumer privacy, or the 
management or destroying of specimens post-testing. The lack of information was of particular 
concern given limited availability of genetic counseling services. Studies to date have 
focused on the on-line DTC sale of health-related genetic tests by companies, some of which include 
NG services. Relatively less attention has been paid to the marketing and sales practices of other 
types of organizations that serve as intermediaries between consumers and companies or promote the 
use of NG services. In addition, previous studies have not focused on the types of NG services  
promoted on-line (e.g., conditions and traits, genes profiled, recommendations provided) and the 
frequency of their promotion.  
Given the potential of NG research to improve health, the inadequate oversight of NG 
services, and gaps in information about the promotion and sale of NG services on-line, this study 
seeks to answer the following research questions: Who is involved in the on-line promotion and sale 
of NG services? What types of NG services are promoted? To what extent do websites provide 
information addressing important caveats about at-home genetic testing identified by the FTC?  
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MATERIALS AND METHODS 
 
Search for Organizations Promoting NG Services 
The search strategy was designed to capture the population of organizations that promoted or 
sold NG services on-line in the months following release of the FTC fact sheet regarding at-home 
genetic testing. To be eligible for inclusion, organizations had to host at least 1 publicly-accessible 
website with a unique domain name (i.e., address that identifies a site on the Internet) promoting or 
selling at least 1 NG service. An organization was considered to promote NG services on-line if 
services could be purchased from the organization, the primary content of its website included 
traditional advertising features (e.g., prominent product placement, cost information, persuasive 
messages, sponsor information), or its website directed readers to another website selling NG 
services. Organizations were considered to sell NG services on-line if consumers could purchase NG 
services by entering their contact, delivery, and payment information on its website (e.g., on-line 
shopping cart, order form).  
A pilot study was conducted to identify a practical number of search terms, similar to 
previous studies (Ribisl et al 2003). As illustrated in Figure 3.1, 25 terms were used to search the web 
using Google™. All Uniform Record Locators (URLs) listed in the first 5 pages of results (10 URLs 
per page) for each search were followed. Web pages were coded for primary content and 26 promoted  
or sold at least 1 NG service. All 26 websites were captured by 9 terms and selected for inclusion in a 
broader systematic search. To identify additional terms, the HTML code for each relevant website 
was searched for metatags (i.e., optional codes that identify webpage content in search engine 
indexes). Eleven new terms related to genetics, diet, and testing were selected for inclusion in the 
final search.  
The systematic search was conducted in October 2006 using 20 terms and the 3 most popular 
search engines by share of total visits: Google, Yahoo and MSN (Sullivan 2006). For each of the 60 
independent searches, all URLs appearing on the first 3 pages of results (up to 10 URLs per page) 
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were followed and coded for web page content (including any sponsored links or advertisements). For 
each relevant URL, Internet Researcher© by Zylox Software, Inc. was used to save web pages under 
the domain name.  To determine how many websites continued to promote NG services when 
submitting this manuscript for review, relevant domains were search for on-line in March 2008. 
 
Content Analysis of Websites 
Methods proposed by Riffe, Lacy, and Fico (1998) for the content analysis of media 
messages were followed. First, variables of interest were selected following review of: 1) websites 
identified in the pilot study, 2) data collection forms used in 1 published (Gollust et al 2003) and 1 
unpublished study (Lubin I, unpublished, 2004) of genetic services promoted on-line, 3) the FTC 
consumer fact sheet regarding at-home genetic testing, and 4) a review of other Internet content 
analysis studies. Selected variables included: 1) organization characteristics (i.e., name, organization 
type, geographic location, laboratory accreditation, ownership, privacy policies, staff mix, other 
services provided, affiliation with other NG service providers, at-home testing, on-line sale), 2) NG 
service characteristics (i.e., commercial name, trademark and registration symbols, purpose of test, 
health conditions evaluated, genes evaluated, evidence regarding test validity, medical evaluation or 
consultation services, cost, FDA review), and 3) other website characteristics (i.e., on-line shopping  
carts, links to other organizations selling NG services, date stamps, logos or seals of approval or 
certification).  
Second, a codebook establishing definitions and coding rules for all variables of interest was 
used to train 1 research assistant (RA). {See Appendix 1 for codebook used in training.} Electronic 
data collection forms (i.e., code sheets) were pilot tested and refined by the author (RS) and RA using 
5 websites varying in host organization type, services promoted, and website complexity. Remaining 
websites were coded independently by RS (all websites) and the RA (60% of websites). Established 
variable definitions were refined periodically (every 6-10 websites) in face-to-face meetings between 
RS and the RA to incorporate newly identified characteristics. Open-coding was used to collect health 
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conditions focused on and genes profiled. Health conditions were defined liberally to include illness, 
disease, risk factors for disease, and physical traits or abilities associated with age or health status. All 
saved pages of each website were reviewed, including pages targeted to physicians. Following 
completion of all coding, any differences were discussed until a final agreement was reached. {See 
Appendix 2 for results from reliability testing.} 
Data were collected and analyzed in Microsoft Access 2007. To capture variation in the 
promotion and sale of NG services, the unit of analysis was a NG test mentioned on a particular 
website. Therefore, if 7 different websites mentioned the same NG test, then 7 observations were 
added to the dataset. Similarly, if 1 website mentioned 5 different NG tests, then 5 observations were 
added to the dataset. Each NG test was linked to the website on which it was mentioned. Each 
website was linked to its host organization.   
Health conditions mentioned in NG test descriptions were searched in the International 
Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007 
(ICD-10) (WHO 2007) to determine whether or not the condition, as named on each website, fit into 
standard diagnostic (Dx) nomenclature. Gene names or symbols mentioned in test descriptions were 
searched in the National Center for Biotechnology Information (NCBI) Entrez Gene database to 
determine whether or not genes, as named on each website, fit into standard gene nomenclature 
(Maglott et al 2005).   
 
RESULTS  
 
The systematic search for websites promoting and selling NG services resulted in 2135 URLs 
eligible for review (see Figure 3.2), including up to 30 URLs per search in main results (1 term 
resulted in less than 30 URLs) and a variable number of sponsored links or advertisements per search 
(range from 1 to 26). The majority of URLs (70%, 1492/2135) did not sell or promote a health-related 
product or service. Health-related products or services were sold or promoted on 643 URLs, and 85% 
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(551/643) of these URLs mentioned a genetic-related product or service. Half (276/551) of the URLs 
promoting a genetic-related product or service did not mention NG services. These URLs promoted 
social-related genetic (SG) testing (e.g., genealogy, ancestry, prenatal sex determination, semen 
detection and infidelity testing, DNA storage); health-related genetic (HG) testing that did not 
highlight associations among diet, genes and disease (e.g., pharmacogenetic testing for cytochrome 
P450 2D6, genetic screening for sickle-cell disease, BRCA1/2 testing for breast cancer); or other 
genetic services (e.g., animal sex or pedigree testing, genetic technologies, DNA analysis, etc.).  
NG services were mentioned on 275 URLs, 39% of which also promoted SG or HG testing. 
After eliminating duplicates, 76 URLs remained. Of these URLs, 2 presented search results from 
comparison shopping websites (i.e., NexTag, Inc., PriceGrabber.com, Inc.) providing minimal 
information about NG services (i.e., product name, truncated description, cost) and direct links to 
another URL appearing in search results. These 2 URLs were excluded. The 74 remaining websites 
included 8 links to separate domains providing additional information about the host organization or 
its services. With the inclusion of these links, the final sample included 82 unique domains or 
websites.  
 
Organizations Promoting NG Services 
The 82 identified websites were hosted by 64 organizations (see Table 3.1 for complete 
listing and select characteristics), 1 of which was not-for-profit. At-home testing was offered by 24 
organizations (defined here when a consumer could purchase or order a NG test at home and receive 
test results directly with no explicit requirement for consultation with a health practitioner or genetic 
counselor, on- or off-staff, pre- or post-testing). Five other organizations provided a direct link to 1 of 
these 24 organizations on its website. 
Ten organizations did not have a location within the US and did not mention any residency 
requirements for testing. Residency requirements or state-specific conditions for NG testing (e.g., test 
requisition by licensed physician, general reference to state-specific restrictions) were mentioned by 8 
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US-based organizations. Where mentioned, locations in which residents could not test or had to 
satisfy special requirements included New York (6/8), New Jersey (1/8), Rhode Island (1/8), 
Massachusetts (1/8), Canada (1/8), and the United Kingdom (2/8). 
To suggest its safety, trustworthiness, or popularity, 14 organizations placed one or more 
stamps on their website, including professional society seals (3/14), TRUSTe (4/14) and HONcode 
(1/14) logos (TRUSTe 2008, Boyer et al 1998), awards for quality of content (2/14), and logos for 
technical features such as privacy protection (4/14) and registration of domain name (1/14). 
Affiliation, distribution, and private labeling opportunities targeted to health professionals and 
independent entrepreneurs seeking to start an Internet business were mentioned on 15 websites.  
Half of the organizations identified in the search (32/64) provided healthcare or wellness 
(HW) services (e.g., physical exams, diagnostic tests for non-genetic biomarkers, digital infrared 
thermal imaging, acupuncture, spiritual retreats, medical spa services), of which 41% (13/32) listed a 
naturopathic doctor as staff, 34% (11/32) listed a medical doctor, 25% (8/32) listed a nutritionist or 
dietician, and 16% (5/32) listed a chiropractor. Seven HW service providers did not mention the 
source of testing on their website, 2 being medical centers with in-house laboratories. Twenty seven 
percent (17/64) of identified organizations were companies (to include biotech companies,  
laboratories, and testing facilities), most of which offered at-home testing (9/17, 53%). Across all 
organizations, 1 HW service provider and 2 companies listed a genetic counselor as staff, and 1 
company listed “genetic trained advisors” as staff.  
NG services were sold directly to consumers through on-line “shopping carts” on 17 websites 
hosted by 7 companies, 4 HW service providers, 5 organizations classified as eVendors (i.e., not a 
biotech company or laboratory, no in-house NG services, no HW services, offer on-line sale), and 1 
other promoter.  Two additional websites provided direct links for the purchase of nutrigenomic 
supplements only. Direct links to one or more these 19 websites appeared on websites hosted by 7 
other organizations. The five organizations that allowed consumers to access their test results on-line 
also sold NG tests through on-line shopping carts. 
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Types of NG Services Promoted 
NG Tests 
Websites included 167 mentions of NG tests using a specific commercial name or generic 
reference (e.g., genomic testing). The majority of organizations (67%, 43/64) named up to 3 different 
NG tests (range 1-8).  In most cases, each test evaluated a different health condition or offered a 
different level of service (e.g., NG test results, NG test results with a weight loss plan, NG test results 
with clinical consultation). Several phenomena made it difficult to count the unique number of NG 
tests mentioned across websites as follows.  
1. Organization without an in-house laboratory using different commercial names for what 
appeared to be the same test. 
2. Multiple organizations without an in-house laboratory using very similar by not identical 
names for tests (e.g., DetoxGenomic Profile, DetoxiGenomic© Profile, DetoxicGenomic 
Profile). 
3. Multiple companies offering a test with identical test descriptions or identical sample 
reports but different commercial names. 
4. Organization without an in-house laboratory not mentioning the source of their test. 
5. Company mentioning an organization without an in-house laboratory as a partner and the 
named partner not mentioning the company as the source of testing. 
6. Organization without an in-house laboratory mentioning one company very prominently 
(e.g., website banner, direct link to shopping cart) and a second company less 
prominently (e.g., passing reference in response to “frequently asked questions”, mention 
in sample test report linked to website) as the source of testing. 
Given this lack of transparency, two factors were used to identify the most frequently mentioned 
tests: 1) mention of company name or commercial test name, and 2) verbatim text or identical 
imagery in all or part of the test description.  
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Three organizations were linked to 56% (93/167) of all test mentions: GenovaDiagnostics®, 
Genelex Corp., and Sciona, Inc., all of which were identified in the search. By far, the most 
frequently and transparently mentioned NG tests (by 15 organizations) were Genovations™ 
Predictive Genomic Testing offered by GenovaDiagnostics® (2006 [1]), formerly Great Smokies 
Diagnostic Laboratories. Offered tests included a CardioGenomicPlus® Profile, OsteoGenomic® 
Profile, DetoxiGenomic® Profile, ImmunoGenomic™ Profile, NeuroGenomic™ Profile, and 
EstroGenomic™ Profile. The genes evaluated by Genovations™ were not mentioned by name and 
advertised as “carefully selected based on their relatively high prevalence in the general population, 
their clinical relevance to each health condition, and most importantly, their innate ability to be 
influenced by preventive interventions” (GenovaDiagnostics [2] 2006).  
All organizations mentioning Genovations™ on their website were HW service providers, 
with the exception of 1 consumer organization.  GenovaDiagnostics® does not offer DTC sale of its 
NG services and interested consumers were encouraged to contact a physician for more information 
on the Genovations™ website. GenovaDiagnostics® reference to “physicians” may be broader than 
medical doctors as HW service providers who did not list a medical doctor as staff also offered these 
tests. 
The second most frequently mentioned NG test (by 10 organizations) was the Genetic 
Nutrition Analysis Panel offered by Genelex Corp. The panel is advertised to “optimize the health of 
your skin and bones; heart and mind by optimizing your personal diet and supplement intake… [The 
panel focuses on] seven areas in which the link between gene variations and lifestyle has been 
scientifically established,… including heart health, bone health, B Vitamin use, detoxification, 
antioxidants, inflammation, and insulin sensitivity” (Genelex [1] 2006). The Genelex website “About 
Us” page (2006 [2]) stated that Sciona, Inc. supplied the analytic technology for its NG test. This 
information was not mentioned on web pages providing detailed information about the test.  
Six organizations mentioned Cellf™ Genetic Assessments offered by Sciona. The Cellf™ 
Genetic Assessment was promoted as one comprehensive assessment and/or 5 different assessments 
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for Antioxidant and Detoxification, Bone Health, Heart Health, Inflammation, and Insulin Resistance. 
The comprehensive NG test was advertised by Sciona (2006) as “an ‘at home’ DNA collection kit for 
genetically-personalized nutrition and health assessment tool that will create a personalized diet and 
lifestyle report based on a scientific analysis of an individual’s unique genetic profile, [so that] 
individuals can make their most important health decisions based not on fads, but on a personalized 
scientific roadmap.” Sciona (but not the Cellf™ Genetic Assessment) was mentioned in test 
descriptions appearing on two of the four websites affiliated with marketAmerica, Inc. and its partner, 
nutraMetrix™. No references to Sciona were found on the marketAmerica or nutraMetrix websites.  
 
Health Conditions and Genes Evaluated 
The primary health condition evaluated by each NG test mentioned, as identified in the test 
name, appears in Table 3.2. Most test mentions (19%, 31/167) were for comprehensive assessments 
addressing several health conditions. Among tests focusing on 1 area of health, heart health was most 
common (16%, 27/167), followed by bone (11%, 19/167), immune system (11%, 18/167), 
detoxification (9%, 15/167), and general health and nutrition (8%, 13/167). Most NG test descriptions 
(80%, 133/167) mentioned more than 1 health condition, with an average of 6 conditions per 
description (range 1-47).  
Over 250 health conditions were mentioned across test descriptions, including multiple terms 
to reference the same or related conditions (e.g., heart health, heart attack, myocardial infarction, 
heart disease, cardiovascular disease, heart muscle cell growth). Almost all mentioned conditions 
could be assigned to an ICD-10 Chapter. Ten conditions could not be assigned because the condition, 
as stated in the test description, was vague (e.g., “aging”), was mentioned in multiple ICD-10 
chapters (e.g., “allergies”), or was not mentioned in any ICD-10 chapter (e.g., “DNA repair”). Five of 
the 8 areas of health most often evaluated by NG tests (i.e., immune system, detoxification, 
antioxidant handling, inflammation, oxidative stress) could not be assigned using this standardized 
classification system.  
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Only 30 test descriptions (by 17 organizations) mentioned the genes evaluated by the test. A 
total of 85 gene names or symbols appeared in test descriptions, including 6 commercial gene 
symbols (e.g., BH-2 or Bone Health gene, OS-1 Gene or Oxidative Stress-1 Gene); and 15 gene 
symbols that were alias, but not official, gene symbols (e.g., PAI-1 for SERPINE1, MEPX or 
mETHX for EPHX1). After replacing commercial or alias gene symbols with official gene symbols, 
73 genes remained. A total of 256 associations were claimed between groups of related conditions (68 
groups) and identified genes (see Table 3.3 for list of conditions and associated genes). {See 
Appendix 3 for analysis of claimed associations between conditions and associated genes.} 
 
Recommendations based on NG Tests 
 Most organizations (73%, 47/64) mentioned that consumers could use test results to inform 
their own diet and lifestyle decision-making or provided consumers with specific recommendations. 
Illustrative of consumer empowerment in the use of test results, Quixtar, Inc. offered on-line DTC 
sale of the GENSONA™ Heart Health Genetic Test by Interleukin Genetics, Inc., which was  
advertised to identify “your genetic predisposition to certain types of heart disease. The results can 
help you determine what adjustments you may want to make in your nutrition, exercise, lifestyle, and  
health care practices” (Quixtar 2006). As a second example, Suracell, Inc. (2006 [1]) advertised a 
“DNA Profile test that identifies your hereditary genetic needs, a DNA Assessment urine test that 
measures levels of oxidative stress, and a recommended DNA repair and nourishment protocol” 
inclusive of supplements that are “designed to interact with five cellular processes that are key to 
wellness and aging: methylation, inflammation, glycation, oxidation and DNA repair.” 
 Of note, Suracell offered both NG and non-genetic diagnostic (Dx) testing, and both tests 
were used to inform health and lifestyle recommendations for consumers. In total, 53% (34/64) of 
organizations promoted Dx tests, most of which were HW service providers (76%, 26/34). These Dx 
tests evaluated areas of health similar to NG tests, some of which included serum homocysteine for 
heart health, toxin levels in hair for detoxification, free radicals in urine for antioxidant handling, 
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Type 1 collagen levels in urine for bone health, and serum food allergies for immune health. Five 
organizations promoted comprehensive health profiles that bundled Dx and NG tests or mentioned 
that results from Dx tests increased in utility when combined with NG test results. Six organizations 
bundled NG and pharmacogenetic tests.  
 Recommendations for dietary intake or supplementation were provided by 34 organizations, 
of which 41% (14/34) sold NG supplements or “nutraceuticals” and 18% (6/34) promoted NG 
supplements provided by another organization. One of these 34 organizations based its “nutritional 
supplement” recommendations on its Dx test and not its NG test. Eight other organizations sold or 
promoted supplements that were not marketed as NG supplements. The standard FDA disclaimer (or 
similar variation) regarding supplements appeared on 8 websites: “Statements regarding dietary 
supplements have not been evaluated by the US FDA and are not intended to diagnose, treat, cure, 
mitigate, or prevent any disease or health condition.”  Other supplement-related disclaimers appeared 
on four websites regarding the need to review package inserts, to consult a physician familiar with the 
brand of supplements, or to consult a physician prior to starting any supplement program. Six 
websites mentioned that statements regarding the NG test had not been evaluated or approved by the 
FDA. 
 
Cost and Coverage 
Cost information was provided by 45% (29/64) of organizations. The average cost per NG 
service was $442.59, ranging from $89.99 for a single condition NG test sold on-line, to $2,200.00 
for a comprehensive NG test (i.e., osteoporosis, cardiovascular disease risks, stroke, cancer, 
thrombosis, drug and nutrition metabolism) including “consultation and debriefing” with an 
unspecified person. On average, NG services offered by HW service providers were most expense 
($529.81 per service), followed by companies ($409.81 per service).  
Six organizations stated explicitly on their website that NG services were not covered by 
most health insurance plans, including 4 HW service providers, 1 organization promoting a service 
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provider, and 1 company.  Tests provided by these 6 organizations were slightly higher in cost than 
average (ranging from $449.00 to $700.00 where provided) and focused on a single condition. Eleven 
organizations provided billing information to consumers that could be used to request reimbursement 
from an insurance company, including 10 HW service providers and 1 company. Tests provided by 
these 11 organizations were lower in cost than average (ranging from $99.00 to $345.00), and all but 
1 focused on a single condition.  
 
FTC Caveats for At-Home Genetic Testing 
As demonstrated in Table 3.4, a large majority of organizations promoting NG services did 
not provide information on their website(s) that would address caveats mentioned in the FTC fact 
sheet regarding at-home genetic testing; however, a greater proportion of organizations offering or 
promoting at-home NG testing did provide this information when compared to organizations not 
offering or promoting at-home NG testing.  
 
Scientific Validity of Tests 
Across organizations, information addressing scientific validity included references to 
published research with or without a specific citation (30%, 19/64), and the genes evaluated by the 
test (27%, 17/64). Only 3 organizations mentioned the specific gene variants evaluated by the test. In 
addition, 7 organizations mentioned the analytic (i.e., how often the test accurately identifies the 
evaluated gene) or clinical validity (i.e., how often the test predicts the health condition associated 
with the evaluated gene) of their NG tests with varying degrees of detail.  
CyGene Laboratories, Inc. (2006) mentioned that its tests were more than 99% accurate in 
genotype determination and made more general reference to clinical validity in stating “this [level of 
accuracy] does not mean that someone who is found to be at increased risk for a health concern will 
be affected.” Suracell (2006 [2]) also quantified the accuracy of its test as, “99.5 percent accurate. 
That means there are essentially no false positives for DNA deterioration or damage.” Interleukin 
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Genetics (2006) made general reference to research when describing the validity of their tests, noting 
that “individuals who are positive for one of these three [IL1 genetic] patterns have a lifelong 
tendency to over-express markers of inflammation. Individuals who test positive have been shown in 
multiple clinical studies to be at increased risk for early CVD. Individuals who test negative for the 
IL1 heart test have no known increased risk due to variations in their IL1 genes. These individuals 
may of course have increased risk for CVD due to other risk factors.”  
Less specific information regarding validity was mentioned by 5 organizations referencing 
the quality of the test or laboratory analyzing the test. For example, Sanoviv Medical Institute (2006 
[1]) described its NG test as, “highly accurate genetic diagnostic testing [that] can clearly pinpoint 
health risks which previously would have been lurking out-of-sight.” In answering a “frequently 
asked question” about the reliability of test results, The LabSafe Company (2006 [1]) mentioned that, 
“You can always be confident when testing with LabSafe, we use the leading national laboratories, 
which are fully accredited, licensed medical reference labs. LabSafe provides you access to the very 
same labs used by your physician.”   
 
Laboratory Qualifications 
Thirteen organizations mentioned 1 or more specific approvals or certifications obtained by 
the laboratory analyzing the test, including Clinical Laboratory Improvement Act (CLIA) (8/13), 
American Association of Blood Banks (AABB) (3/13), College of American Pathologists (CAP) 
(1/13), Academy of Clinical, Environmental, Research and Information Services (ACERIS) (1/13), 
and other international certifications (2/10 US organizations, 2/3 off-shore organizations). The 
LabSafe Company (2006 [2]) was the only organization to mention FDA approval of their laboratory, 
as follows: “LabSafe has contracts with major CLIA-certified clinical laboratories. All of our 
laboratories are certified at both the federal and state level, are approved by the FDA, and perform the 
same standard tests that are offered through a hospital or doctor's office.” Only 6 of the 44 
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organizations that did not have in-house laboratories provided any information (specific certification 
or general reference) about the quality of the laboratory analyzing the test.  
 
Test Interpretation, Medical Evaluation and Counseling 
In regard to the interpretation of test results and medical examination, 36% (23/64) of all 
organizations mentioned on their websites the involvement (suggested or required) of a physician as 
part of the testing process. Nutritionist or dietician involvement in testing was mentioned by 9 
organizations. Through “fine print” disclaimers on websites, 38% (24/64) of organizations advised 
consumers to contact their physician or healthcare practitioner regarding concerns about existing 
health conditions (15/24), treatment (9/24), test results (6/24), and/or medical issues in general (4/24).  
Two organizations drew comparisons to HG testing when discussing genetic counseling on their 
website. GeneCare Molecular Genetics (2006 [1]) noted that although their familial cancer and 
pharmacogenetic tests required extensive genetic counseling, their NG test “requires the involvement 
of a dietician who has been trained to interpret the test results and provide expert advice on dietary 
intervention aimed at cancer risk reduction. Since cancer involves a complex interaction between 
genetic susceptibility, nutritional requirements, and other influences such as smoking and obesity, it is 
becoming increasingly important to understand how the diet can be manipulated to reduce cancer 
risk.”  
Similarly, CyGene’s website (2006 [2]) described the goal of genetic counseling and noted 
that it may not be required for their current line of services because consumers “may find all the 
information [they] need regarding [their] increased risk for thrombosis [as an example] from the 
resources provided on [their] report or from [their] physician.” The website also mentioned that the 
Internet is “an excellent source of health related information for the areas covered by CyGene’s 
genetic profiles,” and pointed consumers interested in genetic counseling to the National Society of 
Genetic Counselors website where “finding a genetic counselor is easy.”  
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The need to consider non-genetic factors in the interpretation of test results (i.e., the larger 
context) was mentioned by 16 organizations, 5 of which offered or promoted at-home testing. 
Organizations that offered or promoted at-home testing (31%, 9/29) were more likely than other 
organizations (14%, 5/35) to mention that NG tests are for risk and not certainty of disease. As stated 
by Gene-Testing.com (2006), “In most cases these diseases are not linked to one specific gene; rather, 
your risk of developing them is part of a complicated equation that involves numerous genes and 
lifestyle factors.”  
Only 8% (5/64) of organizations discussed family history (beyond brief mention of inherited 
risk) and the relevance of test results to family members. The use of NG test results to augment 
information about family history was mentioned by 2 organizations. The Sanoviv Medical Institute 
website (2006 [2]) included a testimonial from a medical doctor noting that, "Most people go through 
life knowing they have a family history of a degenerative disease like heart disease, cancer or 
diabetes, but they don't know what it means for them or how it can impact their health down the road. 
It's exciting to discover what's going on in the body genetically. So if you know if you have a certain 
genetic risk, there are changes you can make now, and it's worth making them." In addition, 
GenovaDiagnostics (2006 [3]) noted, “When conditions ‘run in families’ they often have a genetic 
component. Testing can show what specific genetic factors could pose a potential problem for you... 
Once you have this information, you can develop a focused plan to ‘break the pattern’ and better 
prevent your family risks from turning into realities."  
Sharing test results with family members was mentioned by 3 organizations, 2 of which 
highlighted ethical issues surrounding disclosure. For example, GeneCare Molecular Genetics (2006 
[2]) noted, "The main dilemma arises from a conflict between the right of the individual to personal 
privacy on the one hand and the interest of family members to be made fully aware of available 
information which would play a part in making important life decisions on the other." Cedars-Sinai 
GenRISK® Adult Genetics Program (2006) noted the potential for sharing or discovering unwanted 
information as follows: “Family relationships may be affected by this information… In the process of 
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sharing your genetic risk information, family members may learn things about you that you do not 
want known. In addition, you may learn things about relatives that you did not want to know. For 
example, it may be revealed that a family member is adopted.” 
 
Privacy 
Among the 44 organizations providing privacy statements on their website (e.g., use of 
“cookies” to track website browsing, encryption technology, handling of personal contact and other 
information), 68% (30/44) mentioned the handling of specimens and/or test results, including 13 
companies, 10 HW providers, 5 eVendors, and 2 other organizations.  
 The handling of both specimens and test results was addressed by 19 organizations, of which 
14 mentioned destroying (12/14) or unidentifying specimens (2/14), and keeping test results 
confidential (8/14) or unidentified (6/14). The other 5 organizations did not destroy specimens but 
kept them confidential, and kept test results confidential (3/5) or unidentified (2/5). Among the 11 
organizations addressing the handling of either specimens or test results, 9 organizations addressed 
only test results (8/9 kept results confidential, 1/9 kept results unidentified), and 2 organizations 
addressed only specimens (1/2 destroyed specimens, 1/2 kept specimens confidential). 
Overall, 29 organizations mentioned storing test results (28/29) or specimens (12/29), of which less 
than half (38%, 11/29) mentioned how test results or specimens would be used. These 11 
organizations mentioned using stored test results for future research (8/11), and follow-up, future 
reference, quality improvement, or accreditation-related activities (6/11).  
 
Longevity 
In March 2008, 77% (49/64) of identified organizations continued to promote NG services 
on-line. Eight of these organizations made substantial changes to the graphic design and layout of 
their website, including the addition of a Spanish language version by 1 company. A modified domain 
name or a new organization name was found for 3 organizations. New NG services were promoted by 
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2 companies, the first offering new NG tests for healthy aging, comprehensive cardiovascular, bone 
health, general nutrition, CoQ10 efficiency, and metabolic syndrome; and the second offering a new 
DNA fitness program based on NG test results. In addition, 1 HW provider added an on-line shopping 
cart for DTC sale and 1 company received CLIA certification for its laboratory.  
Eight organizations no longer mentioned NG services on their websites, the majority of 
which were HW providers (4/8) and companies (2/8) offering NG tests for single conditions. Six of 
these eight organizations were affiliated with another company identified in the search (i.e., Cygene, 
Genelex, GenovaDiagnostics, Sciona). Websites could not be found for 7 organizations including 1 
HW provider, 3 eVendors, and 3 companies. Four of these 7 organizations were affiliated with 
another company identified in the search (i.e., DaVinci Laboratories of Vermont, Genelex, Market 
America: Unfranchise® Business, Sciona). 
 
DISCUSSION 
 
The present study demonstrates that a wide variety of organizations were involved in the on-
line promotion and sale of NG tests in the months following the GAO investigation. These 
organizations ranged from a book author providing a direct link to a company offering at-home NG 
testing, to a large medical center with an in-house clinical laboratory also offering a variety of HG 
tests. Similar to previous analyses of commercial website content, this study found less than adequate 
information about important caveats associated with genetic testing; however, organizations 
promoting at-home testing were more likely to address these caveats.  
The majority of websites promoting NG services were hosted by HW service providers. In a 
recent study of public awareness and use of NG tests, Goddard and colleagues (2007) found that 
consumers reporting health professionals as a source of information were more likely to have 
purchased NG services than consumers receiving information from any other source. Although 
evidence suggests that current findings in NG research do not support the use of genetic information 
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to improve individual health, service provider websites described NG tests as a useful tool for 
understanding and improving the health of their patients and in some cases integrated NG tests into a 
panel of other Dx tests. The use of NG tests in combination with Dx tests may indicate an 
understanding that genetic information alone does not provide a complete picture of health. 
Alternatively, service providers may combine NG and Dx tests under the belief that NG test results 
have some distinct and measurable utility above Dx tests, to compensate for the lack of established 
clinical validity for NG tests, or to capitalize on novelty of NG tests.  
The American Society of Human Genetics (2007) highlighted the importance of provider 
education regarding the analytic and clinical validity of genetic tests in its statement regarding the 
DTC marketing of genetic tests. Several findings from the present study suggest that such education 
efforts should cast a wide net. First, a variety of health professionals were found to promote  
NG services. Naturopathic doctors were most often listed as staff in identified organizations, followed 
by nutritionists or dieticians and medical doctors in almost equal numbers, and chiropractors. Second, 
nutraMetrix™ made an open call on its website for “health professionals in all fields” to become 
“certified Nutraceutical Consultants” trained in the use of NG services. Two organizations identified 
in this search appeared to take advantage of this opportunity. Finally, descriptions of affiliation and 
distribution opportunities indicate a concerted effort to not only encourage the use NG services, but 
also to increase the on-line presence of NG services through the creation of web-based businesses, 
customized web-portals, and direct links to on-line shopping carts by independent entrepreneurs.  
The need to establish regulations or guidance for the marketing of genetic services was 
demonstrated by the varied levels of information provided on different websites promoting the same 
NG test. Under conditions of on-line DTC sale or at-home genetic testing, commercial websites are 
akin to product labels. Legal scholars have argued that commercial websites for prescription drugs 
should be regulated by the FDA as “product labeling” (held to strict content standards) since web-
based information is often similar to the package insert information consumers receive with a 
purchased product and can be far greater than what is provided in a traditional print or televised 
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advertisement (Opderbeck 1998). A parallel argument can be made regarding commercial websites 
for NG or other genetic services. Greater levels of consumer autonomy in the purchase of genetic 
services increases the need for commercial websites to present high quality information, particularly 
information regarding product risks and limitations.  
Clearly, information provided on commercial websites will not be the only information 
consumers receive when they purchase a NG service on-line. Companies offering DTC sale of NG 
services often mail consumers a specimen collection kit including a package insert with instructions 
for use and other information. Studies have yet to examine this source of information and compare it 
to website content. In addition, consumers may obtain other important information by contacting 
company representatives (if they know the right questions to ask). Nonetheless, consumers interested  
in at-home genetic testing are likely to use website information to make an initial decision. The 
provision of contact, payment, or other personal information raises concerns about consumers 
receiving advertisements for related services such as NG supplements, skin creams, or weight-loss 
products; or genome-wide profiling services offered by relatively new companies like 23andMe and 
deCODE genetics (GeneWatchUK 2002, Wade 2007). 
 Six organizations stated explicitly on their website that NG services were not covered by 
most health insurance plans.  Based on recommendations from the Secretary’s Advisory Committee 
on Genetics, Health, and Society (2006), NG services will not be covered until there is enough 
evidence to establish analytic and clinical validity, and clinical utility. The inability to classify health 
conditions assessed by the majority of NG tests using standard codes for disease states (i.e., ICD-10) 
will further complicate billing and reimbursement efforts. Therefore, consumers interested in NG 
services, believing that they provide some clinical utility or other perceived benefit, will pay out-of-
pocket.  
Regardless of purchase, the Internet has been noted as a medium that provides a “rich” 
product experience (Evans and Wurster 1999), and may have a greater impact on attitudes than other 
media (Coyle and Thorson 2001). The Internet also is an important and at times preferred source of 
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information about genetics, despite its limitations (Bernhardt et al 2002). Internet users are likely to 
come across websites promoting NG services when searching for genetic services in particular, or 
when searching for other health information such as diet, nutrition, supplements, or fitness—topics 
included among the most popular health topics searched for on-line (Fox 2006).  
On-line promotional materials for genetic services have the potential to educate consumers 
and health providers about advances in the field of genetics, and the benefits and limitations of 
genetic testing. On the other hand, promotional materials also have the potential to foster 
deterministic views about genes (i.e., “I am my genes”) and unwarranted fear or anxiety about future  
health. Despite the potential for consumers to misunderstand the impact of genes on different types of 
health conditions, few websites mentioned the involvement of a genetic counselor or other genetic 
expert as part of the testing process. Furthermore, 2 websites suggested that genetic counseling was 
not as important for NG testing relative to HG testing. 
While the FDA does not have direct authority over advertising for NG or other laboratory 
services, it has requested meetings with several companies identified here regarding the lack of pre-
market review (to assess validity, quality, and clinical interpretation) for their laboratory services 
(Javitt 2007). Both the FDA and the FTC have reported limited oversight and resources to monitor the 
promotion and sale of genetic services (Deen 2004, Katsanis et al 2008), increasing the importance of 
consumer reporting. However, researchers have found that Internet users rarely: 1) look at 
organization information (i.e., “About Us”) provided on websites, 2) remember where they found 
information on-line, or 3) remember who was responsible for the website from where they found 
information (Eysenback and Kohler 2002). In the absence of knowledge about NG or genetic testing, 
Internet users may use less substantive factors to determine website credibility (and thereby 
organization and test credibility), including 3rd party endorsements, quality seals, appealing pictures 
of staff, and professional appearance of the website (Coyle and Thorson 2001, Eysenback and Kohler 
2002). These patterns suggest that consumers may not be a reliable source for reporting misleading or 
fraudulent marketing.   
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Despite release of the GAO report and unfavorable media coverage (ABC 2006, Simmons 
2006), few organizations identified in October 2006 were found to stop promoting NG services in 
March 2008. In fact, companies identified in this search reported expanding their NG services, 
establishing new agreements for their distribution, and targeting new consumer markets on-line 
(PRNewswire 2008, Business Wire 2008, Business Wire 2006). The continued premature marketing 
and sale of NG services is problematic. First, although NG is a promising field of research working 
diligently toward realizing its goal of personalized nutrition, there is currently little evidence to 
support the use of NG services. In a rigorous review of meta-analyses, Janssens and colleagues (2008) 
found insufficient evidence to support the gene-disease associations in NG tests offered by 7 
companies. Four of these companies were identified in this study (Genelex, GenovaDiagnostics’ 
Genovations, Sciona, Suracell) and linked to 57% (95/167) of all NG test mentions across websites.  
Second, commercial websites failed to provide adequate and transparent information for 
informed decision-making and rarely highlighted the importance of consumer consultation with a 
genetics professional. NG test descriptions overestimated the validity and utility of test results and 
often ignored limitations in NG research or services. Consumer and health professional efforts to 
gather specific information about the validity and utility of NG tests may be complicated by the use of 
unofficial gene symbols and commercial gene names on some websites. Furthermore, incomplete and 
conflicting information about the companies analyzing NG tests complicates the selection of a 
“qualified” laboratory.  
In the absence of federal regulation regarding the content of advertisements and other 
promotional materials, organizations that continue to promote NG services on-line should address 
important caveats in genetic testing highlighted by the FTC and the DTC marketing-related issues 
outlined in position statements by professional societies (ACMG 2004, NSGC 2007, Hudson et al 
2007). In addition, organizations should follow long standing principles for the ethical provision of 
health information on-line (Kember 2001, Rippen and Risk 2000, Winker et al 2000).  
 
  59 
Limitations 
Study results are based solely on publicly-accessible (i.e., login or registration not required) 
website content and may not reflect all organization or test characteristics. Companies were not 
contacted to confirm the accuracy of website content. Second, the automated archival feature in 
Internet Researcher© did not capture every item on all pages of each website (e.g., video, automated 
features, Adobe Acrobat files, links to on-line shopping cart, links to other web pages). There were 
less than 20 cases where visible links to content not retrieved appeared to contain NG test-specific 
information. In these cases, the Internet Archive Wayback Machine was used to find web page 
content archived at the same time as this study (http://www.archive.org/web/web.php). In most cases, 
additional content was not identified.  
Finally, in their Internet search, Janssens and colleagues (2008) identified 7 companies 
offering predictive genomic profiles, 3 of which were not identified in this study—GenoSolutions, 
IntegrativeGenomics, Salugen. According to the Wayback Machine, websites for 2 of these 3 
companies were active during the month this search was conducted (October 2006). The Internet 
search methodology used by Janssens and colleagues was not described; however, authors mentioned 
starting with a Genewatch report on “individually tailored nutrition recommendations based on 
genomic profiling” (Wallace 2006). This report mentions 12 companies involved in NG services, 4 
identified in the Janssens and colleagues study, and 6 identified in this study. The reason why 3 
companies identified by Janssens and colleagues did not appear in search results for this study are 
unclear, but plausible explanations include: 1) the absence of search terms used in this study as 
metatags on company websites, 2) the appearance of URLs beyond the first 3 pages of search results 
(not reviewed in this study), or 3) temporary website inactivity or malfunction during this search.  
 
Strengths 
Websites identified in this study are most likely to include those the average US consumer 
would have identified in a search for NG services in October 2006. The review of websites three 
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months following release of the GAO report and the FTC consumer fact sheet provided time for 
organizations promoting NG services on-line to review and improve website content. The content 
analysis included websites with on-line DTC sale, DTC marketing, health professional marketing, and 
more general promotion by a variety of organizations. The broad inclusion criteria allowed for a more 
rich understanding of on-line promotional materials for NG services. Finally, findings from the 
present study add to those of 4 previous studies increasing the potential for longitudinal analyses of 
anticipated growth and change in the promotion of NG and other genetic services.  
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Figure 3.1. Pilot study to select search terms to identify websites promoting or selling 
nutrigenomic services 
 
 
 
 
 
Search Terms Pilot-Tested in Google (n=25) 
 
Nutragenetic test, Nutragenetic testing, Nutragenomic test, Nutragenomic testing 
Nutrigenetic test, Nutrigenetic testing, Nutrigenomic test, Nutrigenomic testing 
Nutrition DNA scan, Nutrition DNA test, Nutrition DNA testing 
Nutrition genetic scan, Nutrition genetic test, Nutrition genetic testing 
Nutrition genome scan, Nutrition genome test, Nutrition genome testing 
Nutrition profile DNA, Nutrition profile genetic, Nutrition profile genomic 
Nutritional gene test, Nutritional genetic test, Nutritional genetic profile 
Nutritional genetic testing, Nutritional genomic profile 
 
Minimum Number of Pilot-Tested Search Terms 
Needed to Capture all Relevant Websites (n=9) 
 
Nutragenetic testing, Nutrigenetic testing 
Nutrigenomic testing 
Nutrition DNA test 
Nutrition genome testing 
Nutrition profile DNA, Nutrition profile genetic, 
Nutrition profile genomic, Nutritional genomic profile New Search Terms Appearing as 
Metatags on Relevant Websites (n=11) 
 
Genetic diet, DNA diet 
Diet test, Diet testing 
Nutrition genetic analysis 
Nutrition genomic analysis 
Genetic assessment 
Lab test genomic, Lab test genetic 
DNA testing kit, Personalized testing 
26 Relevant Websites Identified 
20 Search Terms Selected 
for Comprehensive Search 
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Figure 3.2. Comprehensive search results for websites promoting and selling nutrigenomic 
services and website selection, October 2006 
 
 
 
a
 Excludes 16 URLs whose primary webpage content could not be determined. All values include duplicate 
URLs, excluding values presented in shaded boxes. 
Google, Yahoo, MSN Search Results  
Using 20 Search Terms 
N=2135 URLs 
a
 
Health Product 
Promoted/Sold 
N=643 URLs (29.9%) 
Genetic Product 
Promoted/Sold 
N=551 URLs (25.6%) 
Nutrigenomic Product Promoted/Sold 
 N=275 URLs (12.8%)   
Nutrigenomic Test 168 (61.1%) 
Nutrigenomic, HG and SG   78 (28.4%) 
Nutrigenomic and HG   29 (10.5%) 
No Health Product or Service Promoted/Sold 
N=1492 URLs 
News/Editorial/Press Release   257 (17.2%) 
Education/Advocacy  234 (15.7%) 
Org Info/Staff Profiles/Activities 344 (12.5%) 
Directory/Listing/Search Results  187 (12.5%) 
White Paper/Presentation  184 (12.3%) 
Opinion/Talk/Blog    126 (9.8%) 
Peer Reviewed Paper  132 (8.8%) 
Other        8 (0.5%) 
No Genetic Product Promoted/Sold 
N=92 URLs 
Supplement, Tonic, Tea    54 (69.2%) 
Diagnostic Test     34 (30.8%) 
Diagnostic Test and Supplement 10 (12.8%) 
Other       4 (5.1%) 
No Nutrigenomic Product Promoted/Sold 
N=276 URLs 
Social-Related Genetic Test (SG) 189 (68.5%) 
Health-Related Genetic Test (HG)   52 (18.8%) 
Other Genetic Product or Service   25 (9.1%) 
Social and (Health or Other)    10 (3.6%) 
 
1 URL not in search results promoting 
nutrigenomic test listed on 
Directory/Listing 
76 Unique URLs  
8 links to URLs with  
additional information  
2 Shopping Comparison Websites 
82 Unique Websites 
(Domain Names)  
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Table 3.1.  Select organization and service characteristics mentioned on websites promoting nutrigenomic services (NG) by host 
organization type, October 2006 (N=64) 
 
 Select Characteristics Mentioned On Website 
 Organization (Org) Services  
 
Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Biotechnology Company, Laboratory, Testing Facility (n=17) 
CyGeneDirect™ 
http://www.cygenelabs.com   
https://cygenedirect.com/default.html [ad] 
 Yes Yes Yes   Yes    
DaVinci Laboratories of Vermont  
http://www.davincilabs.com    Yes Yes  Yes     
DDS DNA Test Express 
http://www.ddstest.com/dnatestx/index.html     Yes    Yes  Yes  
Determigene 
http://www.determigene.com/     Yes   Yes   Yes  
GeneCare Molecular Genetics (Pty) Ltd 
http://www.genecare.co.za/index2.html  Yes      Yes  Yes  
Genelex Corporation 
http://www.genelex.com  
http://www.healthanddna.com   
 Yes Yes Yes   Yes  Yes  Yes  
GeneLink, Inc.  
http://www.bankdna.com  
http://www.genelink.info  
  Yes      
Genetic Health 
http://www.genetic-health.co.uk  Yes  Yes    Yes   
GENOSENSE Diagnostics  
http://www.genosense.com/EN/Index.html  Yes      Yes   
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
GenovaDiagnostics® 
http://www.gdx.net/home  
http://www.genovations.com  
http://www.gsdl.com  [ad] 
 Yes Yes      
Interleukin Genetics 
http://www.ilgenetics.com/index.jsp    Yes Yes  Yes 
a
 Yes a Yes   
Nutrigen 
http://www.1-888-nutrigen.com/index.html  
http://www.thecyclingdiet.com [ad] 
        
OnePersonHealth 
http://www.onepersonhealth.com/geneticAnalysis/n
utritional Genetics.jsp  
http://www.onepersongenetics.com  
Yes  Yes Yes  Yes  Yes    
Sciona™, Inc. 
http://www.sciona.com  
http://www.mycellf.com  [ad] 
  Yes Yes   Yes    
Suracell, Inc. 
http://www.suracell.com   Yes Yes Yes  Yes  Yes    
The DNA Testing Centers 
http://thednatestingcenters.com/mainpage.html        Yes  Yes  
The LabSafe Company 
http://www.lab-safe.com     Yes   Yes  Yes  Yes  
Health and Wellness Care Providers (n=21) 
Biamonte Center for Clinical Nutrition 
http://www.health-truth.com     Yes  Yes     
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Carolyn Katzin, CNS--Cancer Nutrition Center, 
The DNA Diet 
http://www.carolynkatzin.com  
http://www.cancernutrition.com  
http://www.thednadiet.com  
  Yes Yes   Yes    
Complete Health 
http://www.completehealthinstitute.com          
Complete Nutrition and Wellness 
http://www.completenutritionandwellness.com/inde
x.html  
    Yes  Yes    
Dawn A. Lancaster, DC 
http://www.wsmcafe.com/new_users/0/3/03100241j
p8/ index.html  
http://www.davincicon.com/Merchant2/agentgo.mv
?AG=DrDawn&SC=SFNT&S=D&RU=http://www
.davincicon.com/welaffiliate.html  [ad] 
    Yes a Yes b   
Holistic Naturopathic Center  
http://www.holisticnaturopath.com/index.htm           
Integrative Health Solutions 
http://www.docbron.com        Yes   
Jacquie Carboni, NMD 
http://www.netsupport.com/drjacquie/index2.htm   Yes  Yes      
Jim Otis, DC, DACNB 
http://www.jimotisdc.com/index.html     Yes 
a
 
 Yes a   
Kristy McKendrix, ND--Healing with Health, 
nutraMetrix™ 
http://www.thewebitect.com/hwhindex.html 
http://drkristy.nutrametrix.com [ad] 
   Yes  Yes  Yes    
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Mommy & Me Chiropractic, Ltd. 
http://www.mommynmeonline.com  
http://www.davincicon.com/Merchant2/agentgo.mv
?AG=DrBrooks&SC=SFNT&S=D&RU=http://ww
w.davincicon.com/welaffiliate.html  [ad] 
    Yes a Yes b   
Natural Family Health Care Center of the Shoreline 
http://www.naturalfamilyhealthct.com          
Natural Health California 
http://www.naturalhealthcalifornia.com          
Naturopathic Clinic of Concord 
http://www.pamelaherring.com          
Nicola McFadzean 
http://www.drnicola.com/201/index.html          
Nutrition In Motion 
http://www.nimdiet.com/healthandlongevity.php  Yes   Yes  Yes     
Neurological Research Institute 
http://www.holistichealth.com/Welcome.html  
http://www.autismanswer.com   
http://www.holisticheal.com   
http://www.testing4health.com  
  Yes Yes   Yes    
Rebecca Muttart, ND 
http://www.docrebecca.com/about.html  Yes        
SOMA Acupuncture & Natural Health Clinic 
http://www.somaacupuncture.com          
The Maas Clinic 
http://www.themaasclinic.com/index.html  Yes        
Time to Unwind Therapeutic Massage, Inc. 
http://www.taketimetounwind.com/index.html      Yes     
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Health and Wellness Care Providers with Medical Doctor (MD) (n=11) 
Alternative Medicine & Healthcare 
http://alternativemedicinehealthcare.com/index.htm          
Breakspear Medical Group 
http://www.breakspearmedical.com/index.html  Yes        
Cedars-Sinai GenRISK Adult Genetics Program 
http://www.cedars-sinai.edu   
http://www.csmc.edu/951.html  
      Yes   
Elan Vital Medical Centers and Spas 
http://www.spadocs.com          
Executive Medicine of Southlake 
http://www.emsouthlake.com      Yes     
Hardy Healthcare Associates 
http://www.hardyhealthcare.com          
Hunter Yost MD 
http://www.hunteryostmd.com          
Integrative Longevity Institute of Virginia 
http://66.241.252.6/index.html          
Sanoviv Medical Institute 
http://www.sanoviv.com/en.html          
Scienta Health Center  
http://www.scientahealth.com/index.php  Yes Yes Yes    Yes   
Vibrance Medical Group 
http://www.vibrancemedicalgroup.com    Yes  Yes   Yes   
eVendor (n=7) 
CVS/Pharmacy      
http://www.cvs.com     Yes   Yes    
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Drugstore.com       
http://www.drugstore.com   Yes  Yes   Yes    
eHealthLabs™       
http://www.ehealthlabs.com   Yes  Yes   Yes  Yes  Yes  
Gene-Testing.com        
http://www.gene-testing.com     Yes  Yes 
a
 Yes a   
LinkTime Productions, Inc.: An Affiliate Of The 
Market America, Inc. UnFranchise®  
http://www.linktime.biz/GeneSNPInfo.html  
 Yes  Yes  Yes     
Market America: UnFranchise® Business: 
Webportal sponsored by Grandeur The Great, 
INTL, LLC 
http://fly.unfranchise.com/index.cfm  
 Yes Yes Yes  Yes  Yes    
Quixtar       
http://www.quixtar.com   Yes Yes Yes  Yes  Yes    
Other Promoters (n=8) 
Book promotion 
Feed Your Genes Right by Jack Challem, The 
Nutrition Reporter™      
http://www.feedyourgenesright.com  
   Yes a  Yes a Yes a  
Consumer organization for support or information 
Alternative Medicine Referral Network--Vibrance 
Medical Group 
http://www.amrn.net/Vibrance/Vibrance_genomic_t
est.html  
 Yes   Yes a  Yes a  
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Domain Names Appearing In Comprehensive URL 
Search (n=74) and Affiliated Domains [ad] Not in 
URL Search  (n=8) 
Off-Shore 
Location 
Only 
(n=10) 
Affiliation/ 
Distribution 
Opportunity 
(n=15) 
Promoted 
by Other 
Org in 
Search 
(n=17) 
At-Home 
NG 
Testing 
(n=28) 
NG 
Supple-
ments 
(n=20) 
On-Line 
Payment 
for NG 
Services 
(n=26) 
Health-
Related 
Genetic 
Testing 
(n=17) 
Social-
Related 
Genetic 
Testing 
(n=7) 
Label Me Sane™      
http://www.labelmesane.com     Yes 
a
 
 Yes a Yes a  
Nutrition Mission Foundation     
http://www.nutritionmission.org     Yes 
a
 
 Yes a   
Suracell Products 
http://stopthepainmd.com/index.html  
http://orthodoc.aaos.org/FBUECHELJRMD  [ad]   
   Yes a Yes a Yes a   
 
Affiliation/Distribution opportunity 
Chemists Commercial Consultancy 
http://www.chemicomconsult.com/index.html  Yes Yes  Yes    Yes 
a
 
 
nutraMetrix™       
http://www.nutrametrix.com   Yes Yes      
Member benefits organization 
Best Discount Benefits—Health Savings Account 
(HSA) Asset Preservation Plans      
http://www.bestdiscountbenefits.com  
    Yes  Yes    
 
a Host organization provides direct link on website to another organization offering service. 
b
 On-line purchasing of nutrigenomic supplements only. 
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Table 3.2.  Primary area of health evaluated by nutrigenomic tests promoted or sold on-line, 
October 2006 (N=167) 
 
 Tests 
Area of Health     N    % 
Heart 27 16.2 
Bone 19 11.4 
Immune System 18 10.8 
Detoxification 15 9.0 
Nutrition (general reference to health/nutrition) 13 7.8 
Antioxidant and Detoxification 6 3.6 
Oxidative Stress 5 3.0 
Nervous System 4 2.4 
Inflammation 3 1.8 
Athletics 2 1.2 
Autism 2 1.2 
Insulin Sensitivity 2 1.2 
Macular Degeneration 2 1.2 
Pregnancy 2 1.2 
Aging 1 0.6 
Cancer 1 0.6 
Methylation Cycle 1 0.6 
Obesity 1 0.6 
Comprehensive (multiple specific conditions) 31 18.6 
Women's Health Comprehensive 6 3.6 
Men's Health Comprehensive 4 2.4 
Not Clear (general reference to genomic test) 2 1.2 
Total 167 100.0 
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Table 3.3.  Claimed associations between groups of health conditions and genes mentioned in 
nutrigenomic test descriptions on-line by ICD-10 Chapter, October 2006 (N=256) 
 
ICD-10 Chapter Grouped Health Conditions (N=68) 
Associated Genes 
(N=73) 
I.  Certain infectious and parasitic diseases  
 Sepsis TNF 
 Hepatitis B VDR 
 Tuberculosis VDR 
II.  Neoplasms  
  
 Cancer (Non-Specific) GSTM1, SOD2 
 Bladder GSTM1, GSTT1 
 Breast AR, BRCA1,a BRCA2, CHEK2, COMT, 
CYP1A1, CYP1B1, MLH1, MSH2, 
MTHFR, PGR, RHOBTB2, TGFBR1, 
TP53, VDR 
 Colon/Colorectal APC, MLH1, MSH2, TGFBR1, TP53 
 Cervical   GSTT1, MTHFR 
 Endometrial  PGR 
 Esophageal   MTHFR 
 Larynx   GSTT1 
 Lung   CYP1A1, GSTM1, GSTP1, GSTT1 
 Ovarian   TGFBR1 
 Prostate   AR, CYP17A1, CYP1B1, ELAC2, 
GSTP1, GSTT1, SRD5A2, VDR 
IV.  Endocrine, nutritional and metabolic diseases 
 Diabetes Type II MTHFR, VDR 
 Cholesterol  APOE, CETP, F2, F5, IL1A, LPL, 
MTHFR, NPY, SREBF2 
 Fatty Acids SREBF2 
 Lipids APOC3, APOE, CETP, LPL, NOS3, 
PPARG, SERPINE1 
 Triglycerides ADRA2B, APOC3 
 Obesity, Weight Gain ADRA2B, ADRB2, ADRB3, GNB3, 
NPY, SERPINE1, SREBF2, TNF 
 Metabolic Syndrome ADRB2 
 Homocysteine, Folate, Vit B  CBS, MTHFR, MTR, MTRR, TCN2, 
XRCC1 
 Calcium VDR 
 Electrolytes ACE 
 Vitamin D VDR 
 Zinc SOD3 
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ICD-10 Chapter Grouped Health Conditions (N=68) 
Associated Genes 
(N=73) 
 Steroid, Hormone  AR, COL1A1, COMT, CYP17A1, 
CYP19A1, CYP1A1, CYP1B1, ESR1, 
F2, F5, GNB3, SRD5A2, VDR 
 Methylation Cycle/Pathway ACAT1, ACAT2, ACE, AHCY, BHMT, 
CBS, COMT, MAOA, MTHFR, MTR, 
NOS3, SUOX, VDR 
 Hyperparathyroidism VDR 
V.  Mental and behavioral disorders 
 Autism  COMT, MTHFR 
 Schizophrenia  GSTM1 
VI.  Diseases of the nervous system 
 Alzheimer's Disease APOE 
 Brain Function APOE 
 Multiple Sclerosis GSTM1 
 Muscular Dystrophy  GSTP1 
 Neurologic Degeneration  APOE 
VII.  Diseases of the eye and adnexa 
 Macular Degeneration SOD2 
IX.  Diseases of the circulatory system 
 Hypertension ACE, ADRB1, ADRB2, AGT, GNB3, 
IL6, NOS3, NPY 
 Thrombosis F2, F5, GNB3, ITGB3, MTHFR 
 Heart Attack ACE, APOC3, F2, F5, IL1A, IL6, MMP3, 
NOS3 
 Stroke F2, F5, IL6, MTHFR, SERPINE1 
 Heart/Vascular ADRA2B, ADRB1, ADRB2, APOA1, 
APOB, APOC3, APOE, CBS, CETP, 
ESR1, F2, F5, GJA4, GNB3, IL1A, IL6, 
LPL, MMP3, MTHFR, MTRR, NOS3, 
NPY, PON1, SERPINE1, SOD3, 
SREBF2, VDR 
X.  Diseases of the respiratory system 
 Asthma GSTM1, GSTP1, TNF 
 COPD TNF 
XI.  Diseases of the digestive system 
 Crohn's Disease TNF 
XIII.  Diseases of the musculoskelet al system and connective tissue 
 Arthritis/Osteoarthritis TNF, VDR 
 Connective Tissue VDR 
 Bone Density COL1A1, IL6, TNF, VDR 
 Osteoporosis/Factures COL1A1, IL6, MTHFR, TNF, VDR 
XIV.  Diseases of the genitourinary system 
 Kidney Stones VDR 
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ICD-10 Chapter Grouped Health Conditions (N=68) 
Associated Genes 
(N=73) 
XV.  Pregnancy, childbirth and the puerperium 
 Early Pregnancy Loss GSTP1 
XVII.  Congenital malformations, deformations and chromosomal abnormalities 
 Down’s Syndrome COMT, MTHFR 
 Neural Tube Defects COMT, MTHFR, MTRR 
XVIII.  Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 
 Insulin, Glucose ACE, ADRB2, IL6, MTHFR, PPARG, 
SERPINE1, TNF, VDR 
XIX.  Injury, poisoning and certain other consequences of external causes 
 Alcohol, Alcoholism ALDH2 
XX. External causes of morbidity and mortality 
 PAI/Plasminogen levels SERPINE1 
Can't Classify 
  
 Aging/Longevity IL10, MTHFR,TNF 
 Antioxidants, Free Radicals GSTM1, GSTP1, GSTT1, MTHFR, 
SOD2, SOD3 
 Cell Growth (Cardiomyocytes) GNB3 
 Cell Growth (Non-Specific) MTHFR 
 Detoxification/Excrete Toxins COMT, CYP1A1, CYP1B1, EPHX1, 
GPX, GSTM1, GSTP1, GSTT1, MTHFR, 
TCN2 
 DNA Repair/Damage GPX, MTHFR 
 Emotions (Non-Specific) ACE, COMT, MTHFR 
 Hair/Skin Repair MTHFR 
 Inflammation/Allergies  COMT, IL10, IL1A, IL6, MTHFR, 
SERPINE1, TNF 
 Oxidative Stress APOE, GPX, GSTM1, PON1, SOD2, 
XRCC1 
 
a
 Nutrigenomic test profiling BRCA1/2 offered by off-shore company. 
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Table 3.4. Organizations providing information on website addressing caveats raised in US Federal Trade Commission (FTC) fact sheet 
regarding at-home genetic testing, October 2006 (N=64) 
 
  
Organizations Providing Information   % (N) 
Caveats Raised by FTC Information Provided On Websites 
All 
Organizations 
At-Home Testing 
Offered/Promoted a 
(n=28) b 
At-Home Testing Not 
Offered/Promoted 
(n=36) 
Scientific Validity Citations for Peer-Reviewed Research c 30 (19) 43 (12) 19 (7) 
 
Genes Evaluated by Test 27 (17) 36 (10) 19 (7) 
 
Impact of Evaluated Genes 25 (16) 32 (9) 19 (7) 
 
Referenced In-House Research c 19 (12) 25 (7) 14 (5) 
 
Limitations of Test or Science 13 (8) 11 (3) 14 (5) 
 
Analytic or Clinical Validity c 11 (7) 18 (5) 6 (2) 
Lab Qualifications Specific Lab Approval or Certification  20 (13) 29 (8) 14 (5) 
 
Residency Requirement for Testing 13 (8) 29 (8) 0 (0) 
 
General Reference to Lab Quality d 13 (8) 18 (5) 8 (3) 
Test Interpretation Interpret Result In Larger Context e 25 (16) 18 (5) 31 (11) 
 
Test For Risk Not Certainty 22 (14) 32 (9) 14 (5) 
 
Relevance of Result to Family Members 8 (5) 4 (1) 11 (4) 
Medical Evaluation and  "See Your Physician…" Disclaimer 38 (24) 57 (16) 22 (8) 
Counseling Physician Involvement 36 (23) 39 (11) 33 (12) 
 
Nutritionist Involvement 14 (9) 21 (6) 8 (3) 
 
Other Provider Involvement 14 (9) 7 (2) 19 (7) 
 
Genetic Counselor Involvement 9 (6) 11 (3) 8 (3) 
 
Physician Consultation Required 11 (7) 0 (0) 19 (7) 
 
Genetic Counseling Required 3 (2) 0 (0) 6 (2) 
Privacy General Privacy Policy 69 (44) 75 (21) 64 (23) 
 
 Mentions Test Result Handling 44 (28) 54 (15) 36 (13) 
 
 Mentions Specimen Handling 33 (21) 50 (14) 19 (7) 
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a
 At-home testing defined here when a consumer received test results directly from the vendor with no explicit requirement for medical 
examination or consultation with a physician, genetic counselor, or other genetic expert, on or off staff, pre- or post-testing.  
b
 Includes 1 healthcare/wellness service provider and 4 organizations classified as “Other Promoters” providing direct links to 1 of the 23 
organizations offering at-home NG testing.  
c
 Referenced research and information regarding analytic/clinical validity in support of NG services. 
d
 Does not mention a specific certification or approval but makes more general reference to the quality of the lab (e.g., “state of the art”, “industry 
leader”, “reliable and responsible”). 
e
 Mentions the need to consider the impact of non-genetic factors (e.g., environment, stress, “harmful agents”) on disease risk when interpreting 
test results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
MANAGING GENOMIC OVERLOAD: A SURVEY OF GENETIC PROFESSIONALS ON 
WHAT CONSUMERS NEED TO KNOW ABOUT NUTRIGENOMIC SERVICES 
 
 
ABSTRACT  
 
Growth in the availability of nutrigenomic services and gaps in the oversight of genetic 
testing increases the potential for harm to consumers who may use nutrigenomic services without a 
full understanding of their benefits, risks, and limitations. To identify what genetic professionals think 
consumers should know about nutrigenomic services, an on-line expert opinion survey was 
disseminated March through August 2007. A convenience sample of 300 respondents rated the 
importance of 55 attributes, ranked the importance of ten topics, and proposed additional attributes in 
open-ended questions. The clinical validity and clinical utility of nutrigenomic tests were ranked as 
most important broad topics. Within broad topics few attributes were rated unimportant raising 
concerns about the potential for information overload. Attributes considered most important included 
any circumstances under which consumer information, test results, or specimens would be shared; the 
use and utility of recommended supplements or dietary changes; non-genetic factors impacting the 
occurrence of and accuracy in the prediction of tested health conditions; and laboratory compliance 
with regulatory standards. Promotional and educational materials for consumers and healthcare 
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providers should prominently present information regarding these issues. Companies promoting 
nutrigenomic services on-line line should manage information overload by increasing the visibility 
and accessibility of critical information.  
 
KEYWORDS 
Direct to consumer marketing, information overload, genetic testing, nutrigenomic testing, Internet, 
informed decision-making 
 
INTRODUCTION 
 
Genetic tests are growing in number and increasingly marketed and sold directly to 
consumers. Over 1200 health-related genetic tests are now available to the public, with almost 300 
additional tests under research (GeneTests 2008). The Department of Health and Human Services 
Secretary’s Advisory Committee for Genetics, Health, and Society (SACGHS) recently issued a 
report identifying 29 gaps in the oversight of genetic testing (SACGHS 2008). Of paramount concern 
was the lack of evidence to demonstrate the clinical validity (correct detection or prediction of disease 
or health condition) and clinical utility (effective use of test results in routine health care) of health-
related genetic tests. In addition, SACGHS (2008) highlighted several concerns about  
direct-to-consumer (DTC) marketing and sale of health-related genetic tests, some of which include 
inadequate federal resources for the pre-market review of genetic tests, insufficient monitoring and 
enforcement of fraud, and a lack of educational materials for consumers and health care providers 
about genetic testing and the use of test results.  
 
DTC Marketing and Sale of Nutrigenomic Services 
Among the various genetic tests marketed directly to consumers as providing health-related 
information, nutrigenomic tests and related services (here forward nutrigenomic services) have 
 83 
received substantial attention. While nutrigenomics (the study of how food affects gene expression) is 
a promising field of research (Lampe 2006, Kaput 2007), the commercialization of nutrigenomic 
services is considered highly premature. The field faces several methodological challenges (Elliot et 
al 2007, Martínez-González and Sudlow 2006, Kaput et al 2005, Mutch et al 2005) that contribute to 
inconsistent findings across gene association studies and complicate the development of interventions 
to improve individual health (Hirschorn et al 2002, Jansenns et al 2008).  
Nutrigenomic services include tests for variants in multiple genes associated with diet-related 
disease or other health conditions that have multiple causes (i.e., complex traits), such as heart 
disease, diabetes, and osteoporosis. Test results often include “genotype-customized” 
recommendations for supplement use or diet and lifestyle changes to reduce disease risk or improve 
overall health and wellness. Nutrigenomic services are increasing in accessibility (among those who 
can afford them) and visibility through the diversification of vendors. In a comprehensive search, 
Sterling (2008 in press) identified a wide variety of organizations selling and promoting the use of 
nutrigenomic services on-line, some of which included large medical centers, private practitioners, 
health spas, diagnostic testing centers, and drugstores.  
While less than one percent of participants reported using nutrigenomic services in a 
nationally-representative study (Goddard 2007), DTC marketing can have an effect on consumers 
beyond, and regardless of, a purchase. As noted by Schudson (1984), advertising has a direct impact 
on consumer opinions about and understanding of new products. Where there is increased uncertainty 
or confusion, advertising can play a stronger role in establishing meaning and significance (Pollay 
1986). The marketing of nutrigenomic services on-line may have a greater impact on consumer 
attitudes than other media (Coyle Thorson 2001) as the Web provides a “rich” product experience 
(Evans an dWurster 1999). Internet users frequent the Web to obtain health and genetics-related 
information (Taylor et al 2001, Bernhardt et al 2002, Case et al 2004, Fox 2005, Saukko et al 2007); 
and have reported using on-line information to make decisions about specific treatments, when to 
visit a doctor, and when to get a second opinion (Fox and Rainie 2000).  
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Informing Consumer Decisions about Nutrigenomic Services 
Consumer decisions about the purchase and use of nutrigenomic services will only be as good 
as the information available to inform their choices. The overwhelming amount of complex and novel 
information available about nutrigenomic and other genetic services may lead to “information 
overload,” whereby an individual receives more information than is useful to effective decision-
making. Information overload is more likely to occur when information is “uncertain, ambiguous, 
novel, complex, or intense” (Herbig and Karmer 1994). While researchers argue that the general 
public can be quite sophisticated in their thinking about genetics (Kerr et al 1998) and can process 
substantial amounts of information when making choices, consumer capacity to process information 
is not unlimited (Malhotra 1984, Elias and Annas 1994). Overloaded consumers are likely to ignore 
some information or employ heuristics to simplify their decision making. As such, two key challenges 
consumers are likely to face when gathering information about nutrigenomic services include, “the 
inability to locate what is relevant due to sheer volume and overlooking what is most critical among 
relevant data” (Herbig and Kramer 1994).   
Government agencies and professional societies have identified several issues consumers 
should be aware of when thinking about purchasing genetic services. For example, a consumer alert 
released by the US Federal Trade Commission noted that no DTC genetic tests have been reviewed 
by the FDA and discussed several important caveats to genetic testing as follows: 1) some genetic 
tests lack scientific validity, 2) genetic testing should be performed by specialized laboratories, 3) 
genetic test results are complex and require expert interpretation, and 4) genetic test results are 
meaningful only in the context of a complete medical evaluation (US FTC 2006). The American 
College of Medical Genetics (2008) noted the importance of consumers understanding that most DTC 
genetic tests do not provide definitive information about future disease, only “highly nuanced” 
information about disease risk. More specific to nutrigenomic services, the Minnesota Department of 
Public Health (Oehlke 2005) released a consumer fact sheet briefly outlining what is known about 
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diet-gene -disease relationships, the limitations of both nutrigenomic science and nutrigenomic tests, 
and the utility of family history in assessing disease risk. 
 
Purpose of this Study 
Nutrigenomic services are somewhat unique when compared to other health-related genetic 
services in that they claim to provide genotype-customized recommendations for the purchase and use 
of other health-related products to improve health. In June 2006, the US Government Accountability 
Office (GAO) investigated the legitimacy of claims made by four companies offering nutrigenomic 
services and found that recommendations “encourage[d] the purchase of supplements that [were] 
overpriced, [made] unproven medical claims, and may even be harmful” (US GAO 2006). The 
unproven validity and utility of nutrigenomic services and their increasing visibility and accessibility 
underscores the importance of identifying information critical to informed decision-making by 
consumers about their use.  
The purpose of this study is to identify what professionals with genetics-related work 
experience (here forward genetic professionals) think consumers should know when deciding whether 
or not to purchase nutrigenomic services. Through an expert opinion survey, respondents ranked 
broad topics and rated specific attributes pertaining to genetic services in general, and nutrigenomic 
services in particular. The survey also asked respondents to propose any additional attributes 
important to share with consumers. Genetic professionals were expected to vary somewhat in their 
responses given different emphases in their professional training, work experience in nutrigenomics, 
and opinions about the DTC marketing and sale of genetic tests.  
Findings from this study will confirm and build on existing knowledge about what consumers 
should know about nutrigenomic services. Researchers have highlighted the importance of 
developing educational resources about genetic services for consumers and health care providers 
alike, and findings from this study can help inform their development. Furthermore, as policy makers 
continue to address gaps in the oversight of genetic testing, findings from this study can inform the 
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development of regulatory requirements and guidelines for the labeling, branding, and marketing of 
nutrigenomic services. In the absence of regulatory requirements, nutrigenomic service providers can 
use findings from this study to improve the organization of information on websites and other media 
used to market, sell, and provide test results to consumers.  
 
MATERIALS AND METHODS 
 
Instrumentation 
A literature review was conducted to identify information that may be important to consumer 
decision-making about nutrigenomic services. A small group of interdisciplinary faculty assisted in 
reducing the initial list of attributes (92 to 64) and formatting survey questions. A Web-version of the 
survey was pilot-tested by four individuals using cognitive think-aloud pilot-testing (Sudman et al 
1996). Pilot-testing resulted in several revisions to the survey structure (i.e., transfer of information 
required for informed consent out of the survey and into recruitment e-mails, reduction of 
instructions, addition of background information, changes to question order and format, elimination 
of confusing attributes, addition of progress bars and other graphics), and survey language (i.e., terms 
used, phrasing of attributes, elimination of redundancies). {See Appendix 4 for complete survey.} 
The final survey began with  general instructions for survey completion and background 
information about the focus of the survey including: 1) a description of nutrigenomic services, 2) an 
introduction to a hypothetical consumer named “Robin” as the focus of the survey, and 3) a brief 
overview of the survey’s four sections (see Figure 4.1). In the first section, respondents were asked to 
rate the importance of 55 attributes of nutrigenomic services (listed in Table 4.2) on a seven-point 
Likert (with verbal anchors “Very Unimportant”, “Unimportant”, “Somewhat Unimportant”, 
“Somewhat Important”, “Important”, “Very Important”, and a “Don’t Know” option) in response to 
the question, “Do you think it is important for consumers like Robin to know any of the information 
below before buying the comprehensive nutrigenomic testing service?” Attributes were stated as 
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points of information (e.g., “If taking supplements can overcome genetic contributors to the health 
conditions the test focuses on”). Attributes unique to nutrigenomic services included findings from 
nutrigenomic research, the collection of health or lifestyle information during the testing process, the 
clinical utility of personalized recommendations provided with test results, and the purchase, use, and 
federal agency review of recommended supplements. 
 The second section of the survey included 11 attributes stated as declarative opinions (e.g., 
“Consumers must see a genetics professional regarding the interpretation and use of nutrigenomic test 
results, e.g., certified genetic counselor, medical geneticist”). Respondents were asked to rate their 
level of agreement with each of the 11 attributes on five-point Likert scale (with verbal anchors 
“Strongly Disagree”, “Disagree”, “Agree”, “Strongly Agree”, and a “Don’t Know” option) in 
response to the prompt and question, “Robin received the answers listed below in response to some of 
her questions about comprehensive nutrigenomic testing services. Do you agree with any of the 
answers Robin received?” (findings not presented here). {See dissertation Appendix 5 for summary 
of results.} 
In the third section, respondents were asked to rank the broad topics listed below by “clicking and 
dragging” each topic to their preferred position in the list with the first topic (position 1) being most 
important and the last topic (position 10) being least important.  
• Cost and purchase information for the nutrigenomic testing service  
• Clinical utility of nutrigenomic testing services in routine health care  
• Findings and quality of nutrigenomic research  
• General information about the health conditions the nutrigenomic test focuses on  
• Vendor and laboratory characteristics  
• Analytic validity of the nutrigenomic test (correct identification of the gene variants targeted 
by the test)  
• Social implications of using nutrigenomic testing services  
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• Supplement, diet, or lifestyle advice based on nutrigenomic test results  
• Nutrigenomic test procedures  
• Clinical validity of the nutrigenomic test (correct prediction of the health condition the test 
focuses on)  
This section also included two open-ended questions as follows: 1) “Is there any other information 
not mentioned in this survey that you feel is important for consumers like Robin to know?” and 2) “Is 
there anything about this survey, this topic, or your work in this area that you would like to share with 
us?”  
Demographic questions in the fourth and final section collected information on current 
profession, years in current profession, nutrigenomics-related work experience, type of organization 
currently employed, geographic region of current workplace, opinions about whether or not DTC sale 
and marketing of nutrigenomic services should be prohibited, highest formal degree obtained, sex, 
age, and race. Finally, respondents were asked if they were aware of the GAO report on nutrigenetic 
testing and its findings to see if opinions varied by knowledge of the report’s conclusion that 
nutrigenomic testing was useless and potentially harmful. 
 
Participants 
Convenience and snowball sampling were used to recruit a cross-section of professionals 
with genetics-related work experience. Of particular interest were biomedical and social science 
researchers, genetic counselors, physicians, nutritionists, policy and legal analysts, consumer 
advocates, and biotechnology representatives given the likelihood of their involvement in future 
policy debates about the commercial availability and use of nutrigenomic services and the regulation 
of DTC marketing. These groups also have a direct impact on the advancement of nutrigenomic 
research, the application of nutrigenomic information, and the delivery of nutrigenomic services.  
The CRISP (Computer Retrieval of Information on Scientific Projects, available at 
http://crisp.cit.nih.gov/) database of biomedical research was searched for projects funded between 
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2005 and 2007 using the following search terms: nutrigenomics, genetics, genomics, nutrition and 
genetics or genomics, genetic testing, genetic counseling, policy and genetics or genomics, and ELSI 
(Ethical, Legal and Social Implications of genetic research). The project title and the Principal 
Investigator (PI) name and e-mail address were extracted from all unique abstracts in search results. 
For the few abstracts missing email addresses, email addresses were searched for using PI names in 
Google™. The search resulted in a 708 person electronic mailing list (here forward CRISP email list). 
Three organizations agreed to disseminate an e-mail request for participation in the study via their 
professional listservs, including the National Society of Genetic Counseling (NSGC), the Genetic 
Alliance, and the American Dietetic Association Dietetic Practice Group in Nutrigenomics (ADA). 
Finally, the recruitment email asked recipients to forward information about the survey to colleagues 
who may be willing to participate. This request also appeared at the end of the survey. 
 
Dissemination 
The Web-based survey was created using Qualtrics survey software and disseminated in 
waves to avoid overburdening the website. Personalized links to the survey (URLs randomly 
generated by Qualtrics) were sent in recruitment emails to the CRISP email list March through May 
2007. A general link to the survey and listserv-specific logins (to assist in calculating response rates) 
were sent in recruitment emails to the NSGC, Genetic Alliance, and ADA listservs June through 
August 2007. Four to six weeks after sending recruitment emails, up to two reminder emails were 
sent. Pilot-testing for this survey, the final instrument, and the dissemination protocol were reviewed 
and approved by the University of North Carolina at Chapel Hill Institutional Review Board (UNC 
IRB #06-0229). 
 
Data Analysis 
Counts and percentages were used to describe survey respondents by demographic 
characteristics. Chi-square tests were used to identify significant differences in respondent 
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demographics by mode of recruitment (i.e., CRISP email list, 3 professional listservs). Response rates 
were difficult to calculate because the exact number of e-mail recipients receiving and reading 
requests for participation was unknown. The most conservative overall response rate would assume 
that all individuals sent an email received and read the request for participation. Conservative 
response rate for the CRISP email list was calculated by dividing the total number of PIs sent an 
email by the number of PIs who completed the survey. To calculate conservative response rates for 
the three professional listservs, the estimated size of each listserv at the time of survey dissemination 
was divided by the number of professionals from each listserv completing the survey.  
 Means and percentages were used to analyze importance ratings for the 55 attributes included 
in the survey. Mean calculations for each attribute excluded “Don’t Know” responses. When 
reporting percentages, several response categories were collapsed due to low numbers, including all 
three response categories on the unimportant end of the Likert scale, and two response categories on 
the important end of the Likert scale (i.e., “Important” and “Somewhat Important”). The collapsed 
Likert scale was treated as categorical and chi-square tests were used to identify significant 
differences in ratings by profession, years in current profession, nutrigenomics-related work 
experience, awareness of the GAO report, and opinions about the DTC sale and marketing of 
nutrigenomic services. 
Means were used to analyze importance rankings for each of the ten broad topics. Mean 
calculations included all rankings assigned to each topic. Topics with lower means were more 
important than topics with higher means as respondents placed the most important topic in position 1. 
Kruskal-Wallis one-way-analysis-of-variance-by-rank tests were used to test for significant 
differences in ranking by the aforementioned demographic variables. Chi-square and Krusal-Wallis 
tests for significant differences in ratings and rankings were conducted with an alpha of 0.05 (p-
value<0.05) using STATA Version 10.  
Open-ended comments were analyzed using content analysis. Comments were reviewed and 
identified attributes were coded for content and format (i.e., point of information or declarative 
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opinion) using an open-coding process. Identified attributes were grouped by the ten broad topics. 
Attributes that did not fall into one of the ten original topics were grouped into a new topic.  
 
RESULTS 
 
Of the 487 individuals who logged into the survey, 300 provided importance ratings for all 55 
attributes and completed the substantial majority of remaining questions. These 300 respondents 
established the analytical sample for this study.  
 
Respondent Demographics and Response Rates 
As described in Table 4.1, the majority of respondents were recruited through the ADA 
(104/300), CRISP (94/300), and Genetic Alliance (71/300) listservs. The conservative overall 
response rate for the CRISP listserv was 13% (94/708). Using the estimated size of the listserv at the 
time of distribution, conservative overall response rates for the ADA, Genetic Alliance, and NSGC 
were 26% (104/400) (note ADA listserv size was best estimate from new administrative staff post-
survey), 7% (71/969), and 2% (31/1395), respectively.  Respondents recruited through the Genetic 
Alliance and CRISP listservs had the greatest amount of professional diversity (χ2=487.77, p<0.001). 
Nutritionists or dieticians (32%, 96/300), researchers (29%, 87/300), genetic counselors 
(13%, 40/300), and health practitioners (10%, 31/300) comprised the majority of the analytical 
sample.  Policy-related professionals (5%, 15/300) and respondents working in other professions (8%, 
25/300) (e.g., teaching, health outreach and education, health technician, unreported) also completed 
the survey and were largely recruited through the Genetic Alliance listserv (86% of policy 
respondents, 72% of other profession respondents).  
Respondents were highly educated and professionally experienced. The vast majority had a 
masters (40%, 119/300) or doctoral level (40%, 121/300) degree, and had been working in their 
current profession for 20 years or more (42%, 125/300). Genetic counselors were more likely to have 
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less work experience in their current profession (χ2=52.39, p<0.001). The primary workplace of most 
respondents was a health care organization (40%, 119/300) and college or university (28%, 84/300), 
with far fewer respondents working in biotech companies or laboratories (3%, 9/300) and consumer 
advocacy groups (3%, 9/300). All regions of the US were well represented.   
Nutrigenomics-related work experience was limited, with 23% (68/300) reporting some or a 
lot of experience in the field. These respondents were more likely to be researchers (49%, 33/68) or 
nutritionists/dietitians (24%, 16/68). Awareness of the GAO report on nutrigenomic testing was 
limited, with only 10% (31/300) of respondents reporting that they were aware of the study and an 
additional 18% (55/300) reporting that they were aware of both the study and its key findings. Men 
(21%, 62/300) and racial/ethnic minorities (10%, 29/300) were underrepresented. 
 
Importance of Attributes and Topics  
Table 4.2 reports means and proportions for all 55 attributes listed in the survey by broad 
topic area. Among respondents who were certain about their views (i.e., did not select “Don’t 
Know”), 60% or more found all attributes important to some degree. As listed in Table 4.3, sixteen 
attributes were considered to be very important by 60% or more of respondents. Among these sixteen 
attributes, those rated very important by the highest proportion of respondents included: 1) 
circumstances under which personal contact information (82%), test results or analytical data (80%), 
and residual specimens (79%) would be shared with a third party; 2) the clinical (79%) and analytic 
(76%) validity of the test; and 3) circumstances under which any recommended supplements should 
not be taken.  
The percentage of total respondents reporting uncertainty about an attribute ranged from less 
than 1% (9 attributes) to 16% (1 attribute). The highest percentage of respondents expressed 
uncertainty about how important it is for a consumer to know if the vendor or lab analyzing the test is 
publicly traded (16%) or affiliated with an academic institution (8%); if there is a money back 
guarantee on the service (9%); biographical information about test developers (9%); and the risk of 
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employment discrimination when taking the test (8%). These attributes also had higher percentages of 
respondents rating them as unimportant (40%, 26%, 17%, 37%, and 11% respectively) (see Table 
4.4). 
Within broad topics, attributes ranged in importance. The widest range in mean ratings were 
found for attributes pertaining to vendor or lab characteristics (mean values 5.6 to 3.8), analytic 
validity (mean values 5.7 to 4.3), nutrigenomic research findings (mean values 5.4 to 4.2), and the 
social implications of testing (mean values 5.7 to 4.6). The relative importance of broad topics by 
mean rank (where 1 is most important and 10 is least important) were as follows: clinical validity 
(mean=2.4, 77% rank in top 3), clinical utility (mean=3.5, 57% rank in top 3), findings and quality of 
nutrigenomic research (mean=4.1, 43% rank in top 3), analytic validity (mean=4.2, 46% rank in top 
3), general information about health conditions assessed by the test (mean=5.1, 24% rank in top 3), 
cost and purchase information (mean=5.9, 19% rank in top 3), supplement, diet, or lifestyle advice 
provided with test results (mean=6.4, 11% rank in top 3), social implications of testing (mean=7.6, 
4% rank in top 3), testing procedures (mean=7.8, 7% rank in top 3), vendor or laboratory 
characteristics (mean=8.0, 1% rank in top 3).   
 
Differences in Importance by Demographic Characteristics  
Few significant differences were found in the rating of attributes, most of which occurred by 
professional group (13 attributes) and opinions about DTC sale (6 attributes) and marketing (4 
attributes). {See dissertation Appendix 6 for results from all chi-square tests.} In regard to attributes 
with the most substantial differences in rating, genetic counselors were less likely to rate risk for 
discrimination as very important to share with consumers (in employment χ2=47.36, p<0.001; in 
health insurance χ2=32.68, p<0.01) along with the admissibility of test results in a court of law 
(χ2=37.83, p<0.001). Nutritionists were more likely to rate these two attributes as very important, and 
researchers were more likely to rate them as unimportant. Genetic counselors and health practitioners 
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were more likely to consider researcher agreement on how nutrigenomic tests results could be used to 
improve health (χ2=32.61, p<0.01) and federal agency review of supplement utility (χ2=29.09, 
p<0.01) as very important. In contrast, nutritionists were four times more likely than all other groups 
to rate government review of supplements as unimportant to share with consumers.  
 Among the ten attributes with statistically significant differences by opinions, the most 
substantial differences occurred in attributes pertaining to federal agency review of supplements and 
the necessity of seeing a genetics professional or primary care physician regarding the use of test 
results. Respondents who did not agree that DTC sale or marketing should be prohibited were more 
likely than respondents who did agree to consider these attributes unimportant to share (no DTC sale: 
agency review of supplements χ2=19.37, p<0.05, need to see genetics professional  χ2=17.92, p<0.05, 
need to see physician χ2=17.00, p<0.05; no DTC marketing: agency review of supplements χ2=16.50, 
p<0.05). {See dissertation Appendix 6 for rating of attributes with significant differences by 
profession and opinion.} 
 In the ranking of topics, the most significant differences were found across profession (4 
topics) and opinions about the DTC sale (2 topics) or marketing (3 topics) of nutrigenomic services. 
{See dissertation Appendix 7 for results from Kruskal-Wallis tests.} The most substantial differences 
(i.e., one or more unit difference in rank) were found among professional groups. Nutritionists ranked 
the importance of sharing information about clinical utility lower (Kruskal-Wallis χ2=45.64, 
p<0.001), personalized recommendations higher (Kruskal-Wallis χ2=10.09, p<0.05), testing 
procedures higher (Kruskal-Wallis χ2=27.41, p<0.0001), and vendor or lab characteristics lower 
(Kruskal-Wallis χ2=14.14, p<0.01) than all other professional groups. In addition, respondents who 
approved of DTC marketing were less likely to rank sharing information about analytic validity 
higher (Kruskal-Wallis χ2=7.7, p<0.05) than respondents who disapproved or were uncertain about 
their view.  
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Other Attributes Considered Important to Share with Consumers  
Sixty-eight respondents (23%, 68/300) reiterated the importance of sharing with consumers 
many of the attributes included in the survey and proposed additional attributes in the open-ended 
comment box. A total of 120 attributes were mentioned. {See dissertation Appendix 8 for additional 
detail on respondent comments.} Attributes were expressed as points of information (e.g., 
qualifications of staff interpreting test results) and declarative opinions (e.g., primary care physicians 
often lack training to interpret test results).  
Respondents most frequently mentioned attributes regarding the findings and quality of 
nutrigenomic research (22/120) and the clinical validity and utility of nutrigenomic tests (18/120). 
Attributes under these two topics not listed in the survey included information about the design of 
nutrigenomic studies (5/22) and conflicts of interest in research (1/22); more precise measures of test 
validity, such as positive predictive value and sensitivity (1/18); variables used to determine the 
validity or utility of tests (2/18) such as race and lifestyle factors; and the extent to which genetic 
versus lifestyle information is used when analyzing a test (2/18). The utility of nutrigenomic tests 
versus the utility of genotype-customized supplements also was noted as important information 
(2/18). According to the opinion of one respondent, “early screening may lead to more effective 
treatment but use of nutraceuticals as preventative medicine is mostly placebo” (Respondent #19). 
(Note: The reference to “nutraceuticals” in the quote from Respondent #19 refers to genotype-
customized supplements.)  
Six respondents expressed concerns about the considerable uncertainty that remains regarding 
the relationships among diet, genes, and health and the potential for consumers to overestimate 
nutrigenomic test benefits.  The sale of nutrigenomic tests despite the lack of replicable findings was 
referred to as “intellectual vanity” (Respondent #45), and a “creative venture to try to apply new 
genetics knowledge” (Respondent #61). Nine respondents referred to nutrigenomic tests as lacking 
evidence, “worthless”, “overhyped”, “not mainstream medicine” and/or “a scam”. 
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Regarding the vendors of nutrigenomic services, respondents added the importance of 
knowing if any complaints have been filed against the company; or if the company or any of its staff 
are facing legal action or are under government review (5/16). Respondents also mentioned the 
importance of financial issues, including the for-profit motivations of companies selling nutrigenomic 
tests (5/16) and companies selling both tests and supplements (3/16). One respondent mentioned that 
consumers should know the names of companies with financial interests in the vendor (e.g., 
shareholders, investors, subsidiaries). Many of these concerns were reflected in one comment, stating 
“the possibility that financial gain may play a big role in the development of these tests without being 
able to provide adequate medical information is an issue, especially if these tests are accompanied by 
specific recommendations for supplements provided by a subsidiary of the laboratory” (Respondent 
#47).  
The presentation of test results and related information emerged as a new topic area with ten 
mentions. The use of the term “nutrigenomics” was considered problematic by several respondents 
(3/10), one of whom referred to the term as "an oxymoron [that] can thrive as a commercialized 
product appealing to consumers who want a quick fix because of our un-regulated privatized health 
‘system’” (Respondent #59). Interest in resources for unbiased information about nutrigenomics was 
noted as important to share with consumers (1/10), and two respondents mentioned that public 
knowledge about genetics was limited. Finally, two respondents addressed the presentation of test 
results, noting that consumers should know how test results would be presented (1/10) and that test 
results and other information should be presented using a lay-friendly language (1/10).  
Believing that consumers could be educated about issues raised in the survey, one respondent 
noted the “delicate balance between overwhelming a person with too much detailed, high level 
information vs. not giving enough for the consumer to make an informed choice” (Respondent #20). 
Ensuring consumer access to information was highlighted by another respondent who reiterated the 
potential for information overload and suggested that “much of the background data [about the test] 
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should be AVAILABLE to the subject, but not all of it needs to be delivered orally or discussed" 
(Respondent # 40 emphasis in original).  
 
DISCUSSION 
 
The purpose of this study was to identify what genetics professionals think consumers should 
know when deciding whether or not to purchase nutrigenomic services. The CRISP database and 
three professional listservs were used to recruit genetic professionals for participation in an on-line 
expert opinion survey. Three hundred survey respondents rated the importance of 55 attributes of 
nutrigenomic services, ranked ten broad topics pertaining to those attributes, and proposed additional 
attributes not mentioned in the survey.  
In addition to information pertaining to genetic services in general, survey respondents also 
found information pertaining to nutrigenomic services in particular important to share with 
consumers. Issues of greatest concern to the SACGHS about the DTC sale and marketing of health-
related genetic services were ranked as most important to share with consumers about nutrigenomic 
services, namely clinical validity and clinical utility. Only one significant difference by profession 
was found in the ranking of these two topics, suggesting a high level of agreement.  
Survey respondents found attributes unique to nutrigenomic services important to share with 
consumers, but not always more important than other attributes. Unlike other health-related genetic 
services, nutrigenomic services provide consumers with specific recommendations for the use of 
supplements and other dietary or lifestyle changes based on nutrigenomic test results. Some of the 
highest ratings were found for attributes regarding personalized recommendations including the 
health benefit, conditions for use, and federal agency review of recommended supplements or dietary 
changes. Respondents proposed additional attributes specific to nutrigenomic services in open-ended 
comments, including differences in the regulation of supplements versus prescription drugs, and 
differences in the cost of and effectiveness of “nutrigenomic supplements” compared to generic 
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supplements. However, when forced to rank the relative importance of broad topics, information 
about personalized recommendations was ranked lower than general information about the health 
conditions assessed by tests and information about the cost and purchase of tests.  
Although few attributes were rated unimportant, several attributes were considered more 
important to share with consumers than others. Variation in the importance of attributes highlights 
what specific information within broad topics should be prioritized for presentation to consumers. 
Attributes falling under the top three ranked topics (i.e., clinical validity, clinical utility, and findings 
and quality of nutrigenomic research), received higher than average ratings with a few exceptions. 
The name and function of specific gene variants targeted by nutrigenomic tests was considered less 
important to share with consumers as a measure of analytic validity, perhaps due to the complexity of 
this information (e.g., genetic nomenclature, role and function of pleiotropic genes that influence the 
expression of multiple traits). The comparative reliability of monogenic (single gene) and polygenic 
(multiple genes) tests was also rated relatively low, suggesting that knowing the reliability of the test 
to be taken alone is adequate. In addition, findings from laboratory-based research were considered 
less important for consumers to know than findings in the peer-reviewed literature. As suggested by 
open-ended comments, concerns about the drive for profits among biotechnology companies and 
laboratories offering nutrigenomic services may reduce the perceived legitimacy of industry research.  
Few significant differences were found by demographic groups in the importance of broad 
topics and attributes, suggesting a high level of agreement across survey respondents. Where 
identified, differences were most likely to occur across professional groups as anticipated. These 
differences were likely due to variation in professional training and practices. For example, 
professional groups differed in their views on the importance of sharing with consumers the potential 
for health insurance or employment discrimination. Genetic counselors were significantly and 
substantially more likely to downgrade the importance of sharing this information (i.e., from very 
important to important) when compared to other groups. Since genetic counselors tend to discuss with 
patients the implications of genetic tests for more severe conditions with higher penetrance (e.g., 
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Huntington’s disease, cystic fibrosis, Fragile X), they may perceive discrimination in the context of 
nutrigenomic testing as relative low and thereby less important to share. Of note, this survey was 
conducted prior to the recent passage of the Genetic Information Non-Discrimination Act (GINA), 
protecting consumers against health insurance discrimination based on genetic test results (Harmon 
2008).  
As a second example, nutritionists were significantly and substantially more likely to rate 
federal agency review of recommended supplements as unimportant. While acknowledging the need 
for increased oversight of supplements and functional foods (ADA 2004), nutritionists may be more 
likely than other groups to recommend the use of supplements and other complementary or 
alternative therapies to improve health given their emphasis on increasing nutrient intake. In addition, 
nutritionists were significantly more likely to rank personalized recommendations about supplements, 
diet and lifestyle as more important to share with consumers than other groups, further suggesting 
their heightened interest in consumer use of test results to improve health through nutrition.   
The sheer volume of information survey respondents considered important for consumers to 
know when making decisions about the use of nutrigenomic services raises concerns about 
information overload. Elias and Annas (1994) have proposed a “generic” informed consent process to 
manage overload among patients and to address the varying capabilities among health care providers 
to effectively explain the complexities and nuances associated with genetic screening (i.e., genetic 
testing for a particular condition for which there is no family history). When testing the utility of 
generic consent, Ormond and colleagues (2007) found participant preferences for information about 
genetic screening to vary based on disease risk, severity of condition tested, and other personal 
characteristics. While tailoring information to patient needs was considered important, Ormond and 
colleagues stressed the importance of a minimum amount of information being shared with all 
patients receiving genetic screening. Standardized information was considered especially important as 
patients may not have the same level of personal empowerment or skill to ask questions of interest, 
and may not always know what additional information is relevant to their situation.  
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The versatile, dynamic, interactive, and customizable nature of the Web increases its potential 
as tool to manage information overload. Websites can provide visual cues to consumers about what 
information is most important to consider. For example, the title of links on standing menu bars, the 
placement of content within the website, pop-up windows, and animated graphics increase user 
attention to specific content. In addition, websites can present critical information on a single 
webpage or post a document, similar to a product label, in a printer-ready format. Findings from this 
survey suggest that information about the validity and utility of nutrigenomic tests, the post-test 
handling and privacy of consumer information (i.e., contact information, health information, test 
results, specimens), conditions under which supplement recommendations should not be followed, 
and whether or not the laboratory analyzing the test is CLIA-approved (i.e., meets guidelines 
established by the Clinical Laboratory Improvement Act), must be easily accessible to consumers. 
Websites can also provide search and filtration tools to help consumers identify other information of 
interest.    
In the context of prescription drug use, Schommer, Doucette and Worley (2001) have 
suggested that follow-up communication between experts and consumers also is important for 
managing information overload. In their study, participants initially held favorable attitudes toward a 
large amount of detailed prescription drug information; however, the cognitive effort required to 
process the information often led to increased reports of frustration, confusion, doubtfulness, anger, 
and vulnerability. Although consumers may be comforted by the availability of information that 
reduces uncertainty in their decision-making, they also may face challenges over time as they work to 
process and apply the information they receive (Shommer Doucette Worley 2001). Furthermore, 
consumers have different belief systems about the causes of illness which can impact understanding 
of genetics (Parrot Silk Weiner et al 2004) and the significance of genetic test results. Through 
genetic counseling, or conversation with a professional that has adequate training in genetics, 
consumers can receive and process information of most relevance to them and improve their 
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understanding of genetic information and its utility. As such, websites should not be used as a 
substitute for consultation with a knowledgeable professional.  
Findings from this study suggest not only what information should be included on 
commercial websites for nutrigenomic services, but also what issues are important to address in 
training programs or educational materials for healthcare providers. Goddard and colleagues (2007) 
found study participants to report a health professional as a source of information about nutrigenomic 
services more often than any other source, including the Internet and other mass media. The 
American Society of Human Genetics highlighted the importance of provider education regarding the 
analytic and clinical validity of genetic tests in their statement regarding the DTC marketing of 
genetic tests (Hudson et al 2007). These and other issues rated as very important in this study should 
be address in educational efforts given the likelihood of patients asking their healthcare providers 
about nutrigenomic services.  
 
STRENGTHS AND LIMITATIONS  
 
As a health-related genetic service with a long history of DTC sale, nutrigenomic services are 
an important case study for understanding how to improve the marketing of genetic services. To the 
author’s knowledge, this is the first expert opinion survey providing information about how best to 
inform consumer decisions regarding about the purchase and use of nutrigenomic services. A multi-
phase process used to develop this survey, including extensive literature review, expert review, and 
cognitive pilot-testing. Invitation and two reminder emails were sent on multiple listservs to recruit a 
variety of professionals with genetics-related work experience. While lay consumers were not 
recruited for this survey given its focus on expert opinion, the Genetic Alliance is a large and 
influential organization among consumer advocates and members of its listserv comprised almost 
25% of the analytic sample.  
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The use of convenience and snowball sampling reduced the generalizability of findings to 
groups represented in the analytic sample and to other types of professionals. Generalizability was 
further reduced by low conservative response rates, due in part to the length of the survey (estimated 
30 minutes) and the lack of incentive for its completion. Possible reasons for survey non-response 
include: 1) failure to receive, notice, or review email request for participation due to a retired email 
address, technical problem, or frequency of incoming email; 2) lack of time to complete the 30 
minute survey; 3) lack of incentive (monetary or otherwise) for participation; 4) little to no interest in 
or knowledge about nutrigenomics; and 5) lack of support for or objection to the availability of 
nutrigenomic services. Among these five reasons, the last is most likely to contribute to any response 
bias in survey findings.  
Survey respondents who did not support the DTC marketing or sale of nutrigenomic services 
did show some statistically significant differences in their rating of individual attributes and ranking 
of broad topics. If those who did not support DTC marketing or sale were less likely to respond, then 
survey results may underestimate observed differences by opinions about DTC marketing and sale. 
Similarly, increased participation by professionals who were underrepresented among survey 
responders—healthcare providers, policy makers, industry representatives—may magnify existing 
differences by profession. Among these underrepresented professions, industry was least represented. 
Industry representatives are more than the other two groups to have: 1) a strong for-profit orientation, 
2) high levels of confidence in the information produced by nutrigenomic testing, and/or 3) high 
levels of support for consumer autonomy in the use of nutrigenomic services. If industry 
representatives do hold these views, then survey results may overestimate opinions associated with 
unsupportive views of DTC marketing and sale.  
Despite the low generalizability of survey findings, very few significant differences by any 
respondent characteristic were found among the most important attributes (i.e., attributes considered 
very important by 70% or more of the sample—one significant difference by profession) and broad 
topics (i.e., topics ranked within the top four—one significant difference by profession and one 
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significant difference by opinions of DTC marketing). This high level of agreement among a variety 
of professionals indicates strong support for the importance of select items. Survey findings have 
practical applications to the development of guidelines or regulations regarding the content of 
commercial websites, other promotional materials, and educational materials for both consumers and 
health professionals. 
 
CONCLUSIONS 
 
Genomic innovation has proved challenging for policy makers working to establish 
regulations to improve consumer health and safety in the proliferation of genetic services. SACGHS 
recently declared DTC genetic services a top priority given the level of expert and public interest in 
the topic (Jones 2008). As federal agencies work to improve oversight, the states of New York and 
California have sent letters to 13 companies offering DTC genetic services prohibiting their sale to 
state residents without the involvement of a clinician (Pollack 2008). Despite restrictions on DTC 
sale, companies are likely to increase DTC marketing for genetic services with few regulatory 
guidelines about the content of promotional materials. To date, genetic services are largely marketed 
on-line. In addition, consumers often are able to access test results through company websites 
providing a second opportunity for informing consumer decisions (Sterling 2008 in press).  
Findings from this study suggest that commercial websites and other informational materials 
(e.g., brochures, package inserts, labels) for nutrigenomic services must provide information about 
evidence used to support claims regarding the validity and utility of nutrigenomic tests, the use and 
utility of recommended supplements, efforts to protect consumer privacy, and the qualification of 
laboratories analyzing collected specimens. Not only should this information be available, but it must 
be presented in a format that is accessible for both consumers and providers alike who may have 
limited knowledge about nutrigenomics. Finally, as nutrigenomic researchers work diligently toward 
realizing their goal of personalized nutrition, maintaining public trust and confidence in genetic 
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services will require companies to acknowledge and ensure consumer awareness of the evolving 
nature of genomic research and changes in widely held opinions about the benefits, risks and 
limitations of genetic information. 
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Figure 4.1. Background information appearing at start of on-line opinion survey titled, What 
Consumers Need to Know about the On-Line Purchase and Use of Nutrigenomic Services, 
implemented March through August 2007 
 
 
Nutrigenomic Testing Services: A Quick Review 
 
Nutrigenomic or nutrigenetic testing services include genetic tests marketed to identify variants 
in several genes that are associated with diet-related, chronic health conditions that can have 
multiple causes. 
 
Nutrigenomic testing services also include supplement, diet, or other lifestyle advice based on 
individual nutrigenomic test results. 
 
Consumers searching the Internet for information about health, diet, nutrition, or genetics may 
come across a website promoting or selling nutrigenomic testing services. What consumers 
learn when reading one of these websites may be different from what experts think consumers 
need to know. 
 
As you think about what consumers need to know and complete this survey, we would like you 
to keep in mind consumers like "Robin". 
 
Consumers Like Robin: The Focus of Our Survey 
 
Robin is a relatively healthy consumer and a layperson with no formal training in genetics or 
healthcare. Robin has read about nutrigenomic testing services in several newspapers and 
magazines. 
 
Robin wants to buy a comprehensive nutrigenomic test that will identify gene variants 
associated with heart health, bone health, immune system health, and insulin resistance. Robin 
has several questions about: 
 
• how the test works, 
• the health conditions the test focuses on, and 
• supplement or lifestyle advice that may be provided with test results. 
 
Robin also wonders if there are things she hasn’t thought of that are important to know. 
 
Survey Overview 
 
When completing this survey please keep in mind consumers like Robin. Survey questions will 
begin on the next page. This survey has four parts as listed below. 
 
Part 1. What do you think consumers like Robin need to know? 
Part 2. Do you agree with the information Robin received? 
Part 3. Important topics to address with consumers like Robin 
Part 4. Your professional and personal background 
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Table 4.1. Survey respondent demographic characteristics by recruitment, March through 
August 2007 (N=300) 
 
Respondents by Recruitment (%) 
 total 100%  
Demographic 
Characteristics 
Total 
Reporting 
Respondents a 
N (%) 
CRISP 
Search 
Genetic 
Alliance ADA NSGC 
Difference by 
Recruitment 
χ2 Stat (p-value)b 
Profession During 
Majority of Week 
     
487.77 (0.000) 
 
Nutritionist/Dietician 96 (32.0) 7.3 0.0 92.7 0.0 
 
Researcher 87 (29.0) 81.6 11.5 4.6 2.3 
 
Genetic Counselor 40 (13.3) 5.0 30.0 0.0 65.0 
 
Health Practitioner 31 (10.3) 35.5 54.8 3.2 6.5 
 
Policy/Advocate/ 
Ethicist 15 (5.0) 6.7 86.7 6.7 0.0 
 
Other Profession 25 (8.3) 4.0 72.0 24.0 0.0 
Years in Current 
Profession 52.38 (0.000) 
 
4 years or less 51 (17.0) 5.9 31.4 31.4 31.4 
 
5-9 years 44 (14.7) 25.0 29.6 34.1 11.4 
 
10-14 years 42 (14.0) 38.1 21.4 31.0 9.5 
 
15-19 years 31 (10.3) 48.4 16.1 32.3 3.2 
 
20 years or more 125 (41.7) 37.6 21.6 37.6 3.2 
Work Experience in 
Nutrigenomics 10.33 (0.035) 
 
No Experience 222 (74.0) 27.5 24.8 36.5 11.3 
 
Some - A lot of 
Experience 68 (22.7) 47.1 17.7 27.9 7.4 
Current Workplace 134.03 (0.000) 
 
Health Care 
Organization 119 (39.7) 18.5 16.0 47.9 17.7 
 
University or College 84 (28.0) 67.9 15.5 10.7 6.0 
 
Other Organization  44 (14.7) 13.6 29.6 52.3 4.6 
 
Government (federal, 
state, local) 25 (8.3) 24.0 32.0 40.0 4.0 
 
Biotech or Laboratory  9 (3.0) 11.1 77.8 0.0 11.1 
 
Consumer Advocacy 
Group 9 (3.0) 0.0 100.0 0.0 0.0 
 
Professional 
Organization 4 (1.3) 25.0 25.0 50.0 0.0 
Region of Current 
Workplace 19.69 (0.478) 
 
South 92 (30.7) 42.4 19.6 29.4 8.7 
 
Northeast 65 (21.7) 27.7 26.2 36.9 9.2 
 
West 53 (17.7) 22.6 22.6 43.4 11.3 
 
Midwest 47 (15.7) 34.0 21.3 34.0 10.6 
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Respondents by Recruitment (%) 
 total 100%  
Demographic 
Characteristics 
Total 
Reporting 
Respondents a 
N (%) 
CRISP 
Search 
Genetic 
Alliance ADA NSGC 
Difference by 
Recruitment 
χ2 Stat (p-value)b 
 
US Territory 1 (0.3) 0.0 100.0 0.0 0.0 
 
Outside US 6 (2.0) 16.7 66.7 16.7 0.0 
Awareness of GAO 
Report 8.71 (0.190) 
 
Aware Study and Key 
Findings 31 (10.3) 29.0 35.5 16.1 19.4 
 
Aware of Study 55 (18.3) 30.9 20.0 38.2 10.9 
 
Not aware of study or 
findings 204 (68.0) 32.4 22.6 36.3 8.8 
Opinions about DTC 
Marketing 6.05 (0.417) 
 
Should be Prohibited 113 (37.7) 33.6 20.4 32.7 13.3 
 
Should not be 
Prohibited 84 (28.0) 25.0 23.8 42.9 8.3 
 
Don’t Know 89 (29.7) 36.0 24.7 30.3 9.0 
Opinions about DTC Sale 11.73 (.068) 
 
Should be Prohibited 131 (43.7) 36.6 22.1 27.5 13.7 
 
Should not be 
Prohibited 71 (23.7) 29.6 16.9 45.1 8.5 
 
Don’t Know 86 (28.7) 26.7 30.2 36.1 7.0 
Highest Formal Degree 
Attained 178.44 (0.000) 
 
Bachelor 36 (12.0) 2.8 22.2 75.0 0.0 
 
Master 119 (39.7) 6.7 26.1 44.5 22.7 
 
Doctorate 121 (40.3) 68.6 19.8 9.9 1.7 
 
Other 17 (5.7) 0.1 0.4 0.5 0.1 
Sex 47.16 (0.000) 
 
Female 225 (75.0) 23.1 21.8 42.2 12.9 
 
Male 62 (20.7) 62.9 27.4 8.1 1.6 
Years of Age 56.32 (0.000) 
 
Less than 30 34 (11.3) 8.8 20.6 35.3 35.3 
 
30-39 45 (15.0) 22.2 22.2 33.3 22.2 
 
40-49 72 (24.0) 45.8 16.7 33.3 4.2 
 
50-59 108 (36.0) 33.3 25.0 38.0 3.7 
 
60-69 29 (9.7) 31.0 37.9 27.6 3.5 
 
70 and Older 1 (0.3) 100.0 0.0 0.0 0.0 
Racial/Ethnic Minority 2.08 (0.721) 
 
No 257 (85.7) 30.7 23.0 35.8 10.5 
 
Yes 29 (9.7) 41.4 24.1 24.1 10.3 
Response Rate 
 
94/708c 71/969 d  104/400 d  31/1395 d    
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a
 Percentages do not add to 100% due to missing values 
b
 Chi-square tests exclude observations with missing values in characteristic 
c
 Denominator equals number of experts sent personalized request for participation. Numerator includes 13 
respondents recruited via snowball sampling. 
d
 Denominator equals approximate number of members on listserv used to distribute broad request for 
participation. ADA listserv size is best estimate provided by new administrative staff post survey distribution. 
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Table 4.2. Respondent rating of nutrigenomic service attributes for consumer decision-making  
by broad topic, March through August 2007 (N=300) 
 
  
 Distribution of Respondents by Rating  
% (N) 
 
 
Certain b   
 total 100%  Uncertain 
c
 
Broad Topic 
Attribute Mean (SD)
a
 
Very 
Important Important 
Not 
Important 
Don't 
Know 
Social Implications 
If there are any circumstances under which 
personal contact information would be shared 
with a 3rd party. 5.7 (0.77) 82 (246) 16 (47) 2 (6) 0 (1) 
If there are any circumstances under which test 
results, other analytical data, or collected health 
information would be shared with a 3rd party. 5.7 (0.83) 80 (238) 17 (49) 3 (9) 1 (4) 
If there are any circumstances under which 
residual specimens would be shared with a 3rd 
party. 5.7 (0.80) 79 (233) 19 (55) 2 (7) 2 (5) 
If any specific efforts are made to ensure 
consumer privacy and confidentiality.d 5.6 (0.83) 71 (213) 25 (76) 3 (10) 0 (1) 
What is done with test results, other analytical 
data, or collected health information after testing. 5.4 (0.94) 65 (190) 31 (90) 4 (13) 2 (7) 
What is done with residual specimens after 
testing.  5.3 (1.00) 54 (158) 40 (119) 6 (17) 2 (6) 
If test results are admissible in a court of law.d 5.2 (1.19) 57 (158) 34 (94) 9 (26) 7 (22) 
The risk of health insurance discrimination.d 5.1 (1.20) 47 (133) 43 (122) 10 (27) 6 (18) 
The risk of employment discrimination.d 5.0 (1.25) 48 (133) 41 (113) 11 (31) 8 (23) 
If test results provide any information about the 
health of the test taker’s family members. 4.9 (0.98) 31 (91) 62 (183) 7 (20) 2 (6) 
How often test takers experience anxiety post 
testing. 4.6 (1.12) 23 (63) 64 (179) 13 (36) 7 (22) 
Personalized Recommendations       
If there are any conditions under which 
recommended supplements should not be taken. 5.7 (0.76) 76 (227) 22 (67) 2 (5) 0 (1) 
If supplement use can help cure, manage, or 
prevent the health conditions on which the test is 
focused. 5.6 (0.81) 68 (201) 30 (88) 2 (5) 2 (6) 
If dietary changes can overcome genetic 
contributors to the health conditions the test 
focuses on. 5.6 (0.74) 68 (203) 31 (92) 1 (4) 0 (1) 
Physiological changes that will occur as a result 
of supplement use. 5.4 (0.88) 60 (175) 38 (112) 2 (7) 2 (6) 
If taking supplements can overcome genetic 
contributors to the health conditions the test 
focuses on.d 5.3 (0.96) 55 (160) 41 (121) 4 (11) 3 (8) 
If there are any differences between advice 
provided with test results and advice provided in 
current dietary guidelines issued by the USDA. 5.2 (1.04) 53 (155) 43 (125) 4 (13) 2 (7) 
If the FDA or FTC has reviewed the utility of 
supplements recommended to the consumer.d e 5.2 (1.04) 51 (150) 42 (122) 7 (21) 2 (7)d  
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 Distribution of Respondents by Rating  
% (N) 
 
 
Certain b   
 total 100%  Uncertain 
c
 
Broad Topic 
Attribute Mean (SD)
a
 
Very 
Important Important 
Not 
Important 
Don't 
Know 
Analytic Validity 
  
How often the test correctly identifies the 
targeted gene variants. 5.7 (0.74) 76 (227) 22 (66) 2 (5) 1 (2) 
If there are any differences between the 
reliability of tests for variants in a single gene 
and the reliability of tests for variants in multiple 
genes. 5.1 (0.93) 41 (117) 54 (152) 4 (12) 6 (19) 
The name and function of the specific gene 
variants targeted by the test.e 4.3 (1.14) 16 (47) 63 (183) 20 (59) 4 (11) 
Clinical Validity 
How often the test correctly predicts the health 
conditions the test focuses on. 5.7 (0.81) 79 (237) 19 (57) 2 (6) 0 (0) 
Non-genetic factors that can affect the 
development of the health conditions the test 
focuses on. 5.5 (0.80) 60 (179) 38 (115) 2 (5) 0 (1) 
If the test will detect health conditions currently 
affecting the test taker (i.e., existing health 
condition).d 5.3 (0.96) 55 (162) 41 (121) 3 (10) 2 (7) 
Clinical Utility 
To what extent test results can be used to treat or 
prevent the health conditions the test focuses on. 5.6 (0.82) 68 (202) 31 (92) 2 (5) 0 (1) 
If there are specific populations for whom the 
test is more appropriate. 5.0 (0.96) 36 (105) 59 (174) 5 (15) 2 (6) 
Vendor or Lab Characteristics 
If the lab analyzing the test meets government 
standards (e.g., Clinical Laboratory Improvement 
Act). 5.6 (0.79) 69 (205) 29 (86) 2 (6) 1 (3) 
If the lab analyzing the test is certified by 
professional organizations (e.g., American 
Association of Blood Banks, the College of 
American Pathologists). 5.3 (0.94) 56 (163) 40 (117) 4 (12) 3 (8) 
Complete contact info for the vendor and lab, 
including a phone number and physical street 
address. 5.1 (0.98) 45 (132) 51 (148) 4 (12) 3 (8) 
If the vendor or lab is affiliated with an academic 
institution.e 4.2 (1.27) 17 (46) 57 (156) 26 (73) 8 (25) 
If the vendor or lab is publicly traded.e 
3.8 (1.39) 13 (34) 46 (116) 40 
(102
) 16 (48) 
Biographical sketch of vendor or lab staff 
involved in the research, development, or 
analysis of the test. 3.8 (1.32) 11 (31) 51 (140) 37 
(101
) 9 (28) 
Findings and Quality of Nutrigenomic 
Research 
If researchers agree on how test results can be 
used to improve individual health.d 5.4 (1.13) 63 (188) 31 (91) 6 (19) 1 (2) 
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 Distribution of Respondents by Rating  
% (N) 
 
 
Certain b   
 total 100%  Uncertain 
c
 
Broad Topic 
Attribute Mean (SD)
a
 
Very 
Important Important 
Not 
Important 
Don't 
Know 
If any studies in the peer reviewed literature find 
supplements recommended to the consumer to be 
clinically useful. 5.4 (0.93) 55 (162) 41 (120) 4 (11) 2 (7) 
If any studies in the peer reviewed literature find 
the test to be valid or useful.e 5.3 (0.99) 58 (171) 37 (111) 5 (14) 1 (4) 
The definition of nutrigenomics.d 4.8 (1.35) 39 (117) 48 (143) 13 (40) 0 (0) 
If any studies conducted by the vendor or lab 
find the test to be valid or useful. 4.2 (1.41) 21 (62) 53 (155) 26 (78) 2 (5) 
If any studies conducted by the vendor or lab 
find supplements recommended to the consumer 
to be clinically useful. 4.2 (1.39) 20 (58) 53 (154) 27 (78) 3 (10) 
Test Procedures 
If genetic counseling or physician consultation is 
required to take the test. 5.4 (0.91) 55 (161) 41 (120) 4 (12) 2 (7) 
If health services, referrals, or other health-
related resources are included with testing 
services. 5.3 (0.86) 49 (143) 48 (142) 3 (9) 2 (6) 
When the consumer will receive test results.d 5.2 (0.86) 42 (125) 56 (165) 2 (6) 1 (4) 
If it is necessary to see a genetics professional 
regarding the interpretation and use of test 
results.e 5.2 (1.08) 49 (139) 44 (126) 7 (20) 5 (15) 
If personal health or lifestyle information is 
collected. 5.2 (0.89) 40 (117) 57 (167) 3 (10) 2 (6) 
The type of specimen that is analyzed for the 
test. 5.1 (0.92) 40 (121) 56 (167) 4 (12) 0 (0) 
How the specimen will be collected (e.g., 
location, technology, persons involved).d e 5.1 (0.85) 37 (109) 60 (178) 4 (11) 1 (2) 
If it is necessary to see a primary care physician 
regarding the interpretation and use of test 
results.e 4.7 (1.18) 29 (82) 58 (163) 12 (35) 7 (20) 
Cost and Purchase Information 
If there are any additional financial costs 
associated with taking the test given a positive or 
negative test result. 5.3 (0.90) 49 (143) 47 (138) 4 (12) 2 (7) 
If Medicare, Medicaid, or other insurance will 
cover the cost of the testing service.d 5.1 (1.03) 41 (120) 53 (156) 6 (18) 2 (6) 
If more than one vendor offers recommended 
supplements. 4.8 (1.07) 30 (89) 61 (178) 8 (24) 3 (9) 
If there is a money back guarantee when a 
consumer is not satisfied with the services or 
information received. 4.5 (1.30) 25 (68) 57 (158) 17 (46) 9 (28) 
If more than one laboratory offers the test.d 4.3 (1.14) 14 (39) 66 (185) 19 (54) 7 (22) 
General Info about Health Conditions Test 
Focuses On 
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 Distribution of Respondents by Rating  
% (N) 
 
 
Certain b   
 total 100%  Uncertain 
c
 
Broad Topic 
Attribute Mean (SD)
a
 
Very 
Important Important 
Not 
Important 
Don't 
Know 
Personal characteristics of individuals who are at 
greatest risk for developing the health conditions 
the test focuses on. 5.0 (1.12) 38 (110) 56 (163) 7 (20) 2 (7) 
If there are any health conditions that are not 
focus of the test but are associated with the gene 
variants targeted by the test. 5.0 (1.01) 35 (100) 58 (167) 7 (19) 5 (14) 
General info about the symptoms of the health 
conditions the test focuses on. 4.8 (1.00) 25 (73) 67 (198) 8 (25) 1 (4) 
The prevalence of the health conditions test 
focuses on. 4.8 (0.96) 23 (67) 70 (209) 7 (21) 1 (3) 
 
a
 Mean calculations based on rescaled Likert scale that excludes survey 4=Don't Know category as follows: 
1=Very Unimportant, 2=Unimportant, 3=Somewhat Unimportant, 4=Somewhat Important, 5=Important, 
6=Very Important. 
b
 Percentage of sample with definitive response on item. Important column includes Likert scale categories 
4=Somewhat Important and 5=Important. Unimportant column includes Likert scale categories 1=Very 
Unimportant, 2=Unimportant, and 3=Somewhat Unimportant. 
c
 Percentage of total sample 
d Statistically significant differences in attribute rating by profession using Chi-square tests, 0.05>p>0 {See 
dissertation Appendix 6 for results of chi-square tests.} 
e
 Statistically significant differences in attribute rating by opinions about DTC sale or marketing using Chi-
Square tests, 0.05>p>0.001 {See dissertation Appendix 6 for results of chi-square tests.} 
 
 
  116 
Table 4.3. Attributes rated “Very Important” for consumers to know about nutrigenomic 
services by the majority of survey respondents, March through August 2007 (N=300)   
 
 Topic 
 Attributes 
Percent of 
Respondents (%) 
 Social Implications  
 
 
If there are any circumstances under which personal contact info would be 
shared with a 3rd party.  82 
 
 
If there are any circumstances under which test results, other analytical data, or 
collected health information would be shared with a 3rd party. 80 
 
 
If there are any circumstances under which residual specimens would be 
shared with a 3rd party. 79 
  If any specific efforts are made to ensure consumer privacy and confidentiality. 71 
 
 
What is done with test results, other analytical data, or collected health 
information after test results are provided to the consumer. 65 
 Clinical Validity 
  How often the test correctly predicts the health conditions the test focuses on. 79 
 
 
Non-genetic factors that can affect the development of the health conditions 
the test focuses on. 60 
 Personalized Recommendations  
 
 
If there are any conditions under which recommended supplements should not 
be taken.  76 
 
 
If dietary changes can overcome genetic contributors to the health conditions 
the test focuses on. 68 
 
 
If supplement use can help cure, manage, or prevent the health conditions on 
which the test is focused. 68 
  Physiological changes that will occur as a result of supplement use. 60 
 Analytic Validity 
  How often the test correctly identifies the targeted gene variants. 76 
 Vendor or Lab Characteristics  
 
 
If the lab analyzing the test meets government standards (e.g., Clinical 
Laboratory Improvement Act). 69 
 Clinical Utility 
 
 
To what extent test results can be used to treat or prevent the health conditions 
the test focuses on. 68 
 Findings and Quality of Nutrigenomic Research  
  If researchers agree on how test results can be used to improve health. 63 
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Table 4.4. Attributes rated “Unimportant” for consumers to know about nutrigenomic services 
by more than 10% of survey respondents, March through August 2007   
 
Topic 
Attributes 
Percent of 
Respondents (%) 
Social Implications  
  The risk of health insurance discrimination when taking the test. 10 
  The risk of employment discrimination when taking the test. 11 
  How often test takers experience anxiety after receiving test results. 13 
Test Procedures  
 
 
If it is necessary to see a primary care physician regarding the interpretation 
and use of test results. 12 
Findings and Quality of Nutrigenomic Research  
  The definition of nutrigenomics. 13 
 
 
If any studies conducted by the vendor or laboratory find the test to be valid or 
useful. 26 
 
 
If any studies conducted by the vendor or lab find recommended supplements 
to be clinically useful. 27 
Cost and Purchase Information  
 
 
If there is a money back guarantee when a consumer is not satisfied with the 
services or info received. 17 
  If more than one lab offers the test  19 
Analytic Validity 
  The name and function of the specific gene variants targeted by the test. 20 
Vendor Characteristics  
  If the vendor or lab analyzing the test is affiliated with an academic institution. 26 
 
 
Biographical sketch of vendor or lab staff involved in the research, 
development, or analysis of the test. 37 
  If the vendor or laboratory analyzing the test is publicly traded. 40 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
THE CLASSIFICATION AND LABELING OF GENETIC SERVICES BY THE US FDA: 
APPLYING DRAFT RECOMMENDATIONS FOR IN VITRO DIAGNOSTIC 
MULTIVARIATE INDEX ASSAYS TO NUTRIGENOMIC SERVICES 
 
ABSTRACT  
 
New inputs in the development of genetic services prompted the US Food and Drug 
Administration (FDA) to reconsider its regulatory approach. In 2007, the FDA published 
recommendations for classifying and labeling genetic services. In this study, websites hosted by 25 
companies were reviewed to assess the adequacy of FDA recommendations for nutrigenomic 
services. Three companies described services recommended for FDA review. Companies rarely 
presented information about immediate and long-term risks associated with genetic testing. FDA 
recommendations could be improved by clarifying the warning information that should appear in 
labels and addressing unique aspects of nutrigenomic services, including the provision of nutritional 
supplements that may be offered by multiple intermediaries. 
 
KEYWORDS 
Direct-to-consumer marketing, nutrigenomics, Food and Drug Administration, policy, genetic testing 
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INTRODUCTION 
 
Genetic services providing health-related information are increasingly marketed directly to 
consumers (Offit 2008). Nutrigenomic services have a relatively long history of direct-to-consumer 
(DTC) sale, beginning early 2000. Nutrigenomic services include genomic (multiple genes) tests for 
diet-related disease or conditions that can have multiple causes (e.g., diabetes, osteoporosis, heart 
disease). Nutrigenomic tests also focus on more nebulous health-related traits, such as detoxification, 
aging, or athleticism. Companies produce a test report indicating whether or not the consumer has 
specific variants in profiled genes that are associated with a genetic predisposition. In addition to this 
genotype information, some companies also provide “genotype-customized” recommendations to 
reduce disease risk or improve overall health and wellbeing. Recommendations may include changes 
to diet or lifestyle, use of dietary supplements with specific formulations, or suggestions to obtain 
additional testing and follow-up from a doctor. Many companies offering nutrigenomic services 
support their claims by findings from nutrigenomic research. 
Nutrigenomic research examines relationships among genes, diet, and health. Specifically, 
nutrigenomics is “the study of how foods affect the expression of genetic information in an individual 
and how an individual's genetic makeup affects metabolism and response to nutrients and other 
bioactive components in food” (Kaput et al 2005). While nutrigenomics is a promising field of 
research (Lampe 2006, Kaput 2007), the commercialization of nutrigenomic services is considered 
highly premature (Haga et al 2003). The field faces several methodological challenges (Elliot et al 
2007, Kaput et al 2005, Martinez-Gonzalez and Sudlow 2006, Mutch et al 2005) that contribute to 
inconsistent findings across gene-disease association studies and complicate the development of 
interventions to improve individual health (Hirschhorn et al 2002, Janssens et al 2008). Furthermore, 
inadequate oversight of health-related genetic services raises concerns about the potential for harm to 
consumers. This study conducts a content analysis of websites promoting nutrigenomic services to 
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evaluate the adequacy of recommendations recently drafted by the US Food and Drug Administration 
(FDA) for improving oversight of nutrigenomic services. 
 
Direct-To-Consumer Genetic Services 
Numerous concerns have been raised about the delivery of health-related genetic services in 
the US, particularly those services sold directly to consumers. The Department of Health and Human 
Services’ Secretary’s Advisory Committee for Genetics Health and Society (SACGHS 2008) 
identified 29 gaps in the oversight of genetic services, highlighting as a major concern the lack 
evidence to demonstrate the clinical validity (correct detection or prediction of disease or health 
condition) and clinical utility (effective use of test results in routine health care) of direct-to-consumer 
(DTC) genetic services. The DTC sale of unvalidated genetic services in a marketplace with few 
regulations increases the potential for harm to consumers. These harms include economic loss from 
the purchase of uninformative tests and unnecessary healthcare services or products. Consumers may 
experience harm if adverse health outcomes result from healthcare decisions guided by unvalidated 
tests. For example, a consumer may receive a NG test result indicating that they do not have gene 
variants associated with increased risk of heart disease. Receiving this information in the absence of 
clinical consultation, the consumer may decide to forgo preventive health screenings despite a family 
history of the disease. Finally, inaccurate, misleading, or fraudulent DTC promotional materials for 
genetic services may also lead to unwarranted anxiety about future health, a decreased understanding 
of genetics, and decreased public trust in genetics and genomics.  
 
FDA Regulation of Genetic Services 
The majority of genetic services are sold as laboratory services or laboratory-developed tests 
(LDT), whereby the laboratory uses an in-house, often proprietary, protocol to analyze specimens and 
report genotype results. According to the Food, Drug, and Cosmetic Act (2004), LDTs are medical 
 121 
devices that require scientific review and pre-market approval by the US Food and Drug 
Administration (FDA). Medical devices are defined as:  
 
“an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or 
other similar related article, including any component, part, or accessory which is… intended 
for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or 
prevention of disease, in man or other animals…” 
 
Prior to 2006, the FDA required scientific review and pre-market (prior to commercial 
availability) approval of LDTs on a discretionary basis because test components included materials 
and equipment that were already regulated by the FDA (e.g. analyte specific reagents or ASRs, 
general purpose reagents and laboratory equipment). Furthermore, tests were performed by 
specialized laboratories whose competence in the use of these test components had been demonstrated 
through their certification by the Clinical Laboratory Improvement Amendments (CLIA) (FDA 
2007). However, innovation in genomic testing has led to the use of test components that have not 
been regulated previously (e.g., technologies for genotypic analysis, software and algorithms for 
determination of risk), rendering discretionary review and approval of LDTs no longer adequate 
(FDA 2007).   
In efforts to improve oversight of health-related genetic services, the FDA released non-
binding (not legally enforceable) draft recommendations in September 2006 clarifying the types of 
genetic services requiring pre-market review and post-market surveillance. In addition, the FDA sent 
letters to 15 companies each requesting a meeting to discuss the lack of pre-market review for their 
genetic services (Javitt 2007). Following a period of public comment (FDA 2006), the draft guidance 
was updated in July 2007 (FDA 2007). 
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Classification as In Vitro Diagnostic Multivariate Index Assays (IVDMIA) 
With release of the draft guidance, the FDA expressed its intent to regulate health-related 
genetic services as medical devices and, more specifically, as In Vitro Diagnostic Multivariate Index 
Assays (IVDMIAs) in need of pre-market review and subject to specific labeling requirements. 
IVDMIAs were defined as appears on the top of the next page. The FDA also noted that “the 
IVDMIA device includes all elements necessary for obtaining the result” (FDA 2007). Further 
explication of terms used in defining IVDMIAs appears in Table 5.1.  
 
“An IVDMIA is a device that: 1) combines the values of multiple variables using an 
interpretation function to yield a single, patient-specific result (e.g., a “classification,” 
“score,” “index,” etc.), [2)] that is intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment or prevention of disease, and [3)] provides a 
result whose derivation is non-transparent and cannot be independently derived or verified by 
the end user” (second characteristic divided into two for clarity) (FDA 2007).  
 
The FDA anticipated that most IVDMIAs would be classified as moderate to high risk 
devices, namely Class II devices requiring pre-market notification and special controls (labeling 
requirements, performance standards, post-market surveillance), or as Class III devices requiring 
extensive scientific review of the “test system” to ensure safety and effectiveness prior to commercial 
availability (FDA 2002). FDA guidance cited IVDMIAs intended to predict disease risk as an 
example of a Class II device, and IVDMIAs intended to inform treatment decisions as an example of 
a Class III device (FDA 2007). Examples of other Class II devices approved by the FDA that use 
genomic technology are listed in Table 5.2. Only one IVDMIA has been approved by the FDA to 
date, the MammaPrint® Microarray to predict breast cancer metastasis (Lababidi 2008).  
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Recommendations for Labeling IVDMIAs 
FDA recommendations for the proper labeling (inclusive of advertising) of IVDMIAs are 
most relevant when genetic services are approved for marketing. Given the lack of evidence to 
demonstrate clinical validity and utility (SAGHS 2008), nutrigenomic services are unlikely to receive 
pre-market approval in the near future; however, federal government investments in genome wide 
association studies may lead to new evidence in support of personalized nutrition (GenomeWebNews 
[1-2] 2008).  
The FDA recommended that labels for IVDMIA be publicly available on the Internet and 
contain the following information: proprietary and established names for the test (if any), the name 
and business location of the manufacturer, the intended uses of the test, and warnings and precautions 
in the use of the test (FDA 2007). Among these topics, warnings and precautions are important to 
information consumer decision making about the use of nutrigenomic services, particularly when 
services are sold directly to consumers with no requirements for expert consultation.  
The types of warnings or precautions that should be included on IVDMIA labels were not 
specified in the FDA guidance. General labeling requirements for in vitro diagnostic products are 
specified in the Code of Federal Regulations (CFR 2007) Title 21 Part 809.10, which references CFR 
Title 16 Part 1500 for additional information. Regulations in Title16 relate to defining, testing, and 
handling hazardous or harmful substances; identifying substances exempt from regulation; and 
presenting warning information (i.e., placement, text size, use of disclaimers). These regulations are 
not specific to the use of genetic services by consumers.  
A recent opinion survey by Sterling (2008 dissertation) of professionals with genetics-related 
work experience (N=300) can help to identify the types of warnings and disclosures that should be 
included in IVDMIA labels. Specifically, there was a strong consensus among survey respondents 
that companies marking nutrigenomic services should disclose the following: 1) circumstances under 
which personal contact information (82%), test results or analytic data (80%), and residual specimens 
(79%) would be shared with a third party; 2) the clinical (79%) and analytic (76%) validity of the test; 
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3) circumstances under which any recommended supplements should not be taken (76%); 4) whether 
or not the laboratory analyzing the test meets government standards (69%); and 5) the impact of 
supplements on health condition tested (68%). The high level of agreement regarding the importance 
of these items warrants their inclusion on labels, particularly when nutrigenomic services are sold 
directly to consumers.  
 
Purpose of Study  
The purpose of this study was to assess the adequacy of the FDA draft guidance on IVDMIAs 
for improving the oversight of nutrigenomic services, and to make recommendations for the 
improvement of future drafts of the guidance. Commercial websites archived shortly following 
release of the guidance were reviewed to determine: 1) the extent to which websites presented 
information that could be classified nutrigenomic services as IVDMIAs, and 2) the extent to which 
websites presented information recommended by the FDA for the proper labeling of IVDMIAs. 
Given the lack of specific information about warnings and precautions, this study also determined the 
extent to which websites presented information considered by professionals with genetics-related 
work experience to be very important to share with consumers. 
Websites promoting nutrigenomic services are a useful case study for evaluating the FDA 
guidance for several reasons. First, the FDA has used website content to identify and take action 
against companies offering genetic services in need of pre-market review (Gutman 2005). 
Furthermore, promotional material on commercial websites should also adhere to labeling 
recommendations as the definition of labeling includes “most, if not all, advertising” according to an 
appellate court interpretation of CFR Title 21 (FDA 2003). In addition, among the 15 companies 
receiving letters from the FDA, nearly half of them offered nutrigenomic services. Finally, 
nutrigenomic services have a relatively long history of DTC marketing and sale on the Internet 
however evidence to demonstrate their clinical vali
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This study reviewed the content of commercial websites and identifies nutrigenomic services 
promoted as IVDMIAs on-line. Results provided baseline data for evaluating industry responsiveness 
to the IVDMIA guidelines and other efforts to improve the quality of commercially available genetic 
services. In addition, results provide insights into the types of information companies may present to 
meet electronic labeling requirements and the appropriateness of that information.  
 
STUDY DATA AND METHODS 
 
Selection of Websites 
In a previous study, Sterling (2008 in press) conducted a systematic search for websites 
promoting nutrigenomic services (here forward Web search study). Using 20 pilot-tested search terms 
and three popular search engines, 82 websites hosted by 64 organizations were identified, archived, 
and described using content analysis. Organizations were selected for inclusion in this study if they 
met one of the following three criteria: 1) involvement in the development or analysis of a 
nutrigenomic test, 2) the development of supplements and the sale of a nutrigenomic test, or 3) the 
DTC sale of a nutrigenomic test with or without supplements. Involvement in these activities 
increases the importance of FDA review and consumer access to informative labels.  
 
Classification of Nutrigenomic Services 
Nutrigenomic services were classified as IVDMIA if company websites presented 
information confirming all three criteria in the FDA definition as follows: 1) analyzing multiple 
variables including genetic specimens and non-genetic data (e.g., age, risk behaviors, clinical 
biomarkers), 2) using a unique interpretation function to generate the test result, and 3) generating a 
result used to diagnose, cure, mitigate, treat, or prevent a specific disease or health condition.  
Nutrigenomic services met the first criterion if the company mentioned on its website that 
health or lifestyle-related information was collected during the testing process. The second criterion 
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was met if the company mentioned using proprietary, patented, or scientific algorithms, software, or 
technology to determine test results or recommendations. Finally, the third criterion was met if the 
company mentioned that the nutrigenomic service could be used to address “disease,” “illness,” or a 
specific condition (e.g., heart disease, osteoporosis, obesity). A strict interpretation of the third 
criterion was used in this study, requiring mention of disease or a specific health condition. Therefore, 
the third criterion was not met if the company mentioned using nutrigenomic services only in the 
context of improving or maintaining nutrition, overall health or wellness, or quality of life.  
Nutrigenomic services meeting all three IVDMIA classification criteria, were further 
classified as Class II medical devices (moderate risk) if the website presented information confirming 
use of the test to identify a genetic predisposition. Nutrigenomic services were not classified as Class 
III medical devices as they are not used to inform prescription drug use or other medical treatment.  
 
Labeling of IVDMIAs 
Companies met the FDA criterion for proper labeling of IVDMIAs if any information 
pertaining to each of the following topics appeared on the website: 1) the proprietary and established 
name of the test; 2) name and location of the test manufacturer; 3) intended use of the test; and 4) 
warnings or precautions. “Proprietary names” of nutrigenomic services included names with 
trademark or registration symbols. The criterion to use for an “established name” was not clear. In 
FDA’s summary statement of the only IVDMIA approved for marketing (see Table 5.2), 
“MammaPrint®” was identified as the proprietary name and the established name. Therefore in the 
current study, established names were not coded. Non-proprietary names were coded as general 
names. 
 
Data Collection and Analysis 
Most of the variables required for this analysis were collected in the Web search study using 
methods for the content analysis of media messages (Riffe et al 1998). A codebook was created with 
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definitions and coding rules for all variables of interest and was used to train one research assistant 
(RA). Using electronic coding forms, the author coded all websites and the RA coded 60% of 
websites. Open coding was used to identify reasons for using the test, and warnings or precautions 
regarding use of the test. Following independent coding, all disagreements were discussed until 
consensus was reached. Websites not coded by the RA were reviewed by the author to confirm 
accuracy of coding.  
For the current study, new variables of interest were added to electronic coding forms used in 
the Web search study and coded by the author, including: 1) collection of non-genetic data during the 
testing process, 2) use of proprietary, patented, or scientific algorithms, software, or technology to 
determine test results or recommendations, and 3) name and location of the test manufacturer (which 
may be different from the company promoting the test). Warnings or precautions identified in the 
Web search study were considered very important information if included among the items rated very 
important to share with consumers in the opinion study by Sterling (2008 dissertation) including: 1) 
circumstances under which contact information, test data, and residual specimens would be shared; 2) 
the clinical and analytic validity of the test; 3) laboratory certifications issued by government 
officials; 4) circumstances under which any recommended supplements should not be taken, and 5) 
impact of supplements on health. Descriptive statistics were used to analyze and report findings. 
Findings were analyzed at the company level as four companies provided relevant information on 
more than one website. 
 
FINDINGS  
 
Company Characteristics 
A total of 25 companies were selected for inclusion in this study, including nine developers 
of nutrigenomic tests and/or supplements, five laboratories, and 11 on-line distributors (intermediaries 
providing on-line DTC sale of nutrigenomic tests purchased as specimen collection kits and, in some 
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cases, supplements) (see Table 5.3). All companies engaged in DTC marketing of nutrigenomic 
services; however, companies varied in the ways in which consumers purchased services.  
Figure 5.1 illustrates four pathways mentioned on websites for the purchase and delivery of 
nutrigenomic services. In the first pathway, the consumer purchased the service and received results 
(genotype and customized recommendations) from a clinician who may or may not be the consumer’s 
usual doctor and did not work for the company. In this pathway, DTC sale was not offered. In the 
second and third pathways, the consumer purchased the service from a test distributor, the distributor 
received test results from a laboratory, and the distributor forwarded test results to the consumer. 
These two pathways differed in how specimens were provided. In the second pathway, the consumer 
had to go to a testing facility for specimen collection. In the third pathway, the consumer received a 
specimen collection kit (swab rubbed against inside cheek to gather cells) from the distributor.  
In the final pathway, nutrigenomic tests, customized recommendations, and specific 
supplements (versus recommendations for dietary intake) were available to the consumer. Along this 
pathway, the consumer could purchase a specimen collection kit and receive recommendations and 
supplements directly (no intermediary) from the test developer, supplement developer, or laboratory 
(may or may not be the same organization as some companies in the sample used independent 
laboratories and supplement manufacturers). In addition, the consumer could purchase a specimen 
collection kit from a distributor and receive test results directly from the laboratory. In one case, 
consumers who received test results from a laboratory (Interleukin Genetics) could send their 
genotype information to a test and supplement distributor (Quixtar) to receive nutrigenomic 
supplements. In a second case, a supplement manufacturer (DaVinci Laboratories) sold supplements 
to consumers based on results from a test developed by another company (GeneLink). 
 
Classification of Nutrigenomic Services 
Three organizations presented information meeting all three criteria in the FDA definition of 
an IVDMIA, including CyGene Laboratories, Genelex Corporation, and Quixtar (see Table 5.4 for 
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summary of criteria mentioned on websites). The nutrigenomic test used by Quixtar to obtain 
nutrigenomic supplement recommendations was developed by Interleukin Genetics; however the 
Interleukin Genetic website did not mention the collection of non-genetic information and, therefore, 
did not meet all three IVDMIA criteria.  
The three companies identified as offering IVDMIAs mentioned that nutrigenomic tests 
identified predispositions for disease or other health conditions, thereby classifying as Class II 
(moderate risk) medical devices. Quoted text from the three company websites that met each 
classification criterion are shown in Table 5.5. No companies mentioned the use of nutrigenomic 
services to prescribe medication (characteristic of a Class III medical device); however, the majority 
of companies did mention the use of a specific brand of supplements (8/25) or select dietary 
ingredients (e.g., vitamins, minerals, amino acids) (9/25) to reduce risk of disease or improve, 
maintain, or manage health. Given the less stringent regulation of supplements (e.g., health claims, 
labeling, manufacturing) relative to prescription drugs (e.g., pre-market review, post-market 
surveillance, labeling, DTC advertising), it is unlikely that the FDA would classify IVDMIAs 
recommending supplement use as Class III devices.  
Companies offering nutrigenomic services that did not meet all three criteria most often did 
not mention the use of a proprietary algorithm or software (16/22), and/or did not mention using test 
results to address disease, illness or a specific health condition (12/22). Thirteen companies stated 
explicitly that tests did not diagnose a disease (one of which also mentioned use of the test to address 
a disease).  
 
Labeling of IVDMIAs and other Nutrigenomic Services 
As described above, three companies presented information on their website classifying 
services as IVDMIAs. While review of websites may be an important first step used by the FDA in 
identifying nutrigenomic services in need of pre-market review, it will not be the only source of 
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information used. Therefore, all company websites were reviewed for proper labeling given the 
potential for additional companies to have offered services that would classify as IVDMIAs. 
Information recommended by the FDA for the proper labeling of IVDMIAs included four 
topics: 1) the proprietary name of the test, 2) manufacturer name and place of business, 3) intended 
uses, and 4) warnings and precautions. Table 5.6 presents a summary of label information presented 
on websites. Label information appeared on and across multiple pages within websites. Few websites 
(3/25) presented information addressing all four topics on one webpage or as a single document 
linked or posted to the website. Two eVendors did post a “product flyer” or “product description” as a 
single document addressing all four topics (Quixtar and Kristy McKendrix). In addition, one test 
developer (Interleukin Genetics) posted an informed consent document for consumer signature that 
addressed all four topics. Ten companies presented the greatest quantity of label information on web 
pages answering “frequently asked questions.”  
Names and Location of Manufacturers.  When referencing nutrigenomic services, 12 
companies presented test names with trademark or registration symbols (suggesting a proprietary 
name) at least once on their website (i.e., some websites used symbols inconsistently). Companies 
provided varying levels of information about who was involved in the development, manufacture, or 
analysis of offered services. Eleven companies clearly identified the developer or manufacturer of the 
test, six of which also provided the manufacturer’s business location. The other 14 companies 
presenting less than transparent information did not mention test manufacturers (7/14), mentioned 
multiple companies such that one developer could not be determined (5/14), or made general 
references to unnamed facilities or laboratories involved in product development (2/14).  
Intended Uses.  Companies presented a variety of intended uses for nutrigenomic services on 
websites (see Table 5.7) and were most likely to mention the use of test results to inform consumer 
decision-making about their health (23/25). Slightly more than half (13/23) of these companies stated 
that consumers could use test results to reduce risk for or manage disease, illness, or a specific health 
condition. The remaining companies stated that test results could be used to improve or maintain 
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overall health, wellness, nutrition, or quality of life (10/23). Several companies appeared to 
intentionally avoid using the term “disease” or mentioning specific conditions, referencing instead 
referenced, for example, “heart and circulatory health” or “strong, healthy bones” (emphasis added). 
Seventeen companies described nutrigenomic services as enabling consumers to “take charge of” or 
have “more control” over their health. These references to personal empowerment also included being 
more “proactive” or “motivated” about health, and being more “compliant” with a personal health 
regimen. Twelve companies mentioned using tests to identify predispositions for disease (9/12) or 
poor health (3/12). Eight companies mentioned improving health by “modifying” gene expression 
through dietary and lifestyle changes.  
Warnings and Precautions.  Companies presented warnings and precautions in greater variety 
but far less frequently than intended uses (see Table 5.8). Companies rarely used “warning,” 
“precaution,” or a similar term when presenting such information (3/25). Most of the information 
presented clarified the nature of the test offered. For example, companies mentioned that tests did not 
identify a condition linked to a single gene (11/25), but did identify consumer risk for “modifiable” 
conditions (6/225). Twelve companies mentioned that tests did not diagnose a disease or health 
condition (10/25) or did not diagnose, treat, cure or prevent a disease (2/25). Nine companies 
mentioned that the FDA had not reviewed claims made about the nutrigenomic test (3/9) or 
supplement recommendations (6/9). In addition to contacting the company for more information, six 
companies suggested that consumers contact their physician with questions about their test results. 
Only three companies suggested that consumers contact a genetic counselor. Risk of harm in the use 
of services was presented infrequently, including the potential for genetic information to be misused 
(2/25), for feeling stress or anxiety after receiving test results (2/25), and for discrimination based on 
test results (1/25).  
Information considered very important for consumers to know was presented on several 
websites as shown in Table 5.9. Most companies presented information addressing consumer privacy 
(22/25) and the post-test handling of specimens (14/25) and results (16/25). When addressing analytic 
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(5/25) and clinical validity (4/25), two companies provided quantitative measures of analytic validity 
and the remaining companies provided qualitative assessments. When addressing laboratory 
standards, eight companies mentioned CLIA approval (Clinical Laboratory Improvement 
Amendments) and two companies mentioned state health department approvals including New York 
or Washington. 
 
DISCUSSION 
 
The use of new test components in the development and analysis of health-related genetic 
services prompted the FDA to reconsider its regulatory approach. In its 2007 guidance to industry, the 
FDA clarified the types of in-house genetic services, namely IVDMIAs, recommended for pre-market 
review, labeling, and surveillance. This study identified nutrigenomic services promoted as IVDMIAs 
on commercial websites according to an FDA’s definition, and assessed website content for proper 
labeling as recommended by the FDA and suggested by results of an opinion survey.  
 
Classification of Nutrigenomic Services 
In October 2006, three companies identified in this study self-classified their nutrigenomic 
services as IVDMIAs and Class II medical devices. Two of these three companies (CyGene 
Laboratories and Genelex Corporation) received letters from the FDA in 2006 requesting a meeting to 
discuss pre-market review. While this study used a strict interpretation of the FDA definition (i.e., 
address disease, illness, or specific health condition) to classify nutrigenomic services, the FDA may 
be more liberal in its approach. A more encompassing interpretation or definition would improve the 
regulation of nutrigenomic services which often are marketed often to address overall health, nutrition 
and wellness. For example, Complete Nutrition and Wellness (2006) presented the following test 
description on its website:  
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“The screening results, used in conjunction with the Lifestyle Questionnaire, will show the 
best way for you to achieve and maintain optimal health without having to rely on family 
history alone in determining what the future might hold for you… Unlike medical diagnostic 
tests that simply determine whether you have or do not have a disease, Personal DNA 
Analysis identifies truly individualized ways to help you maintain long-term health and well-
being by looking inside your DNA.”  
 
Suracell (2006), who developed the test offered by Complete Nutrition and Wellness, described the 
test on its website as follows:  
 
“This proprietary analysis pinpoints the cellular processes that need additional nutritional 
support, and recommends a personalized nutraceutical regimen that will work with your 
body's natural repair processes to help promote optimal genetic health.”  
 
Presented at the bottom of the same webpage is the following fine-print disclaimer: “Tests are not 
designed to detect any specific disease processes.” Although these descriptions imply avoiding 
disease as an intended purpose for testing, there is no explicit reference to that purpose.  
These examples suggest ways in which companies and intermediaries may attempt to evade 
classification as an IVDMIA. Future drafts of the FDA guidance should provide additional 
recommendations for in-house tests that may provide health-related information that does not pertain 
to a specific disease or health condition. If diseases or conditions refer to those listed in the 
International Classification of Disease or ICD-10, then several tests providing information about more 
nebulous conditions (e.g., antioxidant and detoxification, oxidative stress) may not meet the current 
definition. 
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Review of Nutrigenomic Services 
FDA’s intent to review nutrigenomic services raises questions about the test components that 
should be submitted for approval and by whom. As defined by the FDA, the “test system” in need of 
review includes: 1) the in vitro assays, and 2) the unique interpretation function or algorithm used to 
generate a test result. In the case of nutrigenomic services, findings from this study suggest that 
multiple algorithms may be used to produce two or more of the following “test results”: 1) genotypic 
information, 2) customized recommendations to improve health, and 3) customized supplements or 
nutrigenomic supplements. Furthermore, when multiple algorithms are used, they may be used by 
different companies. For example, Quixtar required consumers to enter the genetic test results 
received from Interleukin Genetics along with other health information into an on-line questionnaire 
to receive recommendations for nutrigenomic supplements. Quixtar (2006) did not mention how 
supplement recommendations were generated on its website, but described the questionnaire as, 
“created, reviewed, and approved by a team of medical and nutritional experts, under the direction of 
the Nutrilite Health Institute.” Nutrilite manufactured the nutrigenomic supplements sold by Quixtar, 
and both companies are owned by the same parent company.  
GeneLink, Inc. developed the nutrigenomic test used by DaVinci Laboratories to generate 
recommendations for its nutrigenomic supplements. GeneLink (2006) described the use of its test by 
intermediaries as follows, “GeneLink's profile assessments enable health care professionals, 
nutritional and skin care companies to recommend a specific and targeted regime of nutritional 
supplements, skin-care formulations and wellness regimens that have been specifically designed to 
compensate for certain predicted deficiencies” (emphasis not in original). How health care 
professionals and companies would use the test in this regard was not described, nor was GeneLink’s 
process to ensure accuracy or consistency in the use of genotypic information. 
As illustrated by these two examples, the nutrigenomic “test system” may include multiple 
algorithms developed by different companies to generate different types of test results for the same 
consumer. Future drafts of the FDA guidance could be improved by clarifying which companies are 
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responsible for submitting multiple algorithms used concurrently or sequentially for review and 
approval.  
 
Labeling Nutrigenomic Services 
Recommendations outlined in the FDA guidance for the proper labeling of IVDMIAs do not 
adequately address unique characteristics of nutrigenomic services, nor do they address issues raised 
in the professional opinion survey conducted by Sterling (2008 dissertation). Future drafts of the FDA 
guidance could improve oversight of nutrigenomic services by addressing the presentation of 
information pertaining to nutrigenomic supplement use or other recommendations for dietary intake. 
Further explication is particularly important when recommendations include purchase of 
nutrigenomic supplements.  
The FDA has authority over the regulation of supplements as “food” and specific 
requirements have been established for their labeling (FDA 2005), some of which include the types of 
health claims that can be made about the effect of supplements on disease risk (FDA 2008). Labels 
for nutrigenomic tests could present information about the algorithm or protocols used to generate 
supplement or dietary recommendations. Alternatively, supplement labels could present information 
about the significance of genotypic information. In the case of pharmacogenomics (the study of 
associations between genes and drug response), the FDA has approved revised drug labels that 
present information about the increased risk for adverse events among patients with particular 
genotypes. Similarly, supplement manufacturers may seek approval to include health claims about the 
enhanced benefit of supplement use by consumers of a particular genotype. 
 
STRENGTHS AND LIMITATIONS 
 
Findings from this study are based solely on information provided on commercial websites 
which may not accurately represent all company or nutrigenomic service characteristics. Findings 
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from this study should not be misconstrued as company attentiveness or responsiveness to the FDA 
guidance on IVDMIAs as website content reviewed for this study was archived in October 2006, only 
two months after FDA’s release of its first draft. However, findings do provide baseline data for 
evaluating industry responsiveness to the guidance over time. In addition, this study offers 
recommendations for improvements to the guidance while it is still in draft form, allowing for their 
consideration prior to the development of binding guidelines.  
 
CONCLUSIONS 
 
As policy makers continue to address gaps in the oversight of genetic services, documenting 
how and to what extent industry adheres to regulatory approaches and guidelines is critical for policy 
evaluation. This study provided a baseline from which to evaluate nutrigenomic industry 
responsiveness to FDA guidance on IVDMIAs. The guidance states that upon approval of a specific 
IVDMIA the FDA “will address the applicable labeling requirements for that product or type of 
product, as it does for all devices.” However, given the intent of the guidance to “describe the 
Agency’s current thinking on [this] topic,” future drafts could be improved by addressing the 
following questions regarding the labeling and classification of nutrigenomic services: 1) what 
constitutes the test system for nutrigenomic services in need of review (particularly when multiple 
companies are involved in providing tests results to consumers); 2) to what extent should risks 
associated with supplement use or other aspects of nutrigenomic testing be addressed on labels 
(especially given the minimal and variable risk information provided across websites in this study); 
and 3) on which labels and in what formats should recommendations for nutrigenomic supplement 
use be addressed?  
In efforts to evade FDA review, some companies may avoid key terms (e.g., “disease”) or 
strategically employ disclaimers when providing information about their genetic services. Companies 
also may rebrand their services using different names and through partnerships with other 
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organizations. The potential for these practices increases the importance of post-marketing 
surveillance and FDA collaboration with the US Federal Trade Commission to prevent fraud and 
ensure consumer health and safety.  
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Table 5.1. Language used in US Food and Drug Administration classification of laboratory 
developed tests as In Vitro Diagnostic Multivariate Index Assays, July 2007 a 
 
In Vitro Diagnostic Multivariate Index Assay 
Specimens 
taken from 
the human 
body and 
analyzed in 
the 
laboratory 
Used in the diagnosis 
of disease or other 
conditions, or in the 
cure, mitigation, 
treatment, or 
prevention of disease. 
Combines values of multiple 
variables (e.g., gene expression 
levels, age, weight, metabolite level) 
to produce a patient-specific result 
that cannot be independently derived 
from generally accepted or 
established clinical information (i.e., 
“derivation is non-transparent,”  
“unique interpretation function”). 
Reagents, instruments, 
and systems intended 
for use in the 
collection, preparation, 
and examination of 
specimen. 
 
a
 Source: US Food and Drug Administration Center for Devices and Radiological Health, “Draft Guidance for 
Industry, Clinical Laboratories, and FDA Staff: In Vitro Diagnostic Multivariate Index Assays,” 26 July 2007, 
http://www.fda.gov/cdrh/oivd/guidance/1610.pdf (accessed 19 July 2008). 
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Table 5.2. Examples of Class II medical devices approved by the US Food and Drug 
Administration that use genomic technology a 
 
Name Approved For Use By Test 
Genes 
Profiled Intended Use 
Roche 
AmpliChip 
CYP450 Test 
for CYP2C19 
Microarray 
Dec 2004 Multiple 
Labs 
Genotyping for 
drug 
metabolizing 
enzyme 
1 Classify patients according to 
how they metabolize multiple 
drugs, including 
antidepressants, 
antipsychotics, beta-blockers, 
and some chemotherapy.  
Invader® 
UGT1A1 
Molecular 
Assay 
Aug 2005 Multiple 
Labs 
Genotyping for 
drug 
metabolizing 
enzyme 
1 Identify patients who poorly 
metabolize irinotecan 
(colorectal cancer drug) 
leading to toxicity and 
adverse side effects. 
MammaPrint® 
Microarray b 
Feb 2007 Single 
Lab 
Gene expression 
analysis of 
breast tumors 
70 Predict patient risk for breast 
cancer metastasis within 5 to 
10 years after initial cancer. 
 
a
 Sources: Lababidi S. Challenges in DNA Microarray Studies from the Regulatory Perspective. Journal of 
Biopharmaceutical Statistics 2008;18(1):183-202. US FDA. 510(k) Substantial Equivalence Determination 
Decision Summary #k042259 for Roche AmpliChip CYP450 microarray. (no date). Available: 
http://www.fda.gov/cdrh/reviews/K063224.pdf Accessed: August 5, 2008. US FDA. 510(k) Substantial 
Equivalence Determination Decision Summary #k051824 for Invader UGT1A1 Molecular Assay. (no date). 
Available: http://www.fda.gov/cdrh/reviews/K051824.pdf Accessed: August 5, 2008. US FDA. 510(k) 
Substantial Equivalence Determination Decision Summary # k062694 for MammaPrint. (no date). Available: 
http://www.fda.gov/cdrh/reviews/K062694.pdf Accessed: August 5, 2008. 
b
 The only In Vitro Diagnostic Multivariate Index Assay (IVDMIA) reviewed and approved by the US FDA for 
marketing.  
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Table 5.3. Nutrigenomic services offered by select companies identified in a systematic search by company type, October 2006 (N=25) 
 
Company Name and Websites Manufacturer Name of Service 
Developer of Tests or Supplements (n=9)   
Tests Only   
CyGene Laboratories 
https://cygenedirect.com/default.html  
http://www.cygenelabs.com/about.aspx  
CyGene Laboratories 
 
CyGeneDIRECT™ Athletic Performance DNA Analysis, 
Metabolic Health Assessment DNA Analysis, Thrombosis 
DNA Analysis, Osteoporosis DNA Analysis, Glaucoma and 
Macular Degeneration DNA Analysis 
GeneLink, Inc.   
http://www.bankdna.com  
GeneLink Nutragenetic Profile™ for Oxidative Stress 
GenovaDiagnostics®  
http://www.genovations.com  
http://gdx.net  
GenovaDiagnostics Genovations™ CardioGenomicPlus® Profile, 
OsteoGenomic® Profile, DetoxiGenomic® Profile, 
ImmunoGenomic™ Profile, NeuroGenomic™ Profile, 
EstroGenomic™ Profile  
Interleukin Genetics  
http://www.ilgenetics.com/index.jsp  
Interleukin Genetics GENSONA™ Heart Health Genetic Test, General Nutrition 
Genetic Test 
OnePersonHealth 
http://www.onepersonhealth.com/geneticAnalysis/ 
nutritionalGenetics.jsp  
One Person Health ONETest™ 
Sciona™         
http://www.sciona.com 
Sciona Cellf™ Comprehensive Genetic Assessment Kit 
Tests and Supplements   
nutraMetrix™        
http://www.nutrametrix.com  
Not Stated Test: Nutri-Physical Gene SNP DNA Screening Analysis 
Supplements: Gene SNP Customized Nutrition 
Suracell, Inc. 
http://www.suracell.com  
Not Stated Personal Genetic Health™ 
Test: Personal DNA Analysis Profile Kit 
Supplements: Repair-Personal Genetic Formulations (11 
formulas) 
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Company Name and Websites Manufacturer Name of Service 
DaVinci Laboratories of Vermont  
http://www.davincilabs.com  
Test: GeneLink 
Supplements: DaVinci 
Laboratories 
Test: Nutragenetic™ Profile for Oxidative Stress, 
Detoxification, Heart and Circulatory Health, Healthy 
Immune System, Bone Deposition 
Supplements: GENEssentials™ Spectra-SNP Targeted 
Supplements (7 formulas) 
Laboratory Analyzing Tests (n=5)   
DDS DNA Test Express  
http://www.ddstest.com/dnatestx/index.html  
Genelex Genetic Nutritional Analysis 
Determigene         
http://www.determigene.com  
Not Clear a DNA Nutritional Analysis 
Genelex Corporation        
http://www.genelex.com  
Not Clear a b Nutritional Genetic Panel 
The DNA Testing Centers  
http://thednatestingcenters.com/mainpage.html  
Not Stated Nutritional Genetic Testing 
The LabSafe Company  
http://www.lab-safe.com  
Not Stated c Glaucoma & Macular Degeneration DNA Analysis, 
Optimum Athletic Performance DNA Analysis, 
Osteoporosis DNA Analysis 
e Vendor for Tests or Supplements  (n=11)   
Tests Only    
Carolyn Katzin, CNS   
http://www.thednadiet.com  
http://www.cancernutrition.com  
Not Stated d 
 
The DNA Diet™ 
CVS/Pharmacy         
http://www.cvs.com  
Not Stated Cellf Genetic Assessment for 5 Key Health Areas 
Drugstore.com   
http://www.drugstore.com  
Sciona Cellf™ Genetic Assessment for Heart Health, Insulin 
Resistance, Bone Health, Antioxidant and Detoxification, 
Inflammation 
eHealthLabs™         
http://www.ehealthlabs.com  
Genelex Genetic Nutritional Analysis 
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Company Name and Websites Manufacturer Name of Service 
Gene-Testing.com         
http://www.gene-testing.com  
Not Clear e  
 
Test: Gene SNP DNA Screening Analysis Panel 
Supplements: Gene SNP Custom Genetic Nutritional 
Supplements 
Neurological Research Institute  
http://www.testing4health.com   
Not Stated Complete Basic SNP Panel I—Methylation Cycle 
Nutrigenomic Test 
Kristy McKendrix, ND  
http://www.thewebitect.com/hwhindex.html  
http://drkristy.nutrametrix.com  
Test: Not Clear e  nutraMetrix™ NutriPhysical Gene SNP DNA Screening 
Analysis Test Kit  
Tests and Supplements   
Complete Nutrition and Wellness  
http://www.completenutritionandwellness.com  
Test/Supplements: Suracell 
 
Suracell Personal Genetic Health Program 
Test: Suracell Personal Genetic Profile Test 
Supplements: Suracell Core Nutrition 
LinkTime Productions, Inc.: An Affiliate Of The 
Market America, Inc. UnFranchise®  
http://www.linktime.biz/GeneSNPInfo.html  
Not Stated Test: Gene SNP DNA Screening Analysis Test Kit 
Supplements: NutriPhysical™ Gene SNP Custom Formula 
Market America: UnFranchise® Business: 
Webportal sponsored by Grandeur The Great, 
LLC  
http://fly.unfranchise.com/index.cfm  
Test/Supplement: Not 
Clear e 
Supplements: Not Stated 
Test: Gene SNP™ DNA Screening Analysis 
Supplements: Gene SNP Custom Genetic Nutritional 
Formula (6 formulas) 
Quixtar 
http://www.quixtar.com  
Test: Interleukin Genetics 
Supplements: Nutrilite® 
Test: GENSONA™ Heart Health Genetic Test, General 
Nutrition Genetic Test 
Supplements: IL1 Heart Health Nutrigenomic Dietary 
Supplement 
 
a
 Sample test report posted to website generated by Sciona for the Cellf™ Genetic Assessment. 
b
 Company mentions Sciona as supplier of technology for the test.  
c Test names and descriptions similar to CyGene Laboratories, but CyGene is not mentioned no website. 
d
 Genelex Corp website mentions Carolyn Katzin as provider of nutritional services that can be purchased with genetic test results. 
e
 Passing mention(s) of Sciona in test descriptions on website. 
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Figure 5.1. Pathways mentioned on commercial websites for delivery of nutrigenomic services to consumers, October 2006 (N=25) 
 
 
Legend 
[1]=No DTC Sale, DTC Marketing, Tests Only   •   [2-4]=DTC Sale, DTC Marketing, Tests Only   •   [4]=DTC Sale of Tests and Customized Supplements 
DNA=Specimen  • DNA (kit)=Specimen Collection Kit  • ±:Genotype Test Results  •  ±:R=Customized Recommendations  • ±:Sups=Customized Supplements 
Consumer Clinician 
Laboratory 
Test Manufacturer 
±:R ±:R 
DNA 
Consumer Testing Facility 
Laboratory 
Test Manufacturer 
±:R ±:R 
DNA 
[1] 
Test DistributorConsumer 
Laboratory 
Test Manufacturer 
±:R 
DNA (kit) DNA (kit) 
Consumer 
Test Distributor  
Supplement Manufacturer 
Laboratory 
Test Manufacturer 
Supplement Manufacturer 
±:R 
DNA (kit) DNA (kit) 
±:Sups 
DNA (kit) 
± 
[2] 
[4] 
[3] ±:R 
±:Sups 
n=5 
n=1 
n=11 
n=8 
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Table 5.4. Information provided by companies on commercial websites pertaining to the 
classification of nutrigenomic services as an In Vitro Diagnostic Multivariate Assay Index 
(IVDMIA), October 2006 (N=25) 
 
Information Provided on Website 
Non-Genetic 
Information 
Collected 
(n=19) 
Identifies 
Predisposition 
for Disease or 
Condition 
(n=13) 
Used to 
Diagnose, 
Prevent, Treat, 
Cure, Mitigate 
Disease (n=13) 
Proprietary 
Formula or 
Technology 
(n=9) 
Total Websites 
(N=25) 
    5 
    5 
    3 
    2 
    2 
    2 
    2 
    2 
    1 
    1 
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Table 5.5. Quoted text from company websites that met all three criteria for the classification of medical devices as an In Vitro Diagnostic 
Multivariate Index Assay (IVDMIA), October 2006 
 
 Website Text Addressing Criteria a 
Company Non-Genetic Information Proprietary Components Address Disease, Illness,  Specific Condition 
CyGene 
Laboratories 
“The Knowledgebase generates reports 
based on the results of the test panel 
(genetic profile), but also takes into 
account the individual’s personal and 
family history, eating and living 
habits and other environmental 
factors.” 
https://cygenedirect.com/cygene/cygene
-our-dna-services.html    
“To further enhance the relevance of the 
results, CyGene has developed and 
patented an interactive scientific 
platform or ‘Knowledgebase’ for the 
delivery of the analysis results.”  
 
 
https://cygenedirect.com/cygene/cygene
-our-dna-services.html  
“Why Bone Health DNA Analysis is 
Important to you: …Osteoporosis is a 
preventable disease and CyGene’s 
Osteoporosis DNA Analysis can 
identify if a person is at risk of the 
disease and help guide them through 
their available options.” 
https://cygenedirect.com/osteoporosis/d
na-testing_osteoporosis.html  
Genelex 
Corporation 
“DNA test results, combined with 
information from a completed lifestyle 
questionnaire, result in personalized, 
realistic steps pateients [sic] can take to 
improve and maintain good health.” 
 
 
http://www.healthanddna.com/professio
nal/nutrigenetics.html  
“Your Gene Assessment and your Diet 
and Lifestyle Assessment were entered 
into the Genostic Rules Engine™, an 
exclusive software program developed 
specifically for Cellf. This sophisticated 
analytical tool determines your position 
on your Cellf Action Map.”b 
http://www.healthanddna.com/sampleng
preport.pdf  
“Benefits you can expect include: … 
Reduce susceptibility to the big three 
diseases -- heart disease, cancer and 
diabetes -- by harmonizing diet and life-
style with the genome.” 
 
 
http://www.healthanddna.com/nutrigene
ticstest.html  
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 Website Text Addressing Criteria a 
Company Non-Genetic Information Proprietary Components Address Disease, Illness,  Specific Condition 
Quixtar “To find out whether or not any 
supplements are recommended for you, 
you'll key in your genetic test results 
into a special area of the Personalized 
Health Questionnaire on 
Quixtar.com… Then click on “View 
Report” to obtain your 
Recommendation Report, which will 
list any additional recommended 
supplements.” 
http://www.quixtar.com/Products/Perso
nalizedHealth/default.aspx?cid=8585&
pid=7562#33  
“Interleukin’s patented genetic test 
determines variations in the IL1A and 
IL1B genes… While there are other 
genetic tests on the market, none 
provides the IL1 pattern results 
associated with heart disease, as this is 
intellectual property for which 
Interleukin Genetics owns the patents.”  
 
 
http://www.quixtar.com/Products/Perso
nalizedHealth/default.aspx?cid=8585&
pid=7562  
“The Heart Health Genetic Test reveals 
your genetic predisposition to certain 
types of heart disease. The results can 
help you determine what adjustments 
you may want to make in your nutrition, 
exercise, lifestyle, and health care 
practices.”  
 
 
 
http://www.quixtar.com/Products/Perso
nalizedHealth/default.aspx?pid=7562&
cid=8473  
 
a
 All emphases added to quoted text.     
b
 Information appeared on Genelex website in sample test report. Test report references Sciona, Inc. and its trademarked test “MyCellf” suggesting that test 
offered by Genelex was developed by Sciona. No other references to proprietary components found on Genelex website.         
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Table 5.6. Provision of information recommended for proper labeling of commercial websites 
promoting nutrigenomic services, October 2006 (N=25) 
 
Information Provided on Website 
Intended Uses 
(n=25) 
Warnings and 
Precautions  
(n=14) 
Trademark or 
Registration 
Symbol as 
Proprietary 
Name 
 (n=12) 
Manufacturer 
Name and 
Place of 
Business  
(n=6) 
Total Websites 
(N=25) 
    7 
    6 
    5 
    4 
    2 
    1 
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Table 5.7. Intended uses for nutrigenomic services mentioned on commercial websites, October 
2006 (N=25) 
 
 
Companies Presenting Intended Use 
Intended Uses 
Total 
N=25a (%) 
Self-
Classified as 
IVDMIA 
n=3 (%) 
Did Not  
Self-Classify 
as IVDMIA 
n=22 (%) 
Inform Consumer Decision Making  23 (92) 3 (100) 20 (91) 
 To reduce risk for or manage disease, illness, 
 specific health condition 13 (52) 3 (100) 10 (45) 
 To improve or maintain overall health, 
 wellness, nutrition, lifestyle 10 (40) 0 (0) 10 (45) 
Increase Personal Empowerment b  17 (68) 2 (67) 15 (68) 
Understand Health Status 16 (64) 3 (100) 14 (64) 
Identify Predisposition  12 (48) 3 (100) 9 (41) 
 For disease, illness, specific heath condition 9 (36) 3 (100) 6 (27) 
 For poor health, wellness, nutrition, aging  3 (12) 0 (0) 3 (14) 
Modify Gene Expression 8 (32) 0 (0) 8 (36) 
Avoid Impact of Disease or Condition  5 (20) 1 (33) 4 (18) 
Manage Conditions Hard to Diagnose or Treat c 1 (4) 0 (0) 1 (5) 
 
a
 All percentages based on column totals. 
b
 Includes mention of taking “charge of” or having “more control” over health and healthcare;” being 
“proactive,” “empowered,” or “motivated” about health; increasing “compliance” with personal health regimen  
c
 Examples provided on website: “chronic fatigue syndrome, irritable bowel syndrome, fibromyalgia, 
premenstrual syndrome, etc.” 
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Table 5.8. Warnings and precautions for nutrigenomic services mentioned on commercial 
websites, October 2006 (N=25) 
 
 
Companies Presenting 
Warnings and Precautions 
Warnings and Precautions 
Total 
N=25a 
(%)  
Classified as 
IVDMIA 
n=3 (%) 
Did Not 
Classify as 
IVDMIA 
n=22 (%) 
Nature of Test or Supplements 
   
 Not Test for Condition Linked to Single Gene 11 (44) 1 (33) 10 (45) 
 Does Not Diagnose Disease or Other Health Condition 10 (40) 1 (33) 9 (41) 
 Test for Risk Not Certainty 9 (36) 2 (67) 7 (32) 
 Not a Genomic Profile 9 (36) 1 (33) 8 (36) 
 Years of Age for Use of Test 7 (28) 2 (67) 5 (23) 
 Lack FDA Review or Approval for Supplement 
Claims 6 (24) 1 (33) 5 (23) 
 Test for Modifiable Condition Only 6 (24) 0 (0) 6 (27) 
 Does Not Prescribe Medication or Offer Treatment 4 (16) 0 (0) 4 (18) 
 Not a Blood Test 4 (16) 0 (0) 4 (18) 
 Written Informed Consent Required  3 (12) 1 (33) 2 (9) 
 Lack FDA Review or Approval for Test Claims 3 (12) 0 (0) 3 (14) 
 Does Not Diagnose, Treat, Cure, or Prevent a Disease  2 (8) 0 (0) 2 (9) 
 Results May Be Population Specific 1 (4) 0 (0) 1 (5) 
 Limitations in Test or Science 1 (4) 0 (0) 1 (5) 
 Supplements Not a Replacement for Healthy Diet 1 (4) 0 (0) 1 (5) 
Post Testing 
   
 See Doctor with Questions about Test Result  6 (24) 0 (0) 6 (27) 
 Genetic Counseling Should be Conducted  3 (12) 1 (33) 2 (9) 
 Relevance of Test Results to Family Members 2 (8) 0 (0) 2 (9) 
 No Future Contact Regarding Changes in Science 1 (4) 0 (0) 1 (5) 
Risks 
   
 Risk for Misuse of Genetic Information (in general) 2 (8) 1 (33) 1 (5) 
 Risk of Stress or Anxiety Given Test Results 2 (8) 1 (33) 1 (5) 
 Risk of Discrimination 1 (4) 0 (0) 1 (5) 
 
a
 All percentages based on column total. 
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Table 5.9. Information considered “Very Important” to share with consumers about 
nutrigenomic services on commercial websites, October 2006 (N=25) 
 
 
Companies Presenting 
Very Important Information 
Information Very Important to Share with Consumers 
Total 
N=25a 
(%)  
Classified as 
IVDMIA 
n=3 (%) 
Did Not 
Classify as 
IVDMIA 
n=22 (%) 
Privacy 
   
 Contact information kept confidential 22 (88) 3 (100) 19 (86) 
 Specimens destroyed 11 (44) 1 (33) 10 (45) 
 Specimens kept confidential 2 (8) 1 (33) 1 (5) 
 Specimens unidentified  1 (4) 1 (33) 
 
 Test results/data kept confidential 9 (36) 1 (33) 8 (36) 
 Test results/data unidentified 7 (28) 1 (33) 6 (27) 
Scientific Review 
   
 Analytic validity of test b 5 (20) 1 (33) 4 (18) 
 Clinical validity of test c 4 (16) 1 (33) 3 (14) 
Laboratory Standards   
   
 Clinical Laboratory Improvement Amendments (CLIA) 
 approval 8 (32) 1 (33) 7 (32) 
 State health department approval 2 (8) 1 (33) 1 (5) 
Nutrigenomic Supplements d 
   
 Whether or not there are any circumstances under which 
 supplements should not be used 3 (12) 1 (33) 2 (9) 
 Clinical utility of supplements 
   
 Whether or not supplements can manage or prevent 
 disease 3 (12) 1 (33) 2 (9) 
 Whether or not supplements can improve or 
 maintain overall health, nutrition, wellness 7 (28) 1 (33) 6 (27) 
 
a
 Percentages based on column total, except for supplement related items.  
b
 Two companies reported a numeric level of accuracy (99.5%) in profiling gene variants. Remaining 
companies provided a qualitative assessment. 
c Qualitative assessments only. 
d
 Percentages for supplement related items based on total number of companies selling specific brand of 
nutrigenomic supplements (n=8) and total number of companies with IVDMIAs selling nutrigenomic 
supplements (n=1)  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
DISCUSSION 
 
Dissertation supports grand challenges to the integration of genomics into biology, health, and 
society 
The success of the Human Genome Project has fostered ongoing discovery and innovation in 
genetic and genomic science. In its vision statement for the Future of Genomics Research, the 
National Human Genome Research Institute (NHGRI) outlined 15 grand challenges related to the 
integration of genomics into biology, health, and society (Collins et al 2003). The purpose of this 
dissertation was to provide empirical data and policy analysis in support of one of these grand 
challenges, namely “[to] develop policy options for the use of genomics in clinical and non-clinical 
settings.” In describing issues surrounding this grand challenge, NHGRI noted that in the absence of 
federal oversight, “numerous websites offering unvalidated genetic tests directly to the public, often 
combined with the sale of ‘nutraceuticals’ and other products of highly questionable value, are 
proliferating.”  
The specific aims of this dissertation were three-fold: 1) to describe the promotion and sale of 
NG services on the Web, 2) to identify information considered important for consumer decision-
making about the purchase and use of NG services, and 3) to assess the effectiveness of new 
guidelines for improving oversight of NG services. Mixed methods were used to fulfill these aims, 
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including a systematic search of the Web using pilot-tested search terms, quantitative content analysis 
with reliability testing, a Web-based expert opinion survey whose development employed cognitive 
think-aloud pilot testing, and data-driven policy analysis. Study results were reported here in three 
manuscripts for publication in peer-reviewed journals targeting several disciplines, including clinical 
genetics, genetic counseling and testing, health policy, and the ethical, legal and social implications of 
genetic and genomic research. Key findings from this dissertation are reviewed briefly below. 
 
Diverse organizations promoting nutrigenomic services on-line often presented inadequate 
information  
Over 2000 URLs were reviewed in the comprehensive search for websites promoting NG 
services in October 2006. A total of 82 websites were identified, hosted by wide variety of 
organizations (64) ranging from a book author providing a direct link to a company offering at-home 
testing, to a large medical center with an in-house clinical laboratory offering several health-related 
genetic services. The majority of websites were hosted by healthcare and wellness (HW) service 
providers, including naturopathic doctors (41%), medical doctors (34%), nutritionists (25%), and 
chiropractors (16%). These providers described NG services as a useful tool for understanding and 
improving health, and often bundled NG tests with other non-genetic diagnostic tests. Similar to 
previous analyses, this study found less than adequate information on websites about important 
caveats associated with genetic testing, some of which include test validity (7%), laboratory 
certifications (13%), and the importance of genetic counseling (6%). Most websites (75%) presented 
conflicting, trivial, or no information about the companies analyzing and developing offered services. 
 
Industry has been working to increase the accessibility and visibility of nutrigenomic services 
despite their unproven validity 
Opportunities for affiliation, distribution, and private labeling presented on several websites 
(15) suggest a concerted effort within industry to encourage the diffusion of NG services and increase 
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their visibility on-line. References on websites to other companies appearing in search results suggest 
that both HW service providers and independent entrepreneurs were taking advantage of promoted 
opportunities. Despite unfavorable media coverage largely due to the GAO investigation of at-home 
NG testing, most organizations identified in October 2006 continued to promote NG services in 
March 2008 (77%). Three of these organizations had established new NG services, new agreements 
for distribution off-line, or targeted new consumer markets on-line. 
 
Few attributes of nutrigenomic services were rated unimportant to share with consumers 
raising concerns about to potential for information overload 
A total of 300 genetic professionals completed an on-line opinion survey in March through 
August 2007 to identify what experts thinking consumers should know about NG services. 
Respondents rated the importance of 55 attributes, ranked the importance of ten topics, and proposed 
additional attributes in open-ended questions. Few statistically significant differences were found in 
the importance of topics and attributes by demographic characteristics suggesting a high level of 
agreement within the sample. Where identified, differences were most likely to occur across 
professional groups. The clinical validity and clinical utility of NG tests were ranked as the two most 
important topics to consumer decision-making. Within broad topics, respondents rated very few 
attributes as unimportant to share with consumers, raising concerns about the potential for consumers 
to experience information overload. In rating the importance of the 55 attributes, the following were 
rated “very important” by the largest percentage of respondents: circumstances under which personal 
contact information, test results and analytic data, and residual specimens would be shared with a 
third party; the use and utility of recommended supplements or dietary changes; non-genetic factors 
impacting the occurrence of and accuracy in the prediction of tested health conditions; and laboratory 
compliance with regulatory standards. Findings from this study confirmed the importance of 
attributes pertaining to health-related genetic services in general, and also identified new attributes 
important to share with consumers about NG services in particular. 
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Additional guidance is needed from the FDA about the pre-market review and proper labeling 
of nutrigenomic services  
In 2007, the FDA expressed its intent to regulate health-related genetic services as medical 
devices and, more specifically, as In Vitro Diagnostic Multivariate Index Assays (IVDMIAs) in need 
of pre-market review and subject to specific labeling requirements. Websites hosted by 25 companies 
developing or selling NG services directly to consumers were reviewed and three companies 
presented information classifying promoted NG services as IVDMIAs and Class II (moderate risk) 
medical devices in need of pre-market review. The use of NG test results by third parties to generate 
recommendations for health improvements prompted questions about what constituted the IVDMIA 
“test system” in need of pre-market review. In regard to the labeling of IVDMIAs, companies rarely 
presented information on-line about the immediate and long-term risks associated with NG services. 
Findings from this study suggest two important areas for improving future recommendations as 
follows: 1) defining what constitutes a warning or precaution for NG and other genomic services, 
some of which should include risks associated with the use of nutrigenomic supplements; and 2) 
defining what constitutes the NG test system in need of review, particularly when multiple 
organizations are involved in the analysis of test results and the generation of personalized 
recommendations. 
 
Dissertation findings have important implications for multiple stakeholders  
Various stakeholders have raised significant concerns regarding the lack of oversight for 
genetic services, especially DTC health-related genetic services. In the absense of binding 
requirements for scientific review and labeling, unvalidated genetic services continue to be marketed 
directly to consumers using claims that overestimate the clinical utility of test results and ignore or 
give passing mention to limitations in the interpretation and use of provided information.  
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The growing body of gene-disease association research and new investments in translating 
those findings into practice are likely to advance the goals of personalized nutrition and medicine 
(Feero et al 2008, GenomeWeb News 2008, McBride 2008). Until this promise is realized, findings 
from this study suggest the following as some important implications for consumers, health care 
providers, policy makers, and industry. 
Consumers.  Despite their unproven validity, early adopters may find value (clinical or 
otherwise) in the information provided with NG test results and not share policy makers concerns 
about the potential harms associated with genetic testing. The DTC sale of NG services alongside 
other health and non-health related products on- and off-line may minimize perceptions of risk. 
Furthermore, some consumers may not place much importance on the lack of FDA review for most 
at-home genetic tests.  
Warnings about the lack of FDA review or approval has done little to hindered growth in the 
use of supplements (Morris and Avorn 2003, Bent 2008), and claims about the utility of genomic 
information in selecting supplements may lead to greater interest in NG services. To make educated 
decisions, consumers must consider their reasons for using NG services and seek out information 
regarding the ability of services to satisfy their objectives. The lack of enforceable regulations for the 
labeling of NG services (inclusive of advertising by appellate court interpretation) means that 
consumers will encounter promotional materials for NG services that cover the quality spectrum and 
may contain inadequate or misleading information. Findings from the expert opinion survey suggest 
that regardless of the reason for testing, finding out information about the conditions under which 
consumer information and residual specimens might be shared is very important information for 
consumers to consider when making decisions about whether or not to purchase NG services. 
Healthcare and wellness service providers. The need for additional health provider education 
about genetic testing has been highlighted by the American Society of Human Genetics (ASHG) and 
demonstrated in research (Hudson et al 2007, Javitt 2006). Industry marketing of affiliation 
opportunities on websites suggests that educational efforts should target health providers working in a 
 159 
wide variety of fields. ASHG recommended that professional organizations take responsibility for the 
education of their members. However, survey results suggest that differences in professional training 
and practice may have the greatest impact on provider opinions about NG services; therefore, 
collaboration across professional societies may result in more comprehensive educational programs 
informed by interdisciplinary knowledge and perspectives. As a principal gate keeper in the health 
care system, primary care physicians are likely to receive a large share of questions from patients 
about NG services. Moreover, websites promoting NG services often mentioned consulting “your 
doctor” with questions about the use and interpretation of test results. Physicians with little to no 
knowledge or training in genetics and limited time and resources to consider novel or elective 
services may face greater challenges in responding to patient inquiries (Clyman et al 2007, Shields et 
al 2008).  
Industry. The proliferation and DTC sale of NG and other personal genomic services has led 
to increased scrutiny of the genomic services industry. Commercial advancement of genomics will 
require companies to make a good faith effort to gain or maintain public trust and confidence. In the 
absence of federal regulation, industry should work to address the concerns of advocates and policy 
makers regarding the DTC sale and marketing of their services. Recent events suggest that industry is 
willing to collaborate with policy makers, researchers, and advocates to identify and address 
prevailing concerns (Jones 2008, Anderson 2008). Industry can help raise consumer and health 
provider awareness of critical issues associated with the use of NG services through improved 
transparency in content and improved organization of information on commercial websites, the most 
popular vehicle for DTC marketing of genomic services. In creating promotional materials and test 
reports, industry should also consider findings from risk communications studies demonstrating a 
significant association between the verbal and visual presentation of information and consumer 
understanding of risk for disease (Waters 2006, Dolan and Iadarola 2008). Clarity in the presentation 
of information about disease risk is particularly important in the context of DTC sale, offered or 
promoted by almost half (28/64) of the organizations identified in this study. In sum, industry should 
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take care in the content and presentation of all information, ensuring that information is not only 
available, but that it is presented in a consumer-friendly format that reduces the likelihood of 
misinterpretation (NSGC 2007). Finally, while laboratory research may be an important mechanism 
for innovation in genomic technologies, survey results suggest that findings from peer-reviewed 
research are far more important to share with consumers. In this study, companies presenting peer-
reviewed research on their websites did not include studies with null findings regarding gene-disease 
associations.  
Federal policy makers. The recent surge in genetic policy activity was stimulated by the 
GAO report on NG testing and invigorated by the passage of the Genetic Information 
Nondiscrimination Act of 2008 (GINA) after more than 10 years of advocacy (Coalition for Genetic 
Fairness 2008). In the development of new regulatory policy, federal officials will face challenges 
balancing the interests of multiple stakeholders “who stand to gain financially from public investment 
or lack of public control, and those who, for a variety of reasons, see certain technologies as 
potentially harmful or in conflict with their particular values” (Knoppers et al 1999). Moreover, 
keeping pace with growth and change in genomic information and technology increases the need for 
collaboration across agencies that have limited resources to enforce their regulatory authority. For 
example, the FDA, FTC and National Institutes of Health have been collaborating to identify 
companies posing a major threat to consumer health and safety (e.g., clearly misleading advertising, 
large market share, multiple products) as targets for litigation (Javitt and Hudson 2006).  
Although different trademarked names were used in the branding of services, identical text in 
on-line NG test descriptions and passing mentions of other NG companies suggest that fewer 
companies are involved in the development and analysis of NG tests than may appear on the surface. 
Post-marketing surveillance must pay attention to the potential rebranding of NG services by different 
organizations, and the marketing and sales of intermediaries distributing NG services or using NG 
tests results to market other health products. The use of NG test results by various intermediaries also 
highlights the need to consider how best to define the NG “test system” in need of FDA review.  
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In reviewing medical devices, the FDA has taken into consideration their social impact and 
not denied approval based on the potential for adverse effects (e.g., at-home tests for HIV and drug 
abuse) (Kerouac 2002). As such, the FDA may approve or place conditions on the approval of 
devices (e.g., labeling requirements, post-market surveillance) that have a negative social impact 
should the benefits of the device outweigh its risks. Therein resides a critical question for FDA to 
consider in the context of NG services: What are the benefits, if any? Do the risks associated with 
their commercial availability outweigh their benefits? Answers to these questions also have important 
implications for the labeling of NG services. The FDA listed warnings and precautions as an 
important content area for IVDMIAs, but provided little guidance on what constitutes a warning or 
precaution. 
Finally, challenges associated with monitoring and regulating the Web cannot be ignored as 
an important implication for policy makers. Relative to other forms of media, the Web has broad 
reach, relative anonymity, and ease in creating new and rebranding existing websites (Montoya and 
Jano 2007). Off-shore companies can provide US consumers access to unregulated services. 
Circuitous links among websites and the unique branding of websites complicate the identification of 
product manufacturers and repeat violators of the law. Furthermore, questions often arise about the 
extent to which companies comply with privacy protections established by HIPAA (Health Insurance 
Portability & Accountability Act of 1996) in the on-line sale of health products and the delivery of 
test results on-line (Montoya and Jano 2007).  
In developing an action plan to address the on-line sale of prescription drugs, the FDA used a 
three-pronged approach including a national media campaign promoting safety tips for on-line drug 
purchasing, partnerships with professional organizations to establish and disseminate standards, and 
collaboration with international governments (Montoya and Jano 2007). Among these three, 
international collaboration appears to be lacking in efforts to improve oversight of NG services. For 
example, health and beauty stores in the United Kingdom stopped selling NG tests developed by 
Sciona, Ltd. after less than one year of sale in 2002 given advocate and researcher concerns about test 
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validity and unethical marketing (Meek 2002). The company relocated its headquarters to the US in 
2005 and continues to sell NG services today, on- and off-line.  
 
Critique of guiding premises  
This dissertation was guided by several premises, including the belief that: 1) advertising for 
NG services can impact consumer thought and behavior regardless of purchase, 2) the lack of federal 
oversight increases the need for informed-decision making by consumers about the purchase and use 
of NG services, and 3) unique aspects of NG and other genetic services increases the potential for 
harm to consumers and thereby warrants further analysis and policy development. A brief critique of 
these premises is offered below. 
Advertising affects behavior, but with what effects? While advertising is believed to impact 
the behavior of both consumers and physicians, empirical evidence regarding its effects are limited in 
the context of DTC health-related genetic services. The first traditional DTC advertising campaign for 
a genetic test was sponsored by Myriad Genetics, Inc., the company holding patents for 
BRCA1/BRCA2 gene sequencing for inherited breast and ovarian cancer risk. During the five month 
pilot campaign (September 2002 to February 2003), BRACAnalysis® advertisements appeared in 
television, radio, and print in Atlanta, GA and Denver, CO.  The campaign raised substantial concerns 
among policy makers over the wide-scale marketing of the test beyond groups for whom testing was 
considered appropriate (Myers et al 2006). Although the campaign led to increased patient requests 
and physician referrals for testing (Mouchawar, Hensley-Alford, et al 2005), one study found most 
patients (63%) reporting seeing the ads to experience no anxiety at all, and physicians to report no 
negative effects on their relationships with patients (85%) or their daily practice (86%) (Mouchawar, 
Laurion, et al 2005). Those who did experience anxiety were significantly more likely to believe they 
were at greater risk of breast cancer and to be of Hispanic identity, highlighting the importance of 
considering the implications of DTC marketing for those who are members of more vulnerable 
groups. Questions remain about whether or not DTC marketing of genetic services negatively impacts 
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consumers and the SACGHS has identified the lack of information about advertising effects as one of 
29 gaps in the oversight of genetic testing (SACGHS 2008). 
Even with increased oversight, consumers may face challenges making informed decisions. 
Improving oversight of genetic services will increase the quality of services available to consumers 
and the quality of information about those services through regulatory requirements for pre-market 
review and proper labeling. However, the premise that improvements in technology and information 
will lead to improved decision-making may not be valid. Opponents of DTC genetic testing ground 
their arguments in the lack of evidence to demonstrate clinical utility. However, consumers may have 
other reasons for obtaining NG services such as curiosity about their genome or a general fascination 
with technology. When reasons for testing are not grounded in a clinical purpose, what type of 
information is required for informed decision-making and will consumers receive adequate 
information about those issues given the current focus on clinical applications? In addition, regardless 
of information quantity and quality consumers may face challenges in deciding whether or not to 
obtain genetic testing or how to use the information they receive. Michie et al (1997) found study 
participants receiving genetic counseling to report needing advice (50%), reassurance (50%) and 
decision-making support (30%), in addition to information (79%) and education (63%). Furthermore, 
consumers have different levels of knowledge and beliefs about disease which may impact testing 
decisions (Ormond 2007). Findings such as these support concerns about the need for clinical 
consultation or genetic counseling raised by opponents of DTC sale.  
Genetic tests have unique characteristics, but may not be more harmful than other 
diagnostic tests. Genetic exceptionalism, the notion that genetic tests have unique characteristics that 
warrant special consideration, is used to support arguments about the potential for harm to consumers 
and the need for increased oversight. However, whether or not genetic information is exceptional has 
been the subject of some debate. As reviewed by Green and Botkin (2003), the implications of 
genetic testing for complex traits are similar to those of other diagnostic tests, such as tests for HIV, 
tuberculosis exposure, or blood pressure and cholesterol screening. Common among these tests are 
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the prediction of increased risk for future disease, the potential for other family members to also be 
affected, the potential for stigmatization or discrepancies in the processing of life or disability 
insurance policies (i.e., discrimination), and negative psychological effects in response to test results. 
Green and Botkin (2003) argue that tests for conditions that are severely stigmatizing, impact 
reproductive decisions, lack effective treatments, and have results with complex interpretations may 
require increased scrutiny (e.g., Huntington disease, inherited forms of breast cancer), otherwise 
standard protocols for testing and the management of medical information may be adequate, 
including confidentiality and informed consent. However, under conditions of DTC sale, standard 
protocols are not consistently followed. Thereby, the mode of genetic service delivery may be the 
more direct cause of potential harm than the nature of genetic tests in and of themselves. In support of 
this view, reports of actual harm to consumers in the use of genetic testing are believed to be rare 
(Wolfberg 2006), and a recent literature review suggests that results of tests for genetic 
predispositions to complex traits (i.e., breast cancer, colorectal cancer, Alzheimer disease) have short 
lived or few adverse consequences for patients (Heshka et al 2008). 
  
Dissertation strengths and limitations 
Research aims fulfilled by this dissertation addressed a current and salient health policy issue 
through the use of mixed methods and interdisciplinary perspectives, including clinical genetics, 
genetic counseling, marketing, and policy. The commercialization of NG services was an important 
case study for understanding how to improve the oversight of genetic services given their relatively 
long history of DTC marketing and sale (when compared to other personal genomic services) despite 
unproven validity; their provision of personalized recommendations for supplement use, or dietary or 
lifestyle changes; and the popularity of diet, nutrition, supplements, or fitness as health topics most 
often searched for on-line.  
Findings from this dissertation added to the literature a comprehensive description of on-line 
sale and promotional practices used for NG services. Methods used to identify websites promoting 
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NG services were systematic and, unlike previous studies, included websites hosted by both test 
developers and other organizations serving as intermediaries between developers and consumers. The 
content analysis was guided by a codebook developed following review of similar studies and other 
peer-reviewed literature. A trained research assistant and the candidate reviewed and reached 
agreement on all discrepancies in coding. In addition, the candidate reviewed websites and variables 
that were not coded by the RA to confirm accuracy prior to descriptive analyses. The analysis of 
website content also contributed suggestions for improving FDA guidelines for the classification, 
review, and labeling of IVDMIAs while they were still in draft form. The archiving of websites two 
months after initial release of the FDA IVDMIA guidelines allowed for the collection of baseline data 
for evaluating industry responsiveness to FDA guidelines over time.  
Finally, the opinion survey was finalized following review of relevant literature, review by an 
interdisciplinary group of faculty representing the individuals targeted for survey participation, and 
cognitive think-aloud pilot testing. Results from the expert opinion survey suggested how best to 
present information (content and organization) about NG services to consumers on websites and in 
other promotional materials. In the absence of federal guidelines, industry can use survey findings to 
improve the information they provide to both consumers and health care and wellness service 
providers. 
The primary limitation of this dissertation is that findings from the content analysis are based 
solely on publicly-accessible website content and may not reflect all organization or test 
characteristics. Organizations hosting websites reviewed in this dissertation were not contacted to 
confirm the accuracy of content. Although the Web search strategy was systematic and elaborate, 
three NG companies identified in another study were not captured in this search. The reasons why 
these companies were not captured are unclear, but plausible explanations include: 1) the absence of 
search terms used in this study as metatags on company websites, 2) the appearance of website URLs 
beyond the first three pages of search results which were not reviewed, or 3) temporary inactivity or 
malfunction of the website.  
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In regard to the opinion survey, convenience and snowball sampling were used to recruit 
genetic professionals. This recruitment strategy reduced the generalizability of findings to 
professional groups represented in the analytic sample and to other genetic professionals and may 
have contributed to some response bias. Important stakeholders underrepresented in the survey 
include clinicians, policy makers, industry representatives, professionals with NG-related work 
experience, and consumers. Although consumers were not targeted in survey recruitment, the Genetic 
Alliance is a large and influential organization among consumer advocates and members of its listserv 
comprised almost 25% of the analytical sample. Finally, conservative response rates for this survey 
were lower than reported in other studies, due in part to the length of the survey (approximately 30 
minutes) and the lack of incentive for its completion. 
 
Addressing limitations through future research 
Future studies can improve upon and add to this dissertation in several ways. First, 
researchers investigating the on-line marketing and sale of genetic services should use an iterative and 
multi-faceted search process to capture all companies and websites of interest. While using a 
systematic search of the Web will identify websites the average consumer is most likely to encounter, 
efforts to improve the oversight and monitoring of genetic services will require the identification of 
all companies involved in developing, promoting, and selling NG services. Therefore, establishing 
analytical samples through Web searching and reviews of news coverage, press releases, industry 
reports, and previous studies will more effectively capture the entire population of interest. 
Furthermore, establishing panel datasets will be more useful to analyzing industry responsiveness to 
different government regulations and other guidelines over time than pooling data from multiple 
studies using cross-sectional data which may not capture the same organizations or analyze same 
variables. 
Second, since available health-related genetic services vary in validity and utility, future 
studies should compare the promotional and informative content provided by companies offering 
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different types of genetic services. Comparative data by service type can assist government officials 
in identifying major threats to consumer health and safety and the adding greater specificity to 
labeling requirements placed on different types of services. Collecting and analyzing data at the 
genetic service level can inform the development of policies less likely to stifle innovation across the 
genetic services industry and encourage companies to invest in useful services. Studies reporting 
industry opinions about the DTC marketing and sale of NG and other genetic services are not well 
represented in the literature, if at all. Future studies should target representatives from companies and 
laboratories offering DTC genetic services to gather their opinions about how to improve regulatory 
oversight without stifling technological innovation and consumer access to genomic information that 
may be of interest. 
 Finally, consumer perspectives about and responses to the DTC marketing and sale of 
genetic services warrant additional study. One study by Goddard and colleagues (2007) found survey 
respondents who had used NG services to have obtained information about them from several mass 
media sources, including the Internet—more often than newspapers or radio and less often than 
magazines or television. To the candidate’s knowledge, marketing of NG services off-line has been 
very limited; therefore, respondents in this study were likely to have received off-line information 
from news reports or feature stories. Questions remain about whether or not consumers who view 
promotional materials for NG services would express interest in purchasing those services, and why. 
How promotional material informs consumer understanding of NG services, other genetic services, 
and genetic science and information also is an important area for future research. A final question for 
future research would address the effects of NG test results on consumer behavior and their health 
beliefs. Findings from these studies would provide empirical data about the potential for NG services 
to cause harm, which is far more reliable than anecdotal data or information about anticipated effects.  
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Closing  
NG services are one of many DTC health-related genetic services that may be particularly 
appealing to consumers given their relatively low cost, ease of access, and association with more 
common, less severe, and less stigmatizing health conditions. Consumers searching the Web for 
information about diet, nutrition, supplements, and fitness may come across one or more websites 
selling or promoting NG services.  Organizations hosting websites promoting NG services can use 
various Web-based tools and recommendations from researchers and professional societies to 
increase the visibility, accessibility, and quality of website content. Improving marketing and sales 
practices in the absence of binding regulations can help industry regain or maintain public trust. In the 
absence of good faith efforts, government officials, researchers and health professionals will continue 
to struggle to keep pace with growth and change in the industry and minimize threats to consumer 
health and safety.   
Findings from empirical research will be critical for informed policy making. Research 
findings regarding the promotion and sale of NG services should consider multiple venues for 
dissemination. In addition to peer reviewed journals, researchers should disseminate findings and 
corresponding policy proposals through responses to requests for public comment in the Federal 
Register, articles in professional association newsletters and listservs, consumer fact sheets, and the 
like. Broad dissemination is important to ensuring the public, health professionals, researchers, and 
policy makers are aware of new research findings and receive them in the most accessible (i.e., 
useful) format.  
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The Promotion and Sale of Nutrigenomic Services On-Line 
Rene Sterling, MHA 
Doctoral Candidate, HPM, UNC-CH 
 
Codebook for Research Assistant Training, June 2007 
 
 
Purpose 
 
The purpose of this study is to describe the promotion and sale of nutrigenomic (NGx) testing 
services on-line.  
 
Background 
 
NGx testing services include genetic tests marketed to identify variants in several genes associated 
with diet-related, chronic health conditions that can have multiple causes. Some of these conditions 
include high blood pressure, osteoporosis, insulin sensitivity, obesity, or impaired ability to eliminate 
toxins from the body. NGx testing services also include personalized supplement, diet, or lifestyle 
advice based on individual test results and other individual health and lifestyle information.  
 
Researchers in the field of NGx hope to improve health outcomes through personalized nutrition. 
However, some researchers and policy makers consider the promotion and sale of NGx services to be 
highly premature. Currently, the most extensive promotion of NGx testing services is on the Internet. 
Consumers searching the Internet for information about diet, nutrition, genetics, or health may come 
across a commercial website promoting or selling these services. What consumers learn when reading 
one of these websites may be different from what they need to know before making a purchase.  
 
Research Questions 
 
When searching for information about NGx testing services on-line, what types of websites are 
consumers most likely to come across? 
What types of organizations or individuals host websites that provide interested consumers with 
opportunities to inquire about, order, or purchase NGx services via the Internet? 
What types of organizations or individuals host websites that promote the use of NGx testing 
services? 
What types of NGx services are sold or promoted on commercial websites? 
What other genetic services are sold or promoted by organizations that sell or promote NGx services? 
Do websites provide information about the risks and benefits of testing? 
 
Preliminary Results 
 
Papers regarding this study will present results from a comprehensive search and review of 
commercial websites that promote or sell NGx testing services. Twenty key words and 3 popular 
search engines were used to identify commercial websites for NGx testing services. The first 30 
URLs and all sponsored ads appearing in each keyword search were reviewed.  
 
Sixty-four commercial websites were found for a variety of testing facilities, group and individual 
health care practices, and on-line vendors. Websites were found to promote and sell both NGx testing 
services along with other health or social-related genetic tests. Several NGx testing services were 
displayed with trademark or registration symbols.  
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Variables of Interest 
 
The following pages of this codebook outline all variables of interest to this study. Organization, NGx 
test, and website characteristics will be coded by two reviewers working independently (i.e., principal 
investigator and trained research assistant). A Microsoft Access database has been created for all 
website coding. 
 
There are two primary windows or screens used for data entry. Each screen includes a set of 
overlapping tabbed pages on which additional variables appear. The first data entry screen includes 
fields for entering data regarding variables at the Vendor or website level, such as: the name of the 
vendor, its location, the types of staff working in the organization, the types of genetic tests it offers, 
if the website includes medical disclaimers, and other information (see Appendix 1 Table 1). 
 
The second data entry screen includes fields for entering data regarding variables at the NGx Testing 
Service level, such as: the name and cost of the test, how test results are provided to consumers, if 
information about risks/benefits of testing is provided, if supplements are sold, and other information 
(see Appendix 1 Table 2). 
 
The names of vendors and NGx testing services represented in all relevant websites have been entered 
into the database and appear in drop down lists on each data entry screen. The Vendor and NGx 
Testing Service screens are linked together so that for any particular vendor, the specific NGx testing 
services offered can be identified.  
 
The candidate will provide additional training to the research assistant on the following topics: 
 
Overview of direct-to-consumer marketing for genetic testing services  
What are NGx testing services? 
Microsoft Access databases 
Study database and user-interface  
Reliability testing 
 
 
 
 
 
 
Note (3 November 2008): This codebook was used for research assistant (RA) training. Although 
edited/updated during training and early stages of coding, this document does not represent an 
exhaustive list of all variables and values used in data analysis. For example, this document does not 
include all values created by the candidate and RA for variables with open coding. Some variable 
values were collapsed during analysis. In addition, this document does not include multi-variable 
constructs created during analysis of quantitative data or new variables created to capture recurring 
observations in qualitative data (i.e., notes taken during coding). 
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Appendix 1 Figure 1. Microsoft Access database main window 
 
Click on Favorites to access data entry 
screens for coding websites. 
Click here to access data 
entry screen (saved as a 
“Form” in Access). 
Other objects in 
which entered 
data is stored and 
analyzed. Not for 
data entry.  Do 
not open these 
objects.  
Nutrigenomic study 
database window. 
Access file saved as: 
Ngx_1st_Paper.mdb 
Microsoft Access 
application window.  
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Appendix 1 Figure 2. Microsoft Access data entry screen for vendor (website) characteristics 
 
 
 
 
 
Memo field for typing notes on location of 
“hard to find” codes within website; or coding 
questions/concerns. 
Tabbed pages 
on which 
additional 
variables 
appear. 
Functional 
buttons to add 
new entries, to 
save entries, or 
to auto fill 
fields. 
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Appendix 1 Figure 3. Microsoft Access data entry screen for nutrigenomic testing service characteristics 
 
 
 
 
 
 
All fields 
requiring data 
entry have initial 
code: “NOT 
CHECKED”  
(with a few 
exceptions) 
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Appendix 1 Table 1. Vendor characteristics coded  
 
Note: Variable names, variable formats and Access database table names are consistently defined. 
Variable values are not repeated after first use in table. Rows with multiple variables names include: 
1) the name of the variable in which data is stored in Access (bolded), and 2) the names of other 
variables in which variable formats or values (i.e., codes) are stored and linked (not bolded). 
 
 
Variable  
Access table  
Variable 
Format/Value Description 
HomePageUI
D 
Hidden Auto 
Number  
Unique ID for homepage. Automatically generated number. 
HomePage Hyperlink What is the vendor’s homepage? URL which is the domain name for org 
website. Orgs may have more than one domain name. Vendor 
characteristics are coding at the org level, not the domain name level. 
VendorName Text What is the name of the vendor organization? Name of org that sells or 
promotes at least one NGx test. 
VendorMotto Text What is the vendor’s motto or tagline? 
Usually appears on homepage under vendor name in a prominent location 
or format 
VendorTypeC
ode  
VendorType  
VendorTypeC
ode 
LU1_VendorT
ype Codes 
 What type of organization is the vendor? 
1=Private 
practitioner 
Org for a private practitioner who provides health or wellness services. 
Website highlights the individual practitioner who may have one or two 
other staff (e.g., Carolyn Katzin, Hunter Yost, Rebecca Muttart) 
2=Group 
practice 
Org for two or more health practitioners often with different training. 
More than one provider featured prominently on the website or none at 
all. May be described as a group practice or medical group (e.g., 
Biamonte Center for Clinical Nutrition, SOMA Acupuncture, Executive 
Medicine of Southlake) 
 3=Testing 
facility 
Org does not sell test on-line. Consumer must go into the facility or 
through a designated affiliate to receive testing. Consumer may request 
information or schedule an appt for services on-line or by phone or e-mail 
(e.g., Determigene, DDS Lab Genelex Licensed Distributor, Lab-Safe) 
 4=Trademark 
Holder 
Org owns the trademark for one of its NGx tests or supplements. 
Indicated by TM symbol after name of product (e.g., Sciona, GeneLink, 
OnePersonHealth, Genova Diagnostics) 
 5=Web-based 
genetic testing 
service 
Org sells test on-line and offers related services. Markets itself as a web-
based provider of genetic services. May or may not have a testing facility. 
Must provide consumers an opportunity to purchase on-line (e.g., 
Genelex, Quixtar) 
 6=eVendor Org sells test but does not offer related services which may be obtained 
from another entity. Org is not the developer of the test (e.g., 
eHealthLabs.com, drugstore.com, MarketAmerica)  
 7=Spa Org provides spa beauty and wellness services, in addition to providing 
NGx testing services (e.g., Vibrance Medical Group, Elan Vital, 
Complete Health Institute)  
 8=Insurance 
Package 
Org sells health insurance to consumers, e.g., individual health plan, 
health savings account (e.g., Best Discount Benefits) 
 9=Consumer 
advocates 
Org seeks to provide information and other resources to consumers in the 
general public, usually around a specific health condition or topic (e.g., 
StopThePain, Nutrition In Motion, Nutrition Mission Foundation) 
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Variable  
Access table  
Variable 
Format/Value Description 
 10=Franchise 
Op 
Org provides opportunities for other individuals or orgs to receive 
training, products and materials to become a vendor of its NGx products 
or services (e.g., nutraMetrix) 
 11=Hospital/M
edical facility 
Org provides health care services in a traditional hospital or medical 
center setting (e.g., Cedar-Sinai, Sanoviv. Medical Institute) 
 66=Other 
88=Not sure 
(NS) 
99=Not 
checked (NC) 
Make a note of the item for discussion 
Use when item appears on page but you’re not sure how to code or what 
to discuss 
Default response for all categorical variables 
PhoneContact 
YNResponseI
D 
LU1_YesNoR
esponseID 
0=No 1=Yes 
88=NS 99=NC 
Is a phone number provided for the vendor org? 
 
 
EmailContact 
 
0=No 1=Yes 
88=NS 99=NC 
Is an email address provided for the vendor org? 
E-mail address or link to activate pre-addressed e-mail through program 
on consumer’s computer  
PhysicalAddr
ess 
 
0=No 1=Yes 
88=NS 99=NC 
Is a physical street address provided for the vendor org? 
Street address provided for physical location of org. PO Box is not a 
physical location. Must provide building number, street address, city, 
state, zip code. 
CountryID 
LU2_CountryI
D 
Open coding 
for all 
locations. 
In what country(ies) does the vendor have a physical location? (e.g., 
Scienta Health, Genecare, Genosense with off-shore location only; 
Sanoviv with US and off-shore locations) 
 0=Not provided 
1=US  
2=UK … 
88=NS 99=NC 
Make note of new locations and unique ID numbers for discussion.  
 
{Note: Not a complete list of variable values resulting from open coding} 
Headquarters 
YNResponse7
7ID 
LU1_YesNoR
esponse77ID 
0=No 1=Yes 
77=Not 
Applicable 
(NA) 
88=NS 99=NC  
Is this location noted as the vendor’s headquarters or primary location? 
Choose yes if there is only one location 
Use 77=Not Applicable when country info is NOT provided 
Partner 
 
0=No 1=Yes 
88=NS 99=NC 
Does the website mention any partner organizations with whom or 
through whom the vendor provides NGx services?  Known entity whose 
services are provided by the org or with whom the org has partnered to 
delivery services. Must relate to the delivery of services either tests or 
nutritional supplements, e.g., testing facility, trademark holding org. No 
formal business connection. 
PartnerName
1-3 
(3 variables) 
Text State the names of up to 3 prominently mentioned partners (e.g., first 
mentioned, appearing at the top of the webpage, partner logo or picture 
included). 
Affiliate 0=No 1=Yes 
88=NS 99=NC 
Does the website mention an affiliate organization that owns the vendor 
or is a fiscal partner with the vendor? Known entity that owns the 
organization or has a legal affiliation, e.g., nutraMetrix is an affiliate of 
marketamerica.com. The word affiliate will most likely be used in these 
cases. Formal legal relationship. 
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Variable  
Access table  
Variable 
Format/Value Description 
AffiliateName
1-3 
(3 variables) 
Text State the names of up to 3 prominently mentioned partners (e.g., first 
mentioned, appearing at the top of the webpage, partner logo or picture 
included). 
StaffRN 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one RN (Registered Nurse) on staff? 
 
StaffRD 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one RD (Registered Dietician) on staff? 
 
StaffCNS 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one CNS (certified nutrition specialist) on 
staff? 
StaffCGC 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one CGC (certified genetic counselor) on 
staff? 
StaffMD 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one MD on staff?  
 
StaffPhD 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one PhD on staff? 
 
StaffND 
 
0=No 1=Yes 
88=NS 99=NC 
Does the vendor have at least one ND (Naturopathic Doctor) on staff? 
 
StaffOther1-3 
(3 variables) 
Text State the full name of up to 3 other degrees or certifications held by 
vendor staff. List those most prominently mentioned (e.g., first 
mentioned, appearing at the top of the webpage, partner logo or picture 
included). There are only three slots for additional staff. Prioritize 
licensed professionals or formally degreed professionals over other types 
of staff, e.g., licensed acupuncturist. 
CLIA 
 
0=No 1=Yes 
77=NA  
88=NS 99=NC 
Does the website mention or show signs of (i.e., CLIA graphic) 
certification by the Clinical Laboratory Improvement Act? If vendor is 
promoting the test of another organization, look for mention of the 
source/partner organization’s certification status. If site mentions that the 
source/partner organization is CLIA certified, type the name of the 
organization under OtherLabCert. Use 77=NA if the organization is not a 
testing facility or if it does not mention owning a laboratory  
AABB 0=No 1=Yes 
77=NA  
88=NS 99=NC 
Does the website mention or show signs of (i.e., AABB graphic) 
certification by the American Association of Blood Banks? Use 77=N/A 
if the organization is not a testing facility or if it does not mention owning 
a laboratory 
OtherLabCer
t 
 
0=No 1=Yes 
77=NA  
88=NS 99=NC 
Does the website mention or show signs of certification by another 
regulatory body or professional group? For example: certification from 
the state of NY. Use 77=N/A if the organization is not a testing facility or 
if it does not mention owning a laboratory 
LabCertName
1-3 
(3 variables) 
 
Text State the full name of up to 3 other certifications. List those most 
prominently mentioned (e.g., first mentioned, appearing at the top of 
the webpage, partner logo or picture included). Certification must have 
something to do with lab work or provision of health services. Do not 
include website quality certifications. Type the name of an org mentioned 
on the website as having a laboratory certification followed by acronym 
for certification (e.g., GeneLink CLIA, Genelex AABB) 
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Variable  
Access table  
Variable 
Format/Value Description 
MedDisMDVi
sitCode  
MedDisMDVi
sitCode 
LU1_Disclaim
er 
MedicalMDVi
sitCode 
 Is there a medical disclaimer on the website regarding the GENETIC 
TEST and the need to see a PHYSICIAN or other primary care (or 
medical) health professional?  
Code at the sentence level. Must be in regard to a genetic test or be 
located on a page with no specific product or service so that it appears to 
apply to any or all services. 
 0=No medical 
disclaimer 
No disclaimer regarding seeing a physician or other primary care (or 
medical) health professional 
 1=See MD re: 
health 
condition 
Consumer must see a physician or other health care provider to get more 
information about the health condition associated with the test 
 2=See MD re: 
test results 
Consumer must see physician or other health care provider to get more 
information about the meaning or significance of the test results, or the 
use of test results in making treatment decisions. 
 3=See MD re: 
treatment 
Consumer must see physician or other health care provider to get more 
information about how to treat or manage the condition associated with 
the test. Could refer to a condition that the consumer “suspects” s/he may 
have currently or may have a predisposition to.  
 4=See MD re: 
condition, 
results 
References both condition and results 
 5=See MD re: 
condition, 
treatment 
References both condition and treatment 
 6=See MD re: 
condition, 
results, 
treatment  
References condition, results, and treatment 
 7=See MD re: 
results, 
treatment 
References both results and treatment 
 8=See MD re: 
medical issues 
(non-specific) 
 
 66=Other 
88=NS 99=NC 
Make a note of the item for discussion.  
 
MedDisWebI
nfoCode 
 
0=No 1=Yes 
88=NS 99=NC 
Is there a medical disclaimer regarding the contents of the website, e.g., 
content not health advice, content does not replace conversation with 
clinician? Must reference health 
PromMedDis
Type 
 What type of disclaimer is most prominently located (or first 
mentioned)? 
DisclaimerTyp
eCode 
DisclaimerTyp
e 
1=Need to see a 
physician 
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Variable  
Access table  
Variable 
Format/Value Description 
LU1_Disclaim
erTypeCodes 
2=Limitations 
of test or test 
results 
 
 
3=Residency 
requirements 
for testing 
 
 
4=Content of 
website 
 
 
77=NA 
88=NS 99=NC 
Use N/A if no disclaimer appears on site 
PromMedDis
Place 
Use placement 
codes defined 
under variable: 
WebItemPlace
Code 
Where is the most prominent disclaimer located?  
MedDisHealt
hCode  
MedDisHealth
Code  
LU1_Disclaim
er 
MedicalHealth
Codes 
 Is there a health disclaimer on the website regarding the nature of the 
purpose of the test or the information provided with test results? Does 
not reference role of physician. Refers to information consumer can 
expect to receive when taking the test. Code at the sentence level. 
REFERS ONLY TO THE INFORMATION PROVIDED WITH TEST 
RESULTS 
 0=No health 
disclaimer 
 
 1=Not for 
health purpose 
The test is not for a health purposes. Does not provide health information. 
 2=Does not 
diagnose a 
health 
condition 
The test does not diagnose a health condition. Test results do not tell you 
whether or not you have a particular health condition. The test is not for 
diagnostic purposes. Another test would be required to diagnose a health 
condition. 
 3=Does not 
provide 
medical/ 
treatment 
advice 
Test results do not provide advice on what treatments a person should 
receive (medicine not nutritional supplements). Does not given you 
information that can help you if you are trying to figure out how to treat a 
particular condition.  
 4=Not for 
health, 
diagnosis 
References both no health purpose and no diagnosis 
 5=Not for 
health, 
diagnosis, 
advice 
References no health purpose, no diagnosis, no advice 
 6=Not for 
health, advice  
References no health purpose, no advice 
 7=Not for 
diagnosis, 
advice 
References no diagnosis, no advice 
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 66=Other  
88=NS 99=NC 
 
MedDisPlace
Code  
LU1_Disclaim
erPlaceForTest
ingCode 
 Is there a statement regarding where consumers must live (place of 
residence) in order to purchase a genetic test or services?  
Code explicit statements at the sentence level (i.e., do not assume that an 
international vendor will or will not sell outside its country). 
 0=None No place disclaimer appears on site 
 1=Can’t test in 
NY 
Consumer cannot purchase test or services if living in the state of NY 
 2=Can’t test in 
NY, other US 
state 
Consumer cannot purchase test or services if living in NY AND another 
specified US state (possibly WA)  
 3=Can’t test in 
NY, other US 
state, outside 
US 
Consumer cannot purchase test or services if living in NY AND another 
specified US state (possibly WA) AND outside the US 
 4=Can’t test in 
other US state 
Consumer cannot purchase test or services if living in another specified 
US state (possibly WA). 
 5=Can’t test in 
other US state, 
outside US 
Consumer cannot purchase test or services if living in another specified 
US state (possibly WA) AND outside the US 
 6=Can’t test 
outside its 
country 
Consumer cannot purchase test or services if living outside the country in 
which the vendor’s headquarters or laboratory is located. Could be US or 
other country overseas 
 7=Can’t test in 
NY, UK 
 
 8=Can’t test in 
NY, outside of 
US 
 
 66=Other  
88=NS 99=NC 
Make a note of other item for discussion 
 
CreditCard 0=No 1=Yes 
77=NA 88=NS 
99=NC 
Does the vendor allow for on-line payment by credit card?Only applies 
to vendors that allow consumers to purchase products on-line. Use 77 
when item does not apply (i.e., no on-line sale). Not the same as code 0. 
MoneyOrder 0=No 1=Yes 
77=NA 88=NS 
99=NC 
Does the vendor allow for on-line payment by money order? Only 
applies to vendors that allow consumers to purchase products on-line 
Personal 
Check 
0=No 1=Yes 
77=NA 88=NS 
99=NC 
Does the vendor allow for on-line payment by personal check?Only 
applies to vendors that allow consumers to purchase products on-line 
ATM 
 
0=No 1=Yes 
77=NA 88=NS 
99=NC 
Does the vendor allow for on-line payment by ATM card? Only applies 
to vendors that allow consumers to purchase products on-line. Not likely 
to appear. Code only if there is explicit mention of ATM 
Other 
Payment 
0=No 1=Yes 
77=NA 88=NS 
99=NC 
Does the vendor allow for on-line payment by another method?Only 
applies to vendors that allow consumers to purchase products on-line 
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OtherPaymen
tName 
Text State the name of other payment option(s). Separate each option by a 
comma. 
InsCover   Does website mention insurance coverage for NGx test? 
InsCoverCode  1= Not 
Mentioned 
 
LU2_Insuranc
eCoverage 
Codes 
2=Yes, Private 
Ins Covers 
NGx test 
 
 3=Yes, Public 
Ins Covers 
NGx test 
 
 4=Maybe General Reference to Insurance 
 5=No, NGx test 
NOT 
COVERED by 
Ins 
 
 6=Yes, Private 
Public Ins 
Covers NGx 
test 
 
 7=Provides bill 
info for 
consumer to 
send to ins 
 
 77=NA 88=NS 
99=NC 
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Access table name 
Variable 
Format/ Value Description 
The following Web Placement Codes that apply to variables #1-9 listed on the next page. 
WebItemPlaceCode  Select the most prominent location of the page. 
LU1_WebItem 0=None Item does not appear on website 
PlacementCode 1=All pages 
item prominent 
(prom) 
Item can be seen in a prominent location or style from any page of 
website. Actual information or statement, not a description of what 
appears on another page. Most likely to appear along the perimeter 
toward the top of the page. “Prominent” determined by: 1) font 
larger than majority of text on page, 2) font color different from 
what is used on majority of page, 3) graphic/logo appears at 
location, etc. 
 
2=All pages 
item minimized 
(min) 
Item can be seen in a subdued location or style from any page of 
website. Actual information or statement, not a description of what 
appears on another page. Most likely to appear along the perimeter 
toward the bottom of the page. “Miminized” determined by: 1) 
font smaller than majority of text on page, 2) same color as what is 
used on majority of page, 3) none to small graphic/logo, etc 
 
3=All pages 
link prom 
Link to actual information can be seen in a prominent location or 
style from any page of website. Includes links in standing menus 
or standing menu dropdown items. 
 
4=All pages 
link min 
Link to actual information can be seen in a subdued location or 
style from any page of website. 
 
5=homepage 
link prom 
Link appears prominently on homepage only.  
 
6=homepage 
link min 
Link appears subdued on homepage only. 
 
7=homepage 
item prom 
Item appears prominently on homepage only.  
 
8=homepage 
item min 
Item appears subdued on homepage only. 
 
9=other page 
link prom 
Link appears prominently on another page that is not the 
homepage. Link may appear on more than one page, but not 
homepage. 
 
10=other page 
link min 
Link appears subdued on another page that is not the homepage. 
Link may appear on more than one page 
 
11=other page 
item prom 
Item appears prominently on another page that is not the 
homepage. Link may appear on more than one page 
 
12=other page 
item min 
Item appears subdued on another page that is not the homepage. 
Link may appear on more than one page 
 
13=other 
domain 
Item or link appears on another page that is not under the domain 
name of the homepage currently being coded. A different domain 
does not have the vendor’s homepage as part of the address. 
 
88=NS 99=NC 
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Variable 
Format/ Value Description 
1  
Education 
 
Use 
LU1_WebItem
PlacementCode 
listed on 
previous page 
If the website includes GENETIC-RELATED educational 
material where is it located? Does not refer to information about 
the specific products and services provided by the vendor. More 
general information. Topics may include genetic science, 
technology, info, etc. Page specific. Page must have no product 
promotion on the page. If information (or any of the other 
variable items listed below—NewsMedia-ShopCartCheckout) is 
located in more than one place, select the most prominent location. 
Most prominent locations appear at toward the top of the category 
list (see next page for variable category list). To select “link 
prominent” or “link minimized” title of link must be genetic-
related topic (DNA, breast cancer), or education related topic (for 
more info, learning about..., understanding...) 
2 
NewsMedia  
 
 Does the website include news coverage from newspapers, 
magazines, radio or television FOR THE VENDOR AND 
THEIR GENETIC SERVICES? To select “link prominent” or 
“link minimized” title of link must be news related. Does not 
include press releases the vendor has written (usually have the 
vendor’s letter head or org information at the top). Does not 
include scientific literature. Does not include newsletters 
3  
MoneyBackTest  
Does the vendor offer a money back guarantee on genetic tests? 
Does not include supplements or other types of tests. 
4  
MoneyBackSup 
 
Does the vendor offer a money back guarantee on supplements? 
Does not include tests.  Organization selling the supplements does 
not have to sell a genetic test (e.g., the partner of an organization 
that sells a genetic test). 
5  
InfoEncryption  
 Does the website encrypt information entered by consumers?  
Information may be provided under a privacy topic area or 
statement. Logo may appear indicating encryption of 
submitted/sent information. 
6  
TestimPlaceCode  
 Does user testimony (current or previous) appear on the website? 
REGARDING GENETIC SERVICES 
Need to read the testimonial to see if it makes specific mention of 
genetic testing. To select “link prominent” or “link minimized” 
title of link must be testimony-related (from our patients, patients 
speak out, customer voices) 
7   
TestimPicPlace 
Code 
 Is a photo of the person(s) providing a testimony about a genetic 
test provided on the website?  
8  
ShopCartLink  
Is there a link to a virtual shopping cart in which the consumer 
places items for on-line purchase? 
9 
ShopCartCheckout  
Where is the shopping cart check out page located? 
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Access table name 
Variable 
Format/ Value Description 
DateStampCode 
LU1DateStampCodes 
 
Does a date stamp appear on any of the website pages? Usually 
located on the bottom of a page in left or right corner 
 0=No date 
stamp 
 
 1=all pages ON/ 
AFTER 1 May 
06 
 
 2=all pages 
before 1 May 
06 
 
 3=homepage 
ON/ AFTER 1 
May 06 
 
 4=homepage 
before 1 May 
06 
 
 5=other page 
ON/ AFTER 1 
May 06 
 
 6=other page 
before 1 May 
06 
 
 7=other domain 
 
 88=NS 99=NC 
 
EChat 
 
0=No 1=Yes 
88=NS 99=NC 
Can consumers communicate with vendor staff live on-line via 
instant messaging or other eChat format? 
EApproval 
 
0=No 1=Yes 
88=NS 99=NC 
Do any seals of approval or awards appear on the website for its 
design or information content? 
Also include professional organization logos. 
EApproval1-5 
 
Open coding 
 
What quality or professional seals, approvals, or awards appear 
on the website? 
EApprovalCode 
EApproval 
LU1_EApprovalCode
s 
0=None 
1=American 
Assn of 
Naturopathic 
Physicians 
2=Award of 
Excellence 
Study Sphere… 
List up to 5 of the first listed approvals or professional seals. Open 
ended coding in look up table. New text entries added to list of 
variable categories. Make note of added approvals for discussion. 
Text entry full name of seal or approval. 
 
 
{Note: Not a complete list of variable values resulting from open 
coding} 
 88=NS 99=NC 
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ProvideHgxTest 
 
0=No 1=Yes 
88=NS 99=NC 
Excluding NGx tests, Does the vendor sell or promote 
a health related genetic test? Must be specifically 
named. If offered, it will be mentioned by name. 
HgxTestID 
HgxTestID 
 What health related genetic tests does the vendor sell 
or promote? 
LU2_TestHgxID 1=Prenatal Screening of fetus for a health condition. Not for 
gender. 
 2=Newborn Screening of newborn for health condition 
 3=Diagnostic To identify an existing health condition 
 4=Carrier To identify carrier status for a particular disease 
 5=Predictive Adult Onset 
Health 
To identify predisposition to a health related condition 
that may occur at some point in the future, e.g., 
Alzheimer’s. Do not include common NGx 
conditions: heart, bone, insulin, obesity  
 6=Behavior  To identify a predisposition to or presence of a 
behavior related condition, e.g., alcoholism, violent 
behavior, depression.  
 7=Pharmacogenetic To identify gene variants associated with response to 
specific drugs 
 8=Dermagenetic To identify gene variants associated with aging, skin 
vitality, other cosmetic attributes. 
 9=DNA repair Does not involve specific gene variants. Identifies 
DNA health. 
 66=Other  88=NS  99=NC Make a note of the item for discussion 
ReasonHgxTest1-
10 
ReasonTestCode  
LU2_ReasonFor 
TestingCode 
Open coding If applicable, list up to five reasons for health related 
genetic testing mentioned on site. Select the 10 first 
mentioned reasons. Not brand-name test specific. Code 
at sentence level. If no health related genetic test 
provided than check 77=Not Apply.  
 0=No reason provided  
 1=Diagnose existing 
condition 
Diagnose a specific existing condition. 
 2=Predict onset of condition Determine whether or not the consumer will have a 
specific condition at some point in the future.  
 3=Care and treatment 
decisions 
Making decisions about how to ensure future health, 
prevent disease, manage existing health conditions, etc. 
 4=Peace of Mind Reduce anxiety, improve emotional well-being. 
Involves uncomfortable or difficult to manage 
emotions, feelings, or mental state. 
 5=Personal curiosity 
entertainment 
Curiosity, self-exploration, self-actualization, fun. No 
relation to health or physical/emotional well-being. 
 6=Legal  Employment, insurance, immigration, inheritance, 
custody. Tests results can be provided as evidence in a 
court of law or for some legal proceeding 
 7=Protection Infidelity, victim identification, crime solving, 
forensics 
 8=Determine best 
supplements, nutrients, diet 
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 9=Maximize health, 
wellness, longevity 
Maximize wellness, longevity. Take measures to make 
the body as healthy and fit as possible. Take steps to 
live a long and healthy life. 
 10=Identify poor, inefficient 
gene function 
Identify genes that may not be functioning as they 
should. Identify problem areas in the DNA. Statement 
focus on poor or in appropriate or inadequate gene 
function. 
 11=Better understand 
disease/ condition 
 
 12=Weight loss/weight 
control 
 
 13=Improve interactions 
with health system 
 
 14=Improve interactions 
with legal system 
 
 15=Personal responsibility/ 
empowerment 
 
 16=Compliance/Adherence 
easier 
 
 17=You have a right to your 
health info 
 
 18=Improve pregnancy 
outcomes 
 
 19=Return of lost children  
 20=Better understand your 
health (general) 
 
 21=Slow Aging / Healthy 
Aging 
 
 22=Determine best physical 
activity 
 
 23=Test has high level of 
accuracy 
 
 24=Vendor can provide 
proof it works (biomarker 
test) 
 
 25=modify gene expression  
 26=monitor therapeutic 
effectiveness of 
interventions 
 
 27=save time and money  
 28=action will be effective 
because personalized 
#29 skipped 
 30=improve physical 
appearance / look better 
 
 66=Other 77=N/A  
88=NS 99=NC 
{Note: Not a complete list of variable values resulting 
from open coding} 
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RiskHgxTest1 -5  
TestRiskCode  
LU2_RisksAssociate
dWithTestingID 
Open coding What risks associated with taking a health related 
genetic test does the vendor mention? Select 10 first 
mentioned reasons. Not brand-name test specific. Code 
at sentence level. Broad interpretation of risk to include 
warnings, precautions, caveats. Make note of all other 
risks. If no Hgx test, then check 77=Not Apply.  
 0=None  
 1=health insurance 
discrimination 
Test results may result in loss of or reduced health 
insurance coverage 
 2=employment 
discrimination 
Test results may be used in making current or future 
employment decisions 
 3=anxiety re: test results Test results may cause anxiety regarding future 
personal or familial health. May be warranted or 
unwarranted. 
 4=treatments not available 
or limited 
Treatments for the disease/condition associated with 
the test are limited or not available.  
 5=supplement use may 
cause harm 
Supplements can have side effects or use may lead to 
an unintended negative outcome. 
 6=limitations on genetic 
research or science 
Genetics cannot tell us everything we need to know 
about our health. We don’t know what all genes in the 
body do. There are limits to what genes or genetic 
science can tell us. 
 7=test results must be seen 
in larger context 
You cannot look at test results alone to understand 
current or future health. Must look at other aspects of 
the individual. Must consider other health information 
such as family history, lifestyle, presence of other 
conditions. 
 8=relevance of test results to 
family members 
Genetic information is shared. An individual’s test 
results may indicate that a family member has the 
identified gene (and related condition) as well. Need to 
consider family members’ right to know or not know 
information identified in genetic testing. 
 9=not for single gene 
disorders/Mendelian traits 
 
 10=not for inherited gene 
linked to specific disease 
 
 11=genetic factors not 
tested can cause condition 
 
 12=life insurance 
discrimination 
 
 13=not a complete genetic 
profile 
 
 14=limitation to precision of 
test 
 
 15=lack of definable /clear 
symptoms of condition 
 
 16=not test for conditions 
that are not modifiable 
 
 190 
Variable Names 
Access table name Variable Format/Value Description 
 17=test for risk not certainty 
about future health 
 
 18=no FDA approval of 
supplements 
 
 19=no FDA approval of test  
 20=results may be 
population specific 
 
 66=Other 77=N/A  
88=NS 99=NC  
{Note: Not a complete list of variable values resulting 
from open coding} 
ProvideSgxTest 
 
0=No  1=Yes   
88=NS  99=NC 
Does the vendor sell or promote a social related 
genetic test? Prenatal gender identification, familial 
relationship, ancestry, infidelity, banking DNA. 
SgxTestID 
SgxTestID 
 What social related genetic tests does the vendor sell 
or promote? 
LU2_TestSgxID 1=Prenatal Sex To identify sex of fetus 
 2=Familial To identify an immediate familial relationship, e.g., 
maternity, paternity, sibling, twin, grandparent 
 3=Ancestry To identify racial/ethnic background 
 4=Identity  To create a genetic profile for purposes of future 
identification of DNA. May include provision of a 
genotype identification card. May or may not be for 
purely recreational purposes. 
 5=Infidelity To determine whether or not a spouse has been faithful 
 6=Banking To collect and store DNA for future use (personal or 
research) 
 66=Other 88=NS 99=NC Make a note of other  items for discussion  
ReasonSgxTest1-10  
ReasonTestCode 
LU2_ReasonFor 
TestingCode 
Use LU2_ReasonFor 
TestingCode listed at 
variable ReasonHgxTest1-
10 
What reasons for taking this social related genetic test 
does the vendor mention or discuss?  
Select the 10 first mentioned reasons. Not brand-name 
test specific. Code at sentence level. If no social related 
genetic test provided than check 77=Not Apply 
RiskSgxTest1-10  
TestRiskCode 
TestRisk  
Use 
LU2_RisksAssociatedWith 
TestingID listed at variable 
RiskHgxTest1-10 
What risks associated with taking a social related 
genetic test does the vendor? 
Select the 10 first mentioned risks Not brand-name test 
specific. Code at sentence level. 
If no social-related genetic test provided than check 
77=Not Apply 
PrivacyPolicy 0=No 1=Yes 88=NS 99=NC Is there a privacy/confidentiality statement on the 
site? Include any statement on privacy (e.g., personal 
information, test results, cookies, etc.) 
DestroySpecimen 
SpecimenHandle 
LU1_SpecimenHand 
 Does the site mention what is done with collected 
biological specimens (e.g., DNA, blood, buccal swab) 
when testing is complete? 
ling 0=no/does not mention 
 
 1=yes, destroyed/disposed Collected specimens are destroyed after testing is 
complete 
 2=yes, kept confidential The vendor keeps the specimen. Personally identifying 
information is kept confidential.  
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3=yes, kept confidential for 
specific time period 
The vendor keeps the specimen for a particular time 
period (6 months, 5 years, 20 years). Personal info is 
confidential. DOES NOT MENTION what happens to 
the specimen after the time period ends. 
 
4=yes, kept confidential for 
a time then destroyed. 
The vendor keeps the specimen for a particular time 
period (6 months, 5 years, 20 years). Personal info is 
confidential. The specimen is destroyed at the end of 
the time period. 
 
5=yes, unidentified 
(anonymous) 
The vendor keeps the specimen but removes all 
personally identifying information. The specimen is 
“deidentified” or “unidentified”. The specimen 
becomes anonymous. 
 
6=yes, unidentified and 
stored for researcher. 
The unidentified specimen is kept by the vendor and 
used for research activities which are not related to the 
testing received by the consumer 
 
7=yes, confidential, stored 
for reference, follow-up 
The vendor keeps the specimen so that if there are any 
follow-up questions or concerns confirmatory testing 
or analysis can be completed. 
 
8=yes, unidentified shared 
for accreditation 
 
 
9=yes, unidentified shared 
accreditation, research 
 
 
10=yes, unidentified stored 
for research, reference 
 
 
11=yes, unidentified 
research, reference, QA 
QA quality assurance 
 
88=NS 99=NC  
ResultsHandling  
 
Use LU1_Specimen 
Handling codes at variable 
DestroySpecimen 
Does the site mention what is done with genetic test 
results when testing is complete? 
i3_av (analytic 
validity) 
 How often do their NGx tests correctly identify the 
TARGETED GENE VARIANTS? 
tbl3_LU5_ProductA 0=does not mention at all 
 
cc uracyCodes 1=always accurate/effective 
(99%+) EXPLICIT 
statement 
 
 
2=always accurate/effective 
(99%+) IMPLIED statement 
 
 
3=most of the time 
EXPLICIT statement 
 
 
4=most of the time 
IMPLIED statement 
 
 
5=mentions something 
about it but extent not clear 
 
 
66=Other 77=NA  
88=NS 99=NC 
 
i3_cv (clinical 
validity) 
Use values from tbl3_LU5_ 
ProductAccuracyCodes 
listed at variable i3_av 
How often do their NGx tests PREDICT THE 
CONDITION focuses on? i.e., the likelihood you will 
get the condition if the test results are positive? 
FDARevTest  Has FDA reviewed their NGx tests? 
tbl3_LU2_Presence 0=does not mention 
 
QualifiedCodes 1=yes, stated explicitly  Crystal clear 
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2=yes, stated implicitly  Safe to assume 
 
3=no, stated explicitly 
 
 
4=no, stated implicitly 
 
 
5=maybe  Provides mixed information 
 
6=it may, it could Has potential 
 
66=other  
77=NA  
88=NS  
99=NC 
 
 
 
i7peertest 
tbl3_LU4_Literature 
 Does the vendor provide PEER REVIEWED 
literature regarding the gene and the condition? 
Codes 0=lit/study not mentioned 
 
 
1=access to full text 
definite--provides link that 
works in IR 
 
 
2=access to full text 
possible--link mentions full 
text but can't confirm 
 
 
3=link regarding lit/study 
appears but does not specify 
where link goes 
 
 
4=provides complete 
citation--no link 
 
 
5=describes/mentions 
lit/study BUT no citation 
and no link provided 
 
 
77=NA 99=NC 
 
i7peersup Use 
tbl3_LU4_LiteratureCodes 
listed at variable i7peertest 
Does the vendor provide PEER REVIEWED 
literature regarding the gene, health condition, and 
the supplements? 
i7labtest Use 
tbl3_LU4_LiteratureCodes 
listed at variable i7peertest 
Does the vendor provide LAB CONDUCTED 
STUDIES regarding the gene and the health 
condition? 
i7labsup Use 
tbl3_LU4_LiteratureCodes 
listed at variable i7peertest 
Does the vendor provide LAB CONDUCTED 
STUDIES regarding the gene, health condition, and 
the supplements? 
RequiredMD Use 
tbl3_LU2_PresenceQualifie
d Codes at variable 
FDARevTest 
Is a conversation with a PHYSICIAN (MD) OR 
NURSE REQUIRED to take a NGx test? 
RequiredGx Use 
tbl3_LU2_PresenceQualifie
d Codes at variable 
FDARevTest 
Is a conversation with a GENETIC COUNSELOR 
OR GENETIC EXPERT REQUIRED to take a NGx 
test? 
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Variable Names 
Access table name 
Variable 
Format/Value Description 
NGxTestUID AutoNumber 
(Hidden) 
Unique identifier for NGx test. Automatically generated. 
NGxTestName Text What is the name of the NGx test? Each test listed on the 
website must be coded separately.  
A single test can several different conditions and it should be 
entered as one test—such a test is often not named with a 
particular conditions e.g., Men’s 40 Plus, Comprehensive 
Profile. 
An organization may sell several individual tests that are 
included in a comprehensive test (e.g., Heart Health Test, Bone 
Health Test, Insulin Sensitivity Test, and Comprehensive Health 
Test). The individual and comprehensive tests must be listed 
separately. 
NAME TESTS AS FOLLOWS: [one word or acronym for 
vendor] [name of test manufacturer if provided and different 
from vendor] [name of test] .  Examples: Biamonte Integrative 
Genomics (vendor=biamonte, test name=Integrative Genomics) 
NHC Cardio Genomic Profile (vendor=Natural Health of 
California, test name=Cardio Genomic Profile) 
NGxTMCode 
NGxTMCode 
LU1_NGxTMCode
s 
0=No 
1=Yes, owned by 
vendor 
2=Yes, owned by 
other org 
3=Yes, not sure who 
owns 
88=NS 99=NC 
Does the test have a trademark symbol (TM) after its name? 
NGxRCode 
NGxTMCode 
 [only variable 
name changed] 
0=No 
1=Yes, owned by 
vendor 
2=Yes, owned by 
other org 
3=Yes, not sure who 
owns 
88=NS 99=NC 
Does the test have a registered symbol (®) after its name? 
SupDeliveryCode  
SupDeliveryCode 
LU1_Supplement 
DeliveryCodes 
 Does the vendor provide or recommend supplements based on 
NGx test results? Supplements recommended based on test 
provided with results. Does not include lifestyle 
recommendations (e.g., exercise more, eat less) 
 0=None offered Does not sell or promote NGx supplement use 
 1=Yes, vendor’s Vendor sells supplements that it manufactures and labels 
Example: Suracell, OnePersonHealth  
 2=Yes, other org Vendor sells or promotes supplements manufactured and labeled 
by another entity or encourages consumers to purchase the 
supplements of another entity 
 3=Yes, Not Clear Vendor sells or promotes supplements of an unknown entity 
 88=NS 99=NC  
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LifestyleRec 
 
0=No 1=Yes 88=NS 
99=NC 
Does the vendor provide lifestyle recommendations (e.g., 
exercise more, eat less, don’t smoke) based on test provided 
with results? Does not include supplement recommendations. 
NGxConditionID  Open coding  What health condition does this test address?  
LU2_NGxTestHeal
thConditionID 
0=Not specified 
1=Bone health 
2=Detoxification 
3=Heart/cardiovascu
lar disease 
4=Immune 
5=Insulin / 
insulin/glucose 
6=Neurological 
7=Obesity 
8=Inflammation 
9=Vitamin B use/ 
metabolism/ 
pathways/folate 
uptake   
10=Antioxidant/ 
free radical handling 
11=Cholesterol 
imbalance 
12=Hypertension… 
When new condition is identified, assign code number, create 
variable, use consistently, and note addition for discussion. Use 
terminology presented on website and establish separate codes 
for similar conditions when different terms are used, e.g., 
hypertension vs. high blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
{Note: Not a complete list of variable values resulting from open 
coding} 
GeneVariants 0=No 1=Yes  
88=NS 99=NC 
Are the specific gene variants identified by the test listed? 
VariantsExplain 
 
0=No1=Yes  
77=NA  
88=NS 99=NC 
Does it state what role the gene variant plays in health?  
Use 77=N/A if no gene variants are listed 
GeneVariantsTest
ed 
GeneVariantID 
LU_2GeneVariants
Tested 
Open coding  
Auto Number ID for 
new values 
 
What genetic variants are identified by the test? When new 
gene is identified, create variable, use consistently, and note 
additions for discussion. Use symbols or names presented on 
website and establish separate variables for the same gene if 
different symbols or names are used. 
 0=BRCA1/2 
1=ACAT 
2=ACE 
3=AHCY 
4=ALDH2 
5=APOB 
6=APOC3 
7=APOE 
8=BH-2 
9=BHMT 
10=CBS… 
666=Other 
777=Not Applicable 
888=Not Sure 
999=Not Checked 
 
 
 
 
 
 
 
 
 
 
 
{Note: Not a complete list of variable values resulting from open 
coding} 
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NGxTestCost Enter value  
Currency 
Lowest cost of individual NGx test. If the lowest cost mentioned 
on the site includes counseling, then put cost in the 
NGxTestConCost. There may be a higher cost for an individual 
test if you can buy a consultation with a health care provider with 
the test.  Do not list the cost of a bundle in which the test may be 
included—the bundle may include supplements or other tests. If 
the only costs provided are bundled, add the cost and description 
to Notes2 field 
NGxTestSupCost  Currency Cost of test with genotype customized supplements, if offered. 
Do not list the cost of supplements on  their own. Must state 
explicitly that this is the cost of the test with the purchase of 
supplements. If the only costs provided are bundled, add the cost 
and description to Notes2 field 
NGxTestConCost  Currency Cost of test with a health care provider consultation with 
healthcare provider, if offered. Must mention that consultation 
is provided with the test when stating the price. Do not list the 
cost of a bundle. Must be an individual test with counseling. If 
the only costs provided are bundled, add the cost and description 
to Notes2 field 
HealthBundle 
 
0=No 1=Yes 88=NS 
99=NC 
 
Is the NGx test included for sale in a bundle with other health 
related tests? NGx Test included in a bundle of several health gx 
tests. No social gx tests are included in the bundle  
SocialBundle 
 
0=No 1=Yes 88=NS 
99=NC 
 
Is the NGx test included for sale in a bundle with other tests 
that include social genetic tests? 
NGx Test included in a bundle of several tests that includes 
social (and possibly, but not required) health related genetic tests.  
SupBundle 
 
0=No 1=Yes 88=NS 
99=NC 
 
Is the NGx test included for sale in a bundle with personalized 
supplements? NGx Test bundled with supplements (i.e., buy test 
and get supplements at a discounted price, supplements included 
in the purchase of the test, supplements provided for free with 
purchase of test)  
Service related variables used to code variables 1-4 listed below 
ServiceCode  
LU1_AvailableSer 0=No mention 
Does not mention consultation/genetic counseling in regarding to 
NGx testing anywhere on the site.  
viceCodes 1=Required  Website states explicitly that patient/consumer must receive 
consultation/counseling in order to get test results. Cost 
information may or may not be provided.  
For laboratories, site may say that the patient must come into 
their facilities to receive test results  
For laboratories, site may say that tests can only be ordered by a 
physician who will receive tests results and provide them to the 
consumer. 
 2=Additional cost Consultation/counseling provided for an additional cost that is 
not included in the cost of the test. 
The site shows two costs for the test—one without 
counseling/consultation =$XXX, and a second cost with 
counseling/consultation=$XXX+$XX). Clearly in this case 
counseling/consultation is not required. 
 196 
Variable Names 
Access table name 
Variable 
Format/Value Description 
 3=Available Consultation/counseling services are available when the vendor 
orders test for consumer and provides consumer with test results. 
Cost information may or may not be provided.  
If vendor appears to provide test results but does not mention 
which staff will provide the results than code “not specified 
consultation” as available and all others as no mention. 
 4=Suggested not 
offered 
Recommends or suggests that patient/consumer obtain 
consultation/counseling regarding test results, but it does not 
state that the vendor will provide it and does not provide detailed 
information on where to get it. The vendor may not have 
clinician, nutritionists, or genetic counselors on staff and thereby 
suggests the consumer go elsewhere. 
The site might mention that the patient’s/consumer’s health care 
provider will provide them with information about what the test 
results mean.  
The site might mention that the patient/consumer should see 
someone regarding how to interpret or understand test results. 
 66=Other 88=NS 
99=NC 
Make a note of other items for discussion 
1 
ConsultationCode 
Use ServiceCode 
variables for these 
four 
Is some sort of consultation (not specified) provided by 
someone (not specified)?The answer to the three variables below 
must be “No” if this variable is “Yes” 
2 
GenCounsCode  
 Are genetic counseling services available for NGx testing 
through this vendor? Must refer to genetic counseling in 
particular. Usually provided by a certified genetic counselor or a 
medical geneticist or a clinical geneticist. Must be provided by a 
genetic professional to be considered genetic counseling. 
3 
MDConsultCode  
 Are consultation services with a clinical geneticist, other 
physician, or nurse available for NGx testing through this 
vendor? The consultation is clearly provided by a medical 
professional who may or may not have expertise in genetics. 
Must be a physician (medical doctor, clinical geneticist, MD) or 
nurse (primary care, family practice, RN, NP). Does not include 
other health care practitioners such as ND, DO, MSW, Certified 
Nutritionist, Acupuncturist, registered dietician, etc. 
4 
NutConsultCode  
 Are consultation services with a nutritionist available for NGx 
testing through this vendor? 
Includes certified nutritionist, registered dietician. 
TestDeliveryCode 
LU1_TestDelivery 
 In what ways can the consumer get access to more information 
or actual NGx tests and services? 
Codes 
0=Not discussed 
Website does not provide any contact information for how to get 
services or information.  
Vendor contact information must not appear on site. 
 1=eInquire Consumer enters personal contact information or message into 
fields on page of website to request more info about product or 
services (i.e., does not state that information is provided for 
purchase).    Does not include a link to an e-mail address that 
opens an email in the consumers email software (e.g., Microsoft 
Office Outlook) 
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Variable Names 
Access table name 
Variable 
Format/Value Description 
 2=eSchedule Consumer enters personal contact information or message into 
fields on page of website to receive more information AND/OR 
schedule an appointment. 
 3=ePurchase  Consumer enters personal contact and payment information (e.g., 
credit card, other ePayment) on website to receive testing kit in 
mail for specimen collection at home (i.e., consumer is making 
an on-line purchase). 
 4=Promotes (call for 
more info) 
Consumer cannot enter any personal information on website. 
Must call, e-mail through consumer’s software (email address 
and text not entered on webpage), or visit vendor to receive more 
info, products, or services. 
 5=Promotes (link to 
other company) 
 
 66=Other 88=NS 
99=NC 
Make a note of other items for discussion  
NGxRsltsViaCode 
LU1_NGxResults 
 How are NGx test results provided to the consumer (i.e., via 
what routes of communication)? 
ViaCodes 0=Not mentioned  
 1=In Person  Consumer must receive test results from someone face to face 
 2=Website Log into website to obtain test results on-line. Results are read on 
website. 
 3=E-mail Test results sent to consumer by e-mail. Receipt does not require 
login to website. 
 4=Phone Consumer calls or is called by org to receive test results by 
phone. 
 5=Post Mail Test results sent to consumer in US Postal Mail, FedEx, etc. 
 6=Web, e-mail  
 7=web, phone  
 8=web, postal mail  
 9=Web, e-mail, 
phone 
 
 10=Web, e-mail, 
phone, post mail 
 
 11=e-mail, phone  
 12=e-mail, post mail  
 13=e-mail, phone, 
post mail 
 
 14=phone, post mail  
 15=in person, e-
mail, postal mail 
 
 16=in person, postal 
mail 
 
 66=Other  
88=NS  
99=NC 
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Variable Names 
Access table name 
Variable 
Format/Value Description 
NGxRsltsByCode  
LU1_NGxResults 
ByCodes 
 Who provides test results in person or by phone?  
Person providing test results may not be the same person as the 
one that provides counseling or consultation if provided.  
 0=Not provided No information is provided regarding how the consumer will 
receive test result. Different from #8. 
 1=Print only  Results provided via e-mail, on website, or in postal mail only. 
No human being is involved in the communication or discussion 
of results. If counseling or consultation is required, then select 
the type of professional that provides the counseling/consult 
using one of the other variable categories. 
 2=Vendor genetic 
counselor 
 
 3=Vendor MD/ 
Nurse 
Medical doctor or nurse on staff, including  
 4=Vendor ND  Naturopathic doctor on staff 
 5=Vendor 
nutritionist  
Nutritionist or registered dietician RD, certified nutrition 
specialist CNS 
 6=Vendor geneticist Geneticist who is not a clinician (e.g., researcher in R&D) 
 7=Vendor lab tech  
 8=Vendor staff not 
identified 
It is clear that someone working in the org will provide the test 
results but the profession of that individual is not stated. 
 9=Consumer’s usual 
care provider 
Test results are sent to the consumer’s chosen health care 
provider. Would apply in cases where a consumer-selected care 
provider orders test for consumer. Provider is not on vendor staff 
and is not on staff at lab that analyzes test. Vendor may say to 
“contact your care provider for more info or to get tested.”  
 66=Other 88=NS 
99=NC 
 
DTCResults 
Option 
 
0=No 1=Yes 88=NS 
99=NC 
Does the website mention anything about keeping test results 
out of the consumer’s medical record or keeping the test results 
out of the hands of a physician? Provides some information 
about how the consumer can keep the info from a medical 
record/physician or that the vendor does not report info to a 
medical record/physician. May also mention that people have 
concerns about information in their medical record and testing 
with the vendor can address that concern. 
NGxTestReason1-
10  
 
Use LU2_Reason 
For TestingCode at 
variable Reason 
HgxTest1-10 
What reasons does the vendor provide for NGx testing? Select 
the 10 first mentioned reasons. NGx test specific. Code at the 
sentence level. Do not enter new codes (code 66=other). Record 
new reasons for discussion. 
NGxRiskTest1-10  
 
Use LU2_RisksAss 
ociatedWithTestingI
D listed at variable 
RiskHgxTest1-10 
What risks are associated with taking a social related genetic 
test does the vendor?Select the 10 first mentioned risks Not test 
specific. Code at sentence level. Do not enter new codes (code 
66=other). Record new reasons for discussion. 
OneLiners Text (Memo) Any interesting 1 or 2 sentence statements about the test? Pull 
direct quotes from website and URL 
Notes1-12 Text(Memo) Use Notes fields liberally. Record location of new codes for 
discussion, exemplar quotes, URLs for “hard to find” codes, 
uncertainties or questions. 
    
 
 
 
Appendix 2: Reliability Testing for Content Analysis of Websites  
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 200 
Brief Overview of Reliability Testing for Coding of Commercial Websites for  
Mentioned in Nutrigenomic Test Descriptions 
 
Rene Sterling, MHA 
Drafted August 12, 2008 
 
 
 
Reliability Testing Overview 
 
Kappa statistics were computed to compare results of websites and variables coded by both the 
candidate (RS) and her research assistant (RA). The primary goal of Kappa testing was to improve 
accuracy in the descriptive analysis of websites (i.e., identify the “right” answer for each variable and 
correct all disagreements through consensus).  
 
 
Appendix 2 Figure 1. List of organizations hosting websites coded by candidate and research 
assistant, March – May 2007 (n=36)  
 
 
Complete Health 
CVS/pharmacy 
CyGene Laboratories 
DaVinci Laboratories of Vermont 
Dawn A. Lancaster, DC 
Determigene 
Elan Vital Medical Centers and Spas 
Executive Medicine of Southlake 
GeneCare Molecular Genetics (Pty) Ltd. 
Genelex 
GeneLink, Inc. 
Genetic Health 
Genosense Diagnostics 
GenovaDiagnostics 
Hardy Healthcare Associates 
Holistic Naturopathic Center 
Hunter Yost, MD 
Integrative Health Solutions 
 
 
Jim Otis, DC, DACNB 
Label Me Sane  
marketAmerica  
Mommy & Me Chiropractic 
Natural Health California 
Nicola McFadzean 
nutraMetrix—Kristy McKendrick, ND 
Nutrigen 
OnePersonHealth 
Rebecca Muttart, ND 
Sanoviv Medical Institute 
Sciona 
SOMA Acupuncture & Natural Health Clinic 
Suracell 
The Biamonte Center for Clinical Nutrition 
The DNA Testing Centers 
The Maas Clinic 
Vibrance Medical Group 
 
 
RS and the RA coded 36 of the 64 (56%) websites included in this study (see Appendix 2 Figure 1 
above for list of websites). Websites were selected for reliability testing to maximize diversity in 
website size and structure, host organization type, and mode of consumer access to services. Prior to 
Kappa testing, all qualitative notes fields (used to note new or rare observations) were reviewed to 
ensure that all variable values were captured quantitatively. Similar response values were grouped to 
facilitate analysis and reporting of several variables with open coding, including: 1) risks (e.g., 
employment discrimination, health insurance discrimination, life insurance discrimination), 2) 
reasons (e.g., determine best supplements, determine best physical activity, determine best life-style), 
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and 3) health conditions (e.g., bone fracture, bone loss, bone metabolism, low bone density). 
Variables values with rare occurrences were collapsed where possible (i.e., categorical variables 
redefined as dichotomous variables) as rare occurrences artificially inflate Kappa values (i.e., 
expected agreement for rare occurrence is high). Variables with null values (i.e., item not identified 
on website by either researcher), variables with qualitative entries (e.g., vendor name, vendor motto, 
partner names), and variables not reported in one of the three manuscripts (e.g., payment types, date 
stamps) were excluded from reliability testing. Kappa statistics were calculated for variables of 
interest using original or redefined values as described above.  
 
Landis and Koch (1977) proposed “clearly arbitrary” but “useful ‘benchmarks’” often used in the 
interpretation of Kappa. As summarized in Appendix 2 Table 1 (below) and listed in Appendix 2 
Table 2 (next page), 59% of variables tested had Kappa values with at least a moderate level of 
agreement (0.41< Κ <1.00). The majority of variables with low agreement were for information 
located in obscure locations found by one of the two coders, variables with rare occurrences, and 
variables requiring highly subjective interpretation of text. Face-to-face meetings to reach consensus 
on all disagreements were held between RS and RA.  
 
 
 
 
 
 
Appendix 2 Table 1. Summary of reliability testing results using Kappa interpretations 
proposed by Landis and Koch (1977)a 
  
 
 
Tested Variables 
(N=104) 
Kappa Statistic Strength of Agreement % N 
0.81 – 1.00 Excellent 18.3 19 
0.61 – 0.80 Substantial 27.9 29 
0.41 – 0.60 Moderate 12.5 13 
0.21 – 0.40 Fair 18.3 19 
0.01 – 0.20 Slight 2.9 3 
≤ 0.00 Poor 20.2 21 
 
a
 Source: Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 
1977;33:159-174. 
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Appendix 2 Table 2. Kappa values for candidate and research assistant website coding of 
variables with defined values and open coding, March – May 2007 
 
   % 
Variable Description a K Std Err Agreement 
Expected 
Agreement 
Defined Values     
Physical street address provided? 0.60 0.16 89.19 72.38 
US location only? 0.69 0.12 89.19 65.60 
Any off-shore location? 0.81 0.16 91.89 57.41 
Phone number provided? (p=0.6) -0.03 0.15 91.89 92.18 
Email provided?  0.62 0.16 91.89 78.60 
CLIA certification? 0.75 0.13 86.49 46.82 
AABB certification? 0.79 0.14 89.19 48.87 
Other laboratory certification? 0.65 0.12 81.08 45.36 
Trademarked test? 0.72 0.09 86.49 51.83 
Registered test? 0.85 0.09 99.10 93.89 
How to purchase test/access more info? 0.51 0.05 63.96 27.02 
Purchase restrictions based on place of residence? 0.72 0.11 91.89 71.15 
Insurance coverage for test? 0.64 0.09 78.38 39.74 
Bundled with other health related genetic test? 0.21 0.06 93.69 92.02 
Bundled with other social related genetic test? 0.66 0.20 99.10 97.33 
Bundled with supplements? 0.24 0.06 90.09 86.91 
Provide/recommend supplements? 0.60 0.09 81.98 54.83 
Lifestyle recommendations offered? 0.21 0.08 78.38 72.75 
Identifies gene variants tested? 0.79 0.09 93.69 69.69 
Explains gene variants tested? 0.75 0.08 91.89 67.87 
How are test results provided? 0.42 0.04 59.46 30.20 
Who provides test results? 0.50 0.04 58.56 16.91 
Keep test results out of medical record? 0.00 - 91.89 91.89 
Disclaimer re: content of website? (p=0.002) 0.44 0.15 72.97 51.64 
Disclaimer re: need to see physician? (p=0.001) 0.26 0.08 59.46 45.36 
Disclaimer re: nature/purpose of test or results? 0.47 0.11 75.68 54.13 
Info encryption on site? 0.29 0.09 75.68 65.74 
General privacy policy? 0.72 0.14 86.49 51.86 
Handling of specimens post-testing? 0.52 0.16 72.97 43.24 
Handling of results post-testing? 0.27 0.10 56.76 40.91 
Genetic counseling available? 0.48 0.05 91.89 84.44 
Clinician/genetic expert consultation available? 0.20 0.06 55.86 44.82 
Nutrition consultation? 0.49 0.05 90.09 80.45 
Unspecified consultation provided? 0.17 0.04 74.77 69.65 
MD on staff? 0.72 0.14 86.49 51.42 
PhD on staff? 0.65 0.15 83.78 53.03 
Naturopathic doctor on staff? 0.94 0.16 97.30 56.32 
Registered nurse on staff? 0.66 0.12 97.30 92.11 
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   % 
Variable Description a K Std Err Agreement 
Expected 
Agreement 
Registered dietician on staff? (p=0.01) 0.36 0.16 91.89 87.36 
Certified nutrition specialist on staff? 0.54 0.16 89.19 76.48 
Certified genetic counselor on staff? (p=0.5) 0.00 0.00 97.30 97.30 
Link to on-line shopping cart? 0.34 0.09 67.57 51.06 
Location of on-line shopping cart within site? 0.38 0.09 72.97 56.10 
Open Coding      
Cost of test? 0.92 0.04 95.50 38.15 
Cost of test and consultation? 0.39 0.04 94.59 91.18 
Reasons for testing     
Not specified 0.71 0.09 95.50 84.25 
Understand health status 0.22 0.09 75.68 68.66 
Inform medical decision making 0.35 0.09 67.57 50.17 
Peace of mind/happiness 0.79 0.09 98.20 91.38 
Inform lifestyle decision making 0.29 0.08 62.16 46.48 
Improve wellness/quality of life/appearance 0.50 0.09 74.77 49.89 
Self empowerment/improve compliance 0.38 0.09 73.87 57.85 
Accurate/Effective/Safe 0.00 - 92.79 92.79 
Cost effective/Convenient/Easy -0.01 0.08 96.40 96.45 
Avoid impact of condition 0.00 - 90.99 90.99 
Modify gene expression 0.00 - 87.39 87.39 
Identify predisposition 0.25 0.07 56.76 42.10 
Risks associated with testing     
Not specified 0.26 0.09 75.68 67.19 
Not a complete genetic profile 0.66 0.09 98.20 94.72 
Anxiety/Results affect family -0.01 0.04 84.68 84.94 
Must see results in larger context 0.08 0.05 84.68 83.43 
No FDA approval 0.00 0.00 98.20 98.20 
No treatment provided/prescribed 0.00 0.00 99.10 99.10 
No clear symptoms for health condition 0.00 - 91.89 91.89 
General risk/Undefined risk 0.00 0.00 94.59 94.59 
Not test for single gene disorder 0.79 0.09 97.30 87.36 
Test for modifiable condition only 0.00 0.00 93.69 93.69 
Test for risk not certainty 0.00 0.00 94.59 94.59 
Not for diagnosis 0.27 0.07 95.50 93.79 
Limitations in science/test precision -0.02 0.09 94.59 94.72 
Conditions tested     
Not specified 0.48 0.09 96.40 93.05 
Antioxidants 0.95 0.09 98.20 67.15 
Detoxification 0.86 0.09 93.69 54.15 
Health general 0.73 0.09 92.79 72.83 
Health process general 0.35 0.07 90.99 86.22 
Immune general 0.66 0.09 99.10 97.33 
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   % 
Variable Description a K Std Err Agreement 
Expected 
Agreement 
Inflammation 0.89 0.09 95.50 57.15 
Oxidation 0.97 0.09 99.10 73.44 
Infectious disease 0.79 0.09 98.20 91.38 
Cancer 0.77 0.09 92.79 68.15 
Blood 0.38 0.09 94.59 91.33 
Immune specific 0.97 0.09 99.10 67.67 
Metabolism general 0.77 0.09 90.09 57.15 
Metabolic process 0.83 0.09 96.40 79.30 
Metabolic condition 0.82 0.09 94.59 70.44 
Mental health 0.82 0.09 98.20 89.76 
Nervous system 0.64 0.09 94.59 85.03 
Eye 0.80 0.09 99.10 95.59 
Circulatory/Vascular 0.82 0.09 92.79 60.56 
Heart 0.85 0.09 92.79 52.89 
Respiratory 0.81 0.09 97.30 85.85 
Digestive 0.81 0.09 97.30 85.82 
Skin -0.01 0.09 98.20 98.21 
Muscle/joint 0.85 0.09 97.30 81.42 
Bone 0.94 0.09 97.30 51.03 
Urinary 0.66 0.09 99.10 97.33 
Pregnancy 0.00 0.00 99.10 99.10 
Congenital 0.00 0.00 98.20 98.20 
Symptoms 0.00 0.00 99.10 99.10 
Abnormal biomarker 0.87 0.09 96.40 72.76 
Injury drug related 0.76 0.09 97.30 88.97 
Injury other chemical related 0.74 0.09 98.20 99.10 
Injury physical 0.00 0.00 99.10 99.10 
Stress 0.00 0.00 99.10 99.10 
 
a See codebook in Appendix 1 for variable names and values. 
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Analysis of Claimed Associations between Genes and Health Conditions 
Mentioned in Nutrigenomic Test Descriptions 
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BACKGROUND 
 
The candidate’s manuscript titled, “The On-line Promotion and Sale of Nutrigenomic Services,” was 
submitted to Genetics In Medicine for publication. The candidate received a “revise and resubmit” 
from the journal, and the revised submission is presented in Chapter 3. The primary weakness 
reported by one of the two reviewers was in regard to a face validity assessment of claimed 
associations between genes and health conditions reported in nutrigenomic (NG) test descriptions. 
The face validity assessment was conducted to provide information about the clinical validity and 
utility of NG tests and designed in light of resource and expertise constraints confronting the 
candidate. A total of 256 claimed associations were identified in NG test descriptions. Evidence to 
support these associations was searched for in the National Institute on Aging and the National 
Institutes of Health Center for Informational Technology Genetic Association Database (GAD).1 The 
reviewer’s concerns about the search appear below. 
 
The primary weakness of this manuscript is the assessment of the face validity of the gene-
disease associations upon which nutrigenomic tests are based.  First, the results presented 
seem to be an incomplete assessment of the state of knowledge at the time the assessment was 
done in January 2008.  For example, while the author reports that no studies were found in 
the Genetic Association Database related to GSTT1 and cervical cancer, a search of the 
HuGE Published Literature Database reveals nine seemingly relevant studies published as of 
January 2008.  Second, the methods used to assess the evidence are unfortunately too 
simplistic to provide meaningful insights.  Associations are examined at the level of the gene 
rather than the level of gene variant or haplotype, although it is specific gene variants and 
haplotypes, rather than the genes themselves, that are associated with disease risk.  The 
author's claim that "mixed or no evidence was found to support 72% of claimed associations 
between genes and health conditions", was based on a requirement to meet a seemingly 
arbitrary benchmark of 3:1 for studies reporting an observed association to those reporting 
no observed association.  The ratio does not seem to take into account any features of study 
design or quality, or effect size/direction of effect.  No mention is made of the availability of 
systematic meta-analyses for specific gene-disease associations.  The author notes that the 
evidence supporting the three most mentioned tests identified in this study was recently 
rigorously reviewed (Janssens, et al. 2008)--the added value of the evidence synthesis 
described in this manuscript is unclear and the results are potentially misleading.  Third, the 
primary focus on the validity of gene-disease associations with limited treatment of the 
environmental (dietary) component gives an incomplete picture regarding the paucity of data 
to support validity and utility of nutrigenomic tests which the author correctly states are 
based on "relationships among genes, diet, and health".   
 
The reviewer expressed valid concerns, some of which were noted as limitations in the original 
manuscript. The GAD is a publicly-accessible and populated database. While its sponsors note 
                                                   
1
 Becker KG, Barnes KC, Bright TJ, Wang SA. The Genetic Association Database. Nature Genetics 2004; 
36:431-432. 
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reviewing entries for accuracy, they may not review entries for completeness. In regard to the second 
concern, websites identified in this search rarely reported the specific gene variants profiled by the 
test, rendering a gene variant level analysis impossible. The focus on the number of studies 
addressing claimed associations was selected for this dissertation given the lack of expertise and 
resources to conduct an analysis of the quality of all relevant studies. Furthermore, the reported goal 
of the review was to assess the face validity of claims and not to conduct a systematic meta-analysis.  
 
Given the reviewer’s assessment that “a comprehensive description of the complex landscape of on-
line nutrigenomic testing services would alone be an informative contribution to the field,” the face 
validity assessment was removed from the revised submission. Methods, findings and tables reported 
in the original manuscript appear on the following pages of this appendix with modifications to table 
references. 
 
 
MATERIALS AND METHODS 
 
Published studies regarding claimed associations between health conditions and genes were searched 
for in the National Institute on Aging and the National Institutes of Health Center for Informational 
Technology Genetic Association Database (GAD). This publicly-accessible database is designed to 
“allow the user to rapidly identify medically relevant polymorphism from the large volume of 
polymorphism and mutational data, in the context of standardized nomenclature.” The GAD was 
downloaded January 2008 from http://geneticassociationdb.nih.gov/ as a Microsoft Excel 2003 file. 
The file contained 39919 records at the gene level, such that a separate record existed for each gene 
investigated in a published study. The following data fields were used to identify all studies 
applicable to claimed associations in NG test descriptions: Gene, Broad Phenotype, Disease Class, 
Association(Yes/No), Conclusion, and Year. Complete information was not available for all records.  
 
Records were considered relevant to each search if the gene of interest was mentioned in the Gene 
field, and the condition of interest was mentioned in the Broad Phenotype field (included 1 or more 
conditions). If the condition mentioned in a NG test description lacked specificity, the Disease Class 
field was used to select relevant records. For example, in the case of claimed associations involving 
“inflammation”, all records with a disease class of “Immune” and “Infection” were considered 
relevant. The Disease Class field also was used to exclude studies if the disease class did not parallel 
the health condition of interest. For example, in the case of claimed associations involving “heart 
attack”, records with a broad phenotype including “heart attack” (or synonymous term like 
myocardial infarction) and a disease class of “Cancer” were excluded.  
 
For each association searched, if the Association(Yes/No) field of a relevant records was blank, then 
the Conclusion field was reviewed to impute a study association. The Association(Yes/No) field was 
imputed as “indeterminate” if the Conclusion field had 1 or more of the following characteristics: 1) 
blank or incomplete, 2) included general or vague references (e.g., “data presented here suggest 
genetic risk factors play an important role in thrombosis,” “five SNPs predicted differences in lipid 
levels”), 3) reported a gene-disease association not applicable to the search, or 4) reported other types 
of results (e.g., methodological techniques, population variation, review article summary). The 
Conclusion field was not reviewed to confirm associations reported in the Association(Yes/No) field. 
 
 
FINDINGS 
 
Test descriptions mentioned 256 claimed associations between groups of related health conditions 
and genes [see dissertation Chapter 3 Table 3.3]. Appendix 3 Table 1 provides a summary of GAD 
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search results for claimed associations (see Appendix 3 Table 2). No records were found in the GAD 
for 24% of (62/256) claimed associations, using all possible synonyms for each health condition as 
eligible phenotypes (e.g., bone density, bone mass, low bone mineral density, bone mineralization). 
For 11% (29/256) of claimed associations, only records reporting no association or indeterminate 
records were found (i.e., Association(Yes/No) field was blank and Conclusion field was blank, 
unclear, or not applicable). At least 1 record reporting an observed association was found for the 
majority (64%, 165/256) of claimed associations (ranged from 1 to 80 records per search). However, 
only 28% (72/256) of claimed associations resulted in searches where the ratio of records reporting an 
observed association to records reporting no observed association was at least 3:1.  
 
 
 
 
Appendix 3 Table 1. Summary of search results for gene-health condition associations 
mentioned in nutrigenomic test descriptions using the National Institute on Aging Gene-Disease 
Association Database (GAD), February 2008 
 
  
Gene-Condition  
Associations 
(N=256) 
Records in Search Results N % 
    
Observed Association Study in Gene-Condition Search Results 164 64.1 
    
 Observed Association Studies >=50% of Search Results 130 79.3 
 Observed Association Studies >=75% of Search Results 71 43.3 
 
Observed Association Studies =100% of Search Results a   32 19.5 
    
No Association Study in Gene-Condition Search Results 148 57.8 
    
 No Association Studies >=50% of Search Results 23 15.5 
 No Association Studies >=75% of Search Results 2 1.4 
 
No Association Studies =100% of Search Results a 16 10.8 
    
Indeterminate Records Only 13 5.1 
    
No Records In Database b 61 23.8 
    
a
 Excluding indeterminate studies  
  
b
 Including indeterminate studies 
  
 
 
 
 
 
 
  
209
 
Appendix 3 Table 2.  Records in National Institute on Aging Genetic Association Database (GAD) applicable to claimed associations 
between health conditions and genes mentioned in nutrigenomic test descriptions (October 2006), by International Classification of 
Disease-10 (ICD-10) Chapter, February 2008 (N=256) 
 
 
 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
 
I.  Certain infectious and parasitic diseases  
Sepsis TNF [7] TNF [3] TNF [3] 1995-2006  
Hepatitis B VDR [3]   2002-2006  
Tuberculosis VDR [4]  VDR [4] 2000-2007  
      
II.  Neoplasms  
Cancer (Non-Specific) SOD2 [16] SOD2 [11] SOD2 [17] 2001-2007  
 GSTM1[26] GSTM1[16] GSTM1[87] 1991-2007  
Bladder GSTM1 [3]  GSTM1 [4] 2000-2007  
 GSTT1 [3] GSTT1 [2] GSTT1 [4] 2000-2007  
Breast AR [3] AR [4] AR [8] 1999-2006  
 BRCA1/2 [29] BRCA1/2 [11] BRCA1/2 [63] 1998-2007  
 CHEK2 [8] CHEK2 [11] CHEK2 [14] 2002-2007  
 COMT  [4] COMT  [3] COMT  [16] 2002-2007  
 CYP1A1 [6]  CYP1A1 [10] 1994-2007  
 CYP1B1 [10] CYP1B1 [7] CYP1B1 [11] 1998-2007  
 MLH1 [1]  MLH1 [1] 2004-2005  
 MTHFR [2] MTHFR [4] MTHFR [6] 2004-2007  
 PGR [5] PGR [1] PGR [2] 2001-2006  
  TGFBR1 [2] TGFBR1 [2] 2002-2006  
 TP53 [8] TP53 [1] TP53 [16] 1994-2007  
 VDR [5] VDR [2] VDR [3] 1998-2007  
     MSH2 
     RHOBTB2 
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
Colon/Colorectal APC [11] APC [7] APC [12] 1994-2007  
 MLH1 [3] MLH1 [1] MLH1 [34] 1999-2007  
 MSH2 [5]  MSH2 [34] 1993-2007  
 TGFBR1 [1] TGFBR1 [1] TGFBR1 [3] 2001-2007  
 TP53 [6] TP53 [3] TP53 [8] 1992-2006  
Cervical    MTHFR [1]  2006  
     GSTT1 
Endometrial  PGR [2]  PGR [2] 2002-2006  
Esophageal   MTHFR [5]  MTHFR [3] 2003-2007  
Larynx    GSTT1 [1]  2004  
Lung   CYP1A1 [7] CYP1A1 [4] CYP1A1 [9] 1993-2007  
 GSTM1 [10] GSTM1 [2] GSTM1 [17] 1991-2007  
 GSTP1 [5] GSTP1 [4] GSTP1 [10] 2001-2007  
 GSTT1 [4] GSTT1 [5] GSTT1 [9] 1999-2007  
Ovarian    TGFBR1[2]  2002-2005  
Prostate   AR [8] AR [3] AR [11] 1996-2007  
 CYP17A1 [11] CYP17A1 [6] CYP17A1 [13] 1999-2007  
 CYP1B1 [4] CYP1B1 [1] CYP1B1 [4] 2000-2007  
 ELAC2 [13] ELAC2 [10] ELAC2 [2] 2000-2005  
  GSTP1 [1] GSTP1 [6] 2000-2007  
 GSTT1 [2]  GSTT1 [8] 2001-2007  
 SRD5A2 [10] SRD5A2 [8] SRD5A2 [15] 1997-2007  
 VDR [10] VDR [2] VDR [8] 1996-2006  
      
IV.  Endocrine, nutritional and metabolic diseases 
Diabetes Type II MTHFR [7] MTHFR [4] MTHFR [10] 1997-2005  
 VDR [2]  VDR [2] 2001-2002  
Cholesterol  APOE [7] APOE [2]  1991-2007  
 CETP [10] CETP [1] CETP [15] 2001-2007  
 LPL [9] LPL [2] LPL [14] 1997-2007  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
   MTHFR [1] 2007  
 NPY [4]   2001-2005  
 SREBF2 [1] SREBF2 [1] SREBF2 [1] 2004-2006  
     F2 
     F5 
     IL1A 
Fatty Acids     SREBF2 
Lipids APOC3 [9] APOC3 [2] APOC3 [9] 1987-2006  
 APOE [6] APOE [3] APOE [16] 1991-2007  
 CETP [3] CETP [1] CETP [4] 2000-2005  
 LPL [3]  LPL [4] 2000-2005  
  NOS3 [1]  2007  
 PPARG [1] PPARG [1]  2003-2005  
 SERPINE1 [1] SERPINE1 [1] SERPINE1 [2] 2000-2005  
Triglycerides APOC3 [4] APOC3 [5] APOC3 [23] 1995-2007  
     ADRA2B 
Obesity, Weight Gain ADRA2B [3]  ADRA2B [1] 2001-2004  
 ADRB2 [10] ADRB2 [9] ADRB2 [6] 1995-2007  
 ADRB3 [13] ADRB3 [6] ADRB3 [13] 1995-2007  
 GNB3 [5] GNB3 [2] GNB3 [3] 2001-2005  
 NPY [3]   2002-2006  
 SERPINE1 [4]  SERPINE1 [4] 2001-2006  
 TNF [3] TNF [2] TNF [5] 2000-2007  
     SREBF2 
Metabolic Syndrome ADRB2 [1]   2003  
Homocysteine, Folate, Vit B  CBS [6] CBS [1] CBS [4] 1995-2007  
 MTHFR [12] MTHFR [3] MTHFR [19] 1999-2007  
 MTR [4] MTR [3] MTR [7] 2001-2007  
 MTRR [4] MTRR [2] MTRR [5] 2001-2007  
 TCN2 [1]  TCN2 [2] 2002-2007  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
     XRCC1 
Calcium VDR [4] VDR [1] VDR [2] 2000-2006  
Electrolytes     ACE 
Vitamin D VDR [2]   1999-2006  
Zinc     SOD3 
Steroid, Hormone  AR [7]  AR [1] 1993-2004  
 COMT [2] COMT [1] COMT [5] 2002-2007  
   CYP1A1 [4] 2001-2006  
 CYP1B1 [2] CYP1B1 [1] CYP1B1 [8] 2001-2007  
 CYP17A1 [5] CYP17A1 [3] CYP17A1 [7] 1996-2006  
 CYP19A1 [3]  CYP19A1 [6] 1998-2006  
   ESR1 [5] 2003-2007  
 SRD5A2 [2] SRD5A2 [2] SRD5A2 [1] 2001-2003  
  VDR [1]  2003  
     COL1A1 
     F2 
     F5 
     GNB3 
Methylation Cycle/Pathway   MTHFR [1] 2003  
     ACAT1/2 
     ACE 
     AHCY 
     BHMT 
     CBS 
     COMT 
     MAOA 
     MTR 
     NOS3 
     SUOX 
     VDR 
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
Hyperparathyroidism   VDR [1] 2000  
 
V.  Mental and behavioral disorders      
Autism      COMT 
     MTHFR 
Schizophrenia  GSTM1[1]   2001  
      
VI.  Diseases of the nervous system 
Alzheimer's Disease APOE [80] APOE [38] APOE [75] 1993-2007  
Brain Function APOE [7] APOE [1] APOE [16] 1999-2007  
Multiple Sclerosis     GSTM1 
Muscular Dystrophy      GSTP1 
Neurologic Degeneration  APOE [5] APOE [6] APOE [4] 2001-2007  
      
VII.  Diseases of the eye and adnexa 
Macular Degeneration SOD2 [1]  SOD2 [1] 2000-2005  
      
IX.  Diseases of the circulatory system 
Hypertension ACE [45] ACE [15] ACE [29] 1992-2007  
 ADRB1 [5] ADRB1 [1] ADRB1 [6] 2002-2007  
 ADRB2 [14] ADRB2 [4] ADRB2 [12] 1996-2006  
 AGT [29] AGT [8] AGT [38] 1994-2007  
 GNB3 [17] GNB3 [7] GNB3 [6] 1998-2006  
  IL6 [1]  1999  
 NOS3  [28] NOS3  [19] NOS3  [21] 1997-2007  
 NPY [1] NPY [1] NPY [1] 2001-2007  
Cardiovascular ADRA2B [2] ADRA2B [1]  2002-2005  
 ADRB1 [4] ADRB1 [4]  2000-2007  
   ADRB2 [1] 2003  
 APOA1 [8] APOA1 [2] APOA1 [11] 1989-2007  
 APOB [13] APOB [7] APOB [12] 1990-2006  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
 APOC3 [7] APOC3 [5] APOC3 [15] 2001-2007  
 APOE [17] APOE [2] APOE [25] 1984-2007  
 CBS [4] CBS [3] CBS [3] 1999-2007  
 CETP [10]  CETP [12] 2000-2007  
 ESR1 [6] ESR1 [1] ESR1 [3] 2000-2005  
 F2 [5] F2 [5] F2 [9] 1998-2006  
 F5 [5] F5 [7] F5 [13] 1996-2007  
 GJA4 [1] GJA4 [1] GJA4 [2] 2006-2007  
 GNB3 [4]  GNB3 [2] 2001-2005  
  IL1A [2] IL1A [2] 2001-2004  
 IL6 [12] IL6 [5] IL6 [12] 2000-2006  
 LPL [16] LPL [1] LPL [15] 1996-2007  
 MMP3 [6] MMP3 [3] MMP3 [3] 2000-2007  
 MTHFR [7] MTHFR [12] MTHFR [15] 1998-2007  
 MTRR [1] MTRR [2] MTRR [2] 1999-2007  
 NOS3  [71] NOS3  [28] NOS3  [29] 1999-2007  
 NPY [5] NPY [1]  2001-2004  
 PON1 [33] PON1 [16] PON1 [27] 1998-2007  
 SERPINE1 [6] SERPINE1 [6] SERPINE1 [8] 1999-2006  
   SOD3 [1] 2003  
   VDR [1] 2002  
     IL-6 
     SREBF2 
Heart Attack ACE [15] ACE [5] ACE [6] 1993-2007  
  APOC3 [2] APOC3 [4] 1999-2005  
 F2 [1] F2 [5] F2 [2] 2000-2006  
 F5 [4] F5 [7] F5 [3] 2001-2006  
 IL6 [1] IL6 [2] IL6 [4] 2002-2006  
 MMP3 [6]  MMP3 [2] 1999-2005  
 NOS3 [10] NOS3 [3] NOS3  [3] 1998-2007  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
     IL1A 
Stroke F2 [2] F2 [5] F2 [8] 2000-2007  
  F5 [7] F5 [9] 2001-2007  
 MTHFR [3] MTHFR [2] MTHFR [9] 1999-2007  
 SERPINE1 [3] SERPINE1 [6] SERPINE1 [7] 2001-2007  
     IL-6 
Thrombosis F2 [14] F2 [10] F2 [21] 1999-2007  
 F5 [23] F5 [14] F5 [18] 1996-2007  
 ITGB3 [2] ITGB3 [3] ITGB3 [3] 2001-2006  
 MTHFR [8] MTHFR [10] MTHFR [17] 1998-2007  
     GNB3 
      
X.  Diseases of the respiratory system 
Asthma GSTM1 [2] GSTM1 [1] GSTM1 [2] 2001-2003  
 GSTP1 [2] GSTP1 [3]  1999-2004  
 TNF [11] TNF [10] TNF [13] 1998-2006  
COPD TNF [3] TNF [5] TNF [4] 2001-2007  
      
XI.  Diseases of the digestive system 
Crohn's Disease TNF [8] TNF [2] TNF [1] 2000-2007  
      
XIII.  Diseases of the musculoskeletal system and connective tissue 
Arthritis/Osteoarthritis TNF [8] TNF [9] TNF [17] 1995-2007  
 VDR [3] VDR [2] VDR [2] 1997-2006  
Connective Tissue     VDR 
Bone Density COL1A1 [13] COL1A1 [8] COL1A1 [5] 1999-2007  
 IL6 [15]  IL6 [8] 1997-2007  
 TNF [3] TNF [1]  2002-2007  
 VDR [29] VDR [8] VDR [11] 1996-2007  
Osteoporosis/Factures COL1A1 [10] COL1A1 [4] COL1A1 [3] 1996-2006  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
   IL6 [1] 2003  
 MTHFR [2] MTHFR [1]  2002-2004  
   TNF [1] 2005  
 VDR [5] VDR [3] VDR [7] 1995-2006  
      
XIV.  Diseases of the genitourinary system 
Kidney Stones VDR [3] VDR [1] VDR [1] 2001-2005  
      
XV.  Pregnancy, childbirth and the puerperium 
Early Pregnancy Loss     GSTP1 
      
XVII.  Congenital malformations, deformations and chromosomal abnormalities 
Downs Syndrome MTHFR [2]  MTHFR [2] 2005-2006  
     COMT 
Neural Tube Defects MTHFR [9] MTHFR [5] MTHFR [4] 1999-2007  
 MTRR [4] MTRR [1] MTRR [3] 2003-2006  
     COMT 
      
XVIII.  Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 
Insulin, Glucose ACE [4]  ACE [1] 1994-2004  
 ADRA2B [1]  ADRA2B [2] 2003-2005  
 IL6 [1]  IL6 [1] 2000-2005  
 PPARG [6] PPARG [1] PPARG [6] 2001-2006  
  SERPINE1 [4] SERPINE1 [1] 2002-2007  
 TNF [3] TNF [2] TNF [2] 2000-2006  
     MTHFR 
     VDR 
      
XIX.  Injury, poisoning and certain other consequences of external causes 
Alcohol, Alcoholism ALDH2 [22] ALDH2 [1] ALDH2 [11] 1988-2007  
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
 
XX. External causes of morbidity and mortality 
PAI/Plasminogen levels SERPINE1[3] SERPINE1[4] SERPINE1[9] 2000-2007  
    
 
 
Can't Classify 
Aging IL10 [1] IL10 [3] IL10 [6] 2001-2007  
  MTHFR [1] MTHFR [3] 2001-2005  
  TNF [3] TNF [1] 2001-2006  
Antioxidants, Free Radicals     GSTM1 
     GSTP1 
     GSTT1 
     MTHFR 
     SOD2 
     SOD3 
Cell Growth (Cardiomyocytes)     GNB3 
Cell Growth (Non-Specific)     MTHFR 
Detoxification/Excrete Toxins CYP1A1 [2] CYP1A1 [3] CYP1A1 [10] 2002-2007  
 CYP1B1 [2] CYP1B1 [1] CYP1B1 [5] 2003-2007  
 EPHX1 [7] EPHX1 [2] EPHX1 [13] 2002-2007  
 GSTM1 [9] GSTM1 [6] GSTM1 [28] 2000-2007  
 GSTP1 [5] GSTP1 [4] GSTP1 [21] 2000-2007  
 GSTT1 [9] GSTT1 [3] GSTT1 [26] 2000-2007  
 MTHFR [5] MTHFR [1] MTHFR [7] 2003-2007  
     COMT 
     GPX 
     TCN2 
DNA Repair/Damage   GPX [1] 2006  
   MTHFR [1] 2007  
Emotions (Non-Specific)     ACE 
     COMT 
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 Gene Evaluated [# of records] 
ICD-10 Chapter 
Health Condition Evaluated 
Association 
Observed 
No Association 
Observed Cannot Determine 
Year Study 
Published No Record 
     MTHFR 
Hair/Skin Repair     MTHFR 
Inflammation/Allergies  IL1A [22] IL1A [11] IL1A [23] 1996-2007  
     (GAD Disease Class: Immune) IL6 [18] IL6 [18] IL6 [65] 1989-2007  
 IL10 [36] IL10 [23] IL10 [78] 2001-2007  
 MTHFR [3] MTHFR [2] MTHFR [7] 2001-2007  
 SERPINE1 [10] SERPINE1 [2] SERPINE1 [8] 1997-2007  
 TNF [72] TNF [46] TNF [130] 1989-2007  
Inflammation  IL1A [6] IL1A [2] IL1A [5] 2001-2007  
     (GAD Disease Class: Infection) IL6 [9] IL6 [7] IL6 [19] 2000-2007  
 IL10 [17] IL10 [36] IL10 [0] 2002-2007  
  MTHFR [1] MTHFR [1] 2004-2007  
 SERPINE1 [5] SERPINE1 [1] SERPINE1 [2] 2002-2007  
 TNF [22] TNF [12] TNF [39] 1994-2007  
     COMT 
     MTHFR 
Oxidative Stress  GPX [1]  2000  
 GSTM1 [1]   2006  
 PON1 [1]  PON1 [2] 2002-2006  
   SOD2 [1] 2005  
     APOE 
     XRCC1 
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[Note: In on-line version, new survey webpage (i.e., screen change) appears after solid line beneath 
text that reads, “click grey button…”] 
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Appendix 5: Preliminary Results from Survey Questions Regarding  
Respondent Agreement with Opinions about Nutrigenomic Services  
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Appendix 5 Table 1. Expert agreement with statements regarding nutrigenomic research and 
services, August 2007 (N=300) 
 
% (N) 
 Certain b 
Statements Mean (SD)a Agree Disagree Uncertainc 
Higher Certainty 
        
Nutrigenomics explores relationships among diet, 
genes, and health or disease. 4.51 (0.91) 95% (267) 4% (11) 5% (15) 
Dietary changes and supplement use may not 
overcome genetic factors associated with the types of 
health conditions nutrigenomic tests focus on. 4.21 (1.20) 87% (240) 12% (32) 7% (21) 
Currently, there is not enough scientific evidence to 
justify the use of nutrigenomic testing services. 3.92 (1.30) 81% (203) 18% (46) 15% (45) 
Consumers must see a genetics professional regarding 
the interpretation and use of nutrigenomic test results 
(e.g., certified genetic counselor, medical geneticist). 3.67 (1.35) 74% (183) 25% (62) 17% (50) 
Consumers must see a primary care physician 
regarding the interpretation and use of nutrigenomic 
test results. 3.27 (1.29) 64% (151) 35% (83) 21% (62) 
Nutrigenomic researchers agree on how the results of 
nutrigenomic tests can be used to improve individual 
health. 1.95 (1.17) 13% (34) 87% (225) 13% (39) 
Lower Certainty 
        
Consumers who receive positive nutrigenomic test 
results tend to experience unnecessary anxiety (i.e., 
test results indicate consumer has gene variants 
targeted by test). 3.48 (1.11) 76% (150) 24% (48) 33% (98) 
Dietary and lifestyle advice based on nutrigenomic 
test results will not differ substantially from advice 
provided in current dietary guidelines issued by the 
US Department of Agriculture (USDA). 3.11 (1.29) 55% (117) 44% (95) 28% (82) 
On average, tests for variants in a single gene are 
more reliable than tests for variants in multiple genes 
when predicting health outcomes. 3.10 (1.33) 54% (110) 45% (91) 32% (96) 
There is little to no risk of employment 
discrimination when taking a nutrigenomic test. 2.75 (1.27) 39% (81) 60% (125) 30% (90) 
There is little to no risk of health or life insurance 
discrimination when taking a nutrigenomic test. 2.63 (1.27) 34% (70) 66% (138) 30% (90) 
 
a
 Mean/SD calculated using all values on 5-point Likert scale where 1=Strongly Disagree, 2=Disagree, 3=Don't 
Know, 4= Agree, 5=Strongly Agree.  b Percentage of respondents with definitive response (i.e., did not select 
“Don’t Know”). Agree column collapses respondents selecting 4=Agree and 5=Strongly Agree. Disagree 
column collapses respondents selecting 1=Strongly Disagree and  2=Disagree.  c Percentage of total sample. 
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Appendix 6 Table 1. Chi-square test results for statistically significant differences by demographic characteristics in rating for 
importance of nutrigenomic service attributes for consumer decision-making, August 2007 (N=300) 
 
 
χ2 Test for Differences in Attribute Rating  
p-valuesa 
Topic 
Attributes 
Professionb 
(n=254) 
Years in 
Current 
Profession 
(n=293) 
Work in 
NGx 
(n=290) 
Aware of 
GAO 
Report 
(n=290) 
Opinion of 
DTC Sale  
(n=288) 
Opinion of 
DTC 
Marketing  
(n=286) 
Personalized Recommendations  
If the US Food and Drug Administration (FDA) or the US Federal 
Trade Commission (FTC) has reviewed the utility of supplements 
recommended to the consumer. c 0.0038 0.5775 0.7226 0.5932 0.0130 0.0357 
If taking supplements can overcome genetic contributors to the health 
conditions the test focuses on. 0.0221 0.3224 0.2811 0.6287 0.3500 0.6945 
If there are any differences between advice provided with test results 
and advice provided in current dietary guidelines issued by the US 
Department of Agriculture (USDA). 0.0694 0.8147 0.2955 0.5515 0.7564 0.1955 
If dietary changes can overcome genetic contributors to the health 
conditions the test focuses on. 0.1457 0.2826 0.1019 0.2282 0.1502 0.1893 
Physiological changes that will occur as a result of supplement use. 0.6068 0.3528 0.7340 0.8307 0.1362 0.3554 
If supplement use can help cure, manage, or prevent the health 
conditions on which the test is focused. 0.7676 0.0992 0.4191 0.3817 0.5145 0.3607 
If there are any conditions under which recommended supplements 
should not be taken (i.e., supplements the laboratory or vendor 
recommends to the consumer based on his or her nutrigenomic test 
results). 0.7754 0.3811 0.1561 0.7418 0.5572 0.6783 
Social Implications  
The risk of employment discrimination when taking the test. 0.0000 0.7738 0.9468 0.5296 0.8420 0.7290 
If test results are admissible in a court of law. 0.0002 0.5530 0.2904 0.4550 0.3175 0.2209 
The risk of health insurance discrimination when taking the test. 0.0011 0.5539 0.5005 0.4427 0.6331 0.5237 
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χ2 Test for Differences in Attribute Rating  
p-valuesa 
Topic 
Attributes 
Professionb 
(n=254) 
Years in 
Current 
Profession 
(n=293) 
Work in 
NGx 
(n=290) 
Aware of 
GAO 
Report 
(n=290) 
Opinion of 
DTC Sale  
(n=288) 
Opinion of 
DTC 
Marketing  
(n=286) 
If any specific efforts are made to ensure consumer privacy and 
confidentiality. 0.0123 0.6572 0.9628 0.2288 0.6709 0.8260 
If test results provide any information about the health of the test 
taker’s family members. 0.0955 0.1119 0.4358 0.2147 0.1013 0.1974 
If there are any circumstances under which personal contact 
information would be shared with a third party (e.g., university, 
insurance company, family member). 0.2538 0.3223 0.9366 0.1210 0.6965 0.9458 
What is done with test results, other analytic data, or collected health 
information after test results are provided to the consumer. 0.3235 0.3976 0.9485 0.0829 0.6328 0.1045 
If there are any circumstances under which residual specimens would 
be shared with a third party. 0.4295 0.8099 0.7943 0.8857 0.6903 0.1235 
What is done with residual specimens after test results are provided to 
the consumer. 0.4820 0.4362 0.0184 0.1758 0.7543 0.4828 
If there are any circumstances under which test results, other analytic 
data, or collected health information would be shared with a third 
party. 0.7186 0.2618 0.7431 0.1454 0.7035 0.7978 
How often test takers experience anxiety after receiving test results. 0.9036 0.2218 0.9756 0.7694 0.0770 0.6154 
Scientific Validity of Test 
Clinical Validity 
If the test will detect health conditions currently affecting the test 
taker (i.e., existing health condition). 0.0177 0.0602 0.5023 0.7731 0.5720 0.6225 
How often the test correctly predicts the health conditions the test 
focuses on. 0.4292 0.1108 0.2236 0.8100 0.7579 0.6650 
Non-genetic factors that can affect the development of the health 
conditions the test focuses on. 0.4500 0.6412 0.1904 0.6040 0.4685 0.8118 
Clinical Utility 
If there are specific populations for whom the test is more appropriate. 0.2926 0.6776 0.2338 0.5733 0.5206 0.4462 
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χ2 Test for Differences in Attribute Rating  
p-valuesa 
Topic 
Attributes 
Professionb 
(n=254) 
Years in 
Current 
Profession 
(n=293) 
Work in 
NGx 
(n=290) 
Aware of 
GAO 
Report 
(n=290) 
Opinion of 
DTC Sale  
(n=288) 
Opinion of 
DTC 
Marketing  
(n=286) 
To what extent test results can be used to treat or prevent the health 
conditions the test focuses on. 0.7736 0.1429 0.3993 0.9547 0.7843 0.6755 
Analytic Validity 
The name and function of the specific gene variants targeted by the 
test. 0.3701 0.7994 0.5214 0.7314 0.6451 0.0444 
If there are any differences between the reliability of tests for variants 
in a single gene and the reliability of tests for variants in multiple 
genes. 0.6290 0.7019 0.1011 0.7491 0.8997 0.2705 
How often the test correctly identifies the targeted gene variants. 0.9484 0.4976 0.9152 0.3881 0.8401 0.2674 
Findings and Quality of Nutrigenomic Research    
If researchers agree on how test results can be used to improve 
individual health. 0.0011 0.6728 0.9119 0.3823 0.0927 0.1587 
If any studies in the peer reviewed literature find supplements 
recommended to the consumer to be clinically useful. 0.3040 0.7076 0.3992 0.3219 0.1321 0.0538 
If any studies conducted by the vendor or laboratory find the test to be 
valid or useful. 0.3921 0.1402 0.5914 0.6124 0.1011 0.2229 
If any studies conducted by the vendor or laboratory find supplements 
recommended to the consumer to be clinically useful. 0.5401 0.2515 0.4967 0.8261 0.6075 0.4560 
If any studies in the peer reviewed literature find the test to be valid or 
useful. 0.8463 0.5448 0.5830 0.1110 0.2150 0.5001 
Vendor or Lab Characteristics 
Biographical sketch of vendor or laboratory staff involved in the 
research, development, or analysis of the test. 0.2179 0.8808 0.9963 0.9723 0.3896 0.1900 
If the laboratory analyzing the test is certified by professional 
organizations (e.g., American Association of Blood Banks, the 
College of American Pathologists). 0.4298 0.1571 0.6990 0.4307 0.1550 0.2355 
If the vendor or laboratory analyzing the test is publicly traded. 0.4406 0.6907 0.7297 0.9739 0.0091 0.0163 
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χ2 Test for Differences in Attribute Rating  
p-valuesa 
Topic 
Attributes 
Professionb 
(n=254) 
Years in 
Current 
Profession 
(n=293) 
Work in 
NGx 
(n=290) 
Aware of 
GAO 
Report 
(n=290) 
Opinion of 
DTC Sale  
(n=288) 
Opinion of 
DTC 
Marketing  
(n=286) 
If the laboratory analyzing the test meets government standards (e.g., 
Clinical Laboratory Improvement Act). 0.5723 0.4271 0.4970 0.8764 0.2008 0.3238 
Complete contact information for the vendor and laboratory analyzing 
the nutrigenomic test, including a phone number and physical street 
address. 0.7555 0.6271 0.2327 0.7601 0.0619 0.4328 
If the vendor or laboratory analyzing the test is affiliated with an 
academic institution. 0.9490 0.9912 0.9549 0.4333 0.0047 0.2011 
Test Procedures 
When the consumer will receive test results. 0.0287 0.5343 0.0654 0.6758 0.3181 0.3871 
How the specimen will be collected (e.g., location, technology, 
persons involved). 0.0489 0.1542 0.5336 0.1967 0.0159 0.1175 
If personal health or lifestyle information is collected. 0.0620 0.0178 0.3681 0.4184 0.4618 0.6645 
If it is necessary to see a genetics professional regarding the 
interpretation and use of test results (e.g., certified genetic counselor, 
medical geneticist). 0.0917 0.3997 0.6534 0.3119 0.0218 0.1277 
The type of specimen that is collected and analyzed for the test. 0.2686 0.9142 0.5085 0.3592 0.3120 0.4572 
If genetic counseling or physician consultation is required to take the 
test. 0.2814 0.7889 0.2581 0.0813 0.3577 0.3068 
If it is necessary to see a primary care physician regarding the 
interpretation and use of test results. 0.6923 0.1409 0.8423 0.1131 0.0301 0.2129 
If health services, referrals, or other health-related resources are 
provided to the consumer as part of the testing service. 0.7564 0.7620 0.3053 0.9959 0.3666 0.1115 
Cost and Purchase Information  
If Medicare, Medicaid, or other insurance will cover the cost of the 
testing service. 0.0259 0.1910 0.0544 0.7227 0.2102 0.7407 
If more than one laboratory offers the test (i.e., laboratories other than 
the one from which the consumer will receive test results). 0.0522 0.8460 0.1811 0.7008 0.7377 0.3481 
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χ2 Test for Differences in Attribute Rating  
p-valuesa 
Topic 
Attributes 
Professionb 
(n=254) 
Years in 
Current 
Profession 
(n=293) 
Work in 
NGx 
(n=290) 
Aware of 
GAO 
Report 
(n=290) 
Opinion of 
DTC Sale  
(n=288) 
Opinion of 
DTC 
Marketing  
(n=286) 
If supplements recommended to the consumer can be purchased from 
more than one source. 0.1938 0.0759 0.1555 0.8566 0.9852 0.8831 
If there is a money back guarantee when a consumer is not satisfied 
with the services or information received. 0.2010 0.8615 0.2474 0.5705 0.7786 0.5118 
If there are any additional financial costs associated with taking the 
test given a positive or negative test result (e.g., physician visits, 
genetic counseling, confirmatory testing). 0.2669 0.7724 0.5257 0.3691 0.4074 0.4120 
General Info about Health Conditions the Test Focuses On  
The definition of nutrigenomics. 0.0094 0.8911 0.3053 0.9038 0.1278 0.8325 
Personal characteristics of individuals who are at greatest risk for 
developing the health conditions the test focuses on (e.g., age, 
ethnicity, family history). 0.1966 0.4408 0.6474 0.7448 0.2818 0.1387 
The prevalence of the health conditions the test focuses on. 0.2701 0.4416 0.9013 0.5410 0.6896 0.2917 
If there are any health conditions that are not focus of the test but are 
associated with the gene variants targeted by the test. 0.5397 0.3379 0.7158 0.7899 0.3352 0.7737 
General information about the symptoms of the health conditions the 
test focuses on. 0.7153 0.7421 0.4728 0.2845 0.6922 0.7459 
Count of Attributes with Significant Difference 13 1 2 0 6 4 
 
a
 Chi-square tests exclude observations with missing values in demographic characteristics. 
b
 Includes four professional groups with highest representation in data (i.e., nutritionists, researchers, genetic counselors, and health practitioners) 
c
 Shaded rows show attributes with significant difference by profession, work experience, awareness, and/or opinion. 
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Appendix 6 Table 2. Importance rating of attributes with statistically significant differences by profession, August 2007 (n=13)  
 
 
 
Distribution of Rating by Profession a 
Legend: Nut=Nutritionist/Dietician, Res=Researcher, GC=Genetic Counselor, HP=Health Practitioner 
 
Certain % b 
within profession total 100%  Uncertain % 
c
 
 
Very Important Important Unimportant Don’t Know 
Topic 
Attributes  Nut Res GC HP Nut Res GC HP Nut Res GC HP Nut Res GC HP 
Social Implications 
                  
If any specific efforts are made to 
ensure consumer privacy and 
confidentiality. 80.2 69.0 57.5 63.3 16.7 27.6 37.5 36.7 3.1 3.4 5.0 0.0 0.0 0.0 0.0 0.3 
If test results are admissible in a court 
of law. 68.4 58.0 27.3 55.6 25.3 30.9 63.6 37.0 6.3 11.1 9.1 7.4 0.3 2.0 2.3 1.3 
The risk of employment 
discrimination when taking the test. 67.1 39.3 13.9 46.7 24.7 44.0 75.0 40.0 8.2 16.7 11.1 13.3 3.7 1.0 1.3 0.3 
The risk of health insurance 
discrimination when taking the test. 60.2 40.5 16.7 50.0 36.4 42.9 75.0 36.7 3.4 16.7 8.3 13.3 2.7 1.0 1.3 0.3 
What is done with residual specimens 
after test results are provided to the 
consumer. 56.8 60.0 51.3 40.0 35.8 35.3 41.0 60.0 7.4 4.7 7.7 0.0 0.3 0.7 0.3 0.3 
Scientific Validity of Test 
                
Clinical Validity 
If the test will detect health 
conditions currently affecting the test 
taker (i.e., existing health condition). 58.1 53.5 43.6 55.2 36.6 44.2 51.3 44.8 5.4 2.3 5.1 0.0 1.0 0.3 0.3 0.7 
Analytic Validity 
The name and function of the specific 
gene variants targeted by the test. 22.2 8.3 13.2 19.4 61.1 66.7 73.7 58.1 16.7 25.0 13.2 22.6 2.0 1.0 0.7 0.0 
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Distribution of Rating by Profession a 
Legend: Nut=Nutritionist/Dietician, Res=Researcher, GC=Genetic Counselor, HP=Health Practitioner 
 
Certain % b 
within profession total 100%  Uncertain % 
c
 
 
Very Important Important Unimportant Don’t Know 
Topic 
Attributes  Nut Res GC HP Nut Res GC HP Nut Res GC HP Nut Res GC HP 
Personalized Recommendations 
                 
If taking supplements can overcome 
genetic contributors to the health 
conditions the test focuses on. 56.4 51.2 52.5 50.0 42.6 41.9 45.0 46.4 1.1 7.0 2.5 3.6 0.7 0.3 0.0 1.0 
If the US Food and Drug 
Administration (FDA) or the US 
Federal Trade Commission (FTC) has 
reviewed the utility of supplements 
recommended to the consumer. 36.2 55.3 64.1 58.6 47.9 42.4 33.3 37.9 16.0 2.4 2.6 3.4 0.7 0.7 0.3 0.7 
Findings and Quality of 
Nutrigenomic Research                    
The definition of nutrigenomics. 46.9 32.2 30.0 41.9 43.8 46.0 65.0 51.6 9.4 21.8 5.0 6.5 0.0 0.0 0.0 0.0 
If researchers agree on how test 
results can be used to improve 
individual health. 48.4 72.4 80.0 83.9 45.3 18.4 20.0 16.1 6.3 9.2 0.0 0.0 0.3 0.0 0.0 0.0 
If any studies in the peer reviewed 
literature find supplements 
recommended to the consumer to be 
clinically useful. 46.8 54.1 61.5 65.5 50.0 41.2 33.3 31.0 3.2 4.7 5.1 3.4 0.7 0.7 0.3 0.7 
Vendor Characteristics 
                
If the vendor or laboratory analyzing 
the test is publicly traded. 18.2 9.6 9.1 20.7 39.0 47.9 51.5 37.9 42.9 42.5 39.4 41.4 6.3 4.7 2.3 0.7 
If the vendor or laboratory analyzing 
the test is affiliated with an academic 
institution. 16.5 16.7 16.2 16.7 55.3 56.4 67.6 56.7 28.2 26.9 16.2 26.7 3.7 3.0 1.0 0.3 
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Distribution of Rating by Profession a 
Legend: Nut=Nutritionist/Dietician, Res=Researcher, GC=Genetic Counselor, HP=Health Practitioner 
 
Certain % b 
within profession total 100%  Uncertain % 
c
 
 
Very Important Important Unimportant Don’t Know 
Topic 
Attributes  Nut Res GC HP Nut Res GC HP Nut Res GC HP Nut Res GC HP 
Test Procedures 
                
When the consumer will receive test 
results. 49.0 32.1 42.5 38.7 49.0 65.5 57.5 58.1 2.1 2.4 0.0 3.2 0.0 1.0 0.0 0.0 
How the specimen will be collected 
(e.g., location, technology, persons 
involved). 47.9 24.1 30.0 29.0 50.0 71.3 62.5 67.7 2.1 4.6 7.5 3.2 0.7 0.0 0.0 0.0 
If it is necessary to see a genetics 
professional regarding the 
interpretation and use of test results 
(e.g., certified genetic counselor, 
medical geneticist). 42.9 42.9 58.3 57.1 49.5 46.4 41.7 28.6 7.7 10.7 0.0 14.3 1.7 1.0 1.3 1.0 
If personal health or lifestyle 
information is collected. 40.0 40.2 24.3 51.6 56.8 55.2 73.0 45.2 3.2 4.6 2.7 3.2 0.3 0.0 1.0 0.0 
If it is necessary to see a primary care 
physician regarding the interpretation 
and use of test results. 22.2 32.1 35.1 27.6 61.1 53.1 54.1 65.5 16.7 14.8 10.8 6.9 2.0 2.0 1.0 0.7 
Cost and Purchase Information 
                 
If Medicare, Medicaid, or other 
insurance will cover the cost of the 
testing service. 55.4 30.6 32.5 38.7 38.0 62.4 62.5 48.4 6.5 7.1 5.0 12.9 1.3 0.7 0.0 0.0 
If more than one laboratory offers the 
test (i.e., laboratories other than the 
one from which the consumer will 
receive test results). 15.4 11.4 5.7 20.0 69.2 68.4 65.7 50.0 15.4 20.3 28.6 30.0 1.7 2.7 1.7 0.3 
 
a
 Excludes respondents with unreported profession (n=6) and professional categories with low participation in survey: Policy Analysts/Advocates/Ethicists 
(n=15) and Other (n=25)      b Percentage of sample with definitive response on item     c Percentage of total sample 
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Appendix 6 Table 3. Importance rating of attributes with statistically significant differences by opinions about the direct-to-consumer 
(DTC) marketing and sale of nutrigenomic services, August 2007 (n=10)  
 
 
 
 
Distribution of Ratings by Opinion a 
  
Certain (%) b 
within opinion total 100%  Uncertain (%)
c
 
 
Very Important Important Unimportant Don't Know 
Attributes with Significant Differences  
by Opinions about DTC Sale 
No  
DTC 
Sale 
DTC 
Sale  
OK 
Don’t 
Know 
No  
DTC 
Sale 
DTC 
Sale  
OK 
Don’t 
Know 
No  
DTC 
Sale 
DTC 
Sale  
OK 
Don’t 
Know 
No 
DTC 
Sale 
DTC 
Sale 
OK 
Don’t 
Know 
Personalized Recommendations 
If the FDA or FTC has reviewed the utility 
of supplements recommended to the 
consumer. 53.1 37.7 54.8 43.0 44.9 41.7 3.9 17.4 3.6 1.0 0.7 0.7 
Vendor Characteristics 
If the vendor or laboratory analyzing the 
test is affiliated with an academic 
institution. 19.0 4.8 21.3 58.7 53.2 57.5 22.3 41.9 21.3 3.3 3.0 2.0 
If the vendor or laboratory analyzing the 
test is publicly traded. 17.2 4.9 12.1 49.1 36.1 50.0 33.6 59.0 37.9 5.0 3.3 6.7 
Test Procedures 
If it is necessary to see a genetics 
professional regarding the interpretation and 
use of test results. 54.9 41.2 43.4 38.5 44.1 54.2 6.6 14.7 2.4 3.0 1.0 1.0 
If it is necessary to see a primary care 
physician regarding the interpretation and 
use of test results. 31.2 26.9 26.3 57.6 50.7 67.1 11.2 22.4 6.6 2.0 1.3 3.3 
How the specimen will be collected (e.g., 
location, technology, persons involved). 30.5 40.8 40.5 65.6 54.9 57.1 3.8 4.2 2.4 0.0 0.0 0.7 
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Distribution of Ratings by Opinion a 
  
Certain (%) b 
within opinion total 100%  Uncertain (%) 
c
 
 
Very Important Important Unimportant Don't Know 
Attributes with Significant Differences  
by Opinions about DTC Marketing (Mkt) 
No 
DTC 
Mkt 
DTC 
Mkt  OK 
Don’t 
Know 
No 
DTC 
Mkt 
DTC 
Mkt  OK 
Don’t 
Know 
No 
DTC 
Mkt 
DTC 
Mkt  OK 
Don’t 
Know 
No 
DTC 
Mkt 
DTC 
Mkt  
OK 
Don’t 
Know 
Scientific Validity—Analytic Validity 
            The name and function of the specific gene 
variants targeted by the test. 19.6 8.8 21.7 56.3 70.0 63.9 24.1 21.3 14.5 0.3 1.3 2.0 
Personalized Recommendations 
            If the FDA or FTC has reviewed the utility 
of supplements recommended to the 
consumer. 53.6 42.2 51.2 41.8 44.6 44.2 4.5 13.3 4.7 1.0 0.3 1.0 
Findings and Quality of Nutrigenomic 
Research 
            If any studies in the peer reviewed literature 
find supplements recommended to the 
consumer to be clinically useful. 60.2 49.4 51.1 35.2 47.0 45.5 4.6 3.6 3.4 1.7 0.3 0.3 
Vendor Characteristics 
            If the vendor or laboratory analyzing the test 
is publicly traded. 15.3 8.2 14.3 51.0 32.9 52.9 33.7 58.9 32.9 5.0 3.7 6.3 
 
a
 Excludes respondents with unreported opinions (n=12).  
b
 Percentage of sample with definitive response on item. 
c
 Percentage of total sample. 
 
 
    
 
 
 
 
 
Appendix 7: Results from Kruskal-Wallis Tests for Differences in Survey Responses 
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Appendix 7 Table 1. Ranking of topics covered by attributes by demographic characteristics, August 2007 (N=300) 
 
 
 
Topics Covered by Attributes       
Mean (SD)  
Demographic 
Characteristics 
Clinical 
Validity 
Clinical  
Utility 
Findings/ 
Quality of 
Research 
Analytic  
Validity 
General 
Info  
about Test 
Conditions 
Cost/ 
Purchase 
Info 
Supplement, 
Diet, 
Lifestyle 
Advice 
Social 
Implications 
Testing 
Procedures 
Vendor/Lab 
Characteristics 
Overall a  2.4 (0.11) 3.5 (0.13) 4.1 (0.12) 4.2 (0.14) 5.1 (0.14) 5.9 (0.16) 6.4 (0.13) 7.6 (0.12) 7.8 (0.14) 8.0 (0.11) 
Profession 
Researchers 2.0 (1.42) 3.1 (1.92) 4.2 (2.12) 4.2 (2.29) 5.4 (2.32) 6.3 (2.67) 6.4 (2.09) 7.5 (1.90) 8.4 (1.99) 7.6 (1.83) 
Genetic Counselors 2.3 (1.39) 2.0 (1.33) 3.6 (1.20) 4.7 (2.14) 5.1 (2.15) 6.0 (2.36) 6.9 (1.65) 7.9 (1.65) 8.8 (1.81) 7.9 (1.78) 
Nutritionists 3.0 (2.46) 4.6 (2.4) 4.3 (2.30) 4.1 (2.46) 4.8 (2.40) 5.5 (2.85) 5.9 (2.31) 7.4 (2.14) 6.8 (2.67) 8.5 (1.78) 
Health Practitioners 2.5 (2.19) 3.0 (1.82) 3.5 (1.69) 4.5 (2.30) 4.7 (2.25) 6.0 (2.53) 7.2 (2.08) 7.6 (2.03) 8.3 (1.76) 7.8 (1.77) 
 p-value b 0.1481 0.0000 0.3429 0.3341 0.3159 0.4064 0.0178 0.7569 0.0000 0.0027 
NGx Work Experience 
None 2.7 (2.33) 3.6 (2.27) 4.1 (2.13) 4.3 (2.27) 4.9 (2.20) 5.5 (2.77) 6.6 (2.05) 7.5 (1.97) 7.8 (2.41) 8.1 (1.79) 
Some-A lot 2.7 (2.24) 3.3 (2.24) 3.8 (1.74) 4.3 (2.41) 5.6 (2.58) 6.3 (2.63) 6.1 (2.41) 7.7 (1.89) 7.9 (2.09) 7.4 (2.15) 
 p-value 0.5447 0.2201 0.5458 0.9748 0.0229 0.0753 0.2279 0.5392 0.7273 0.0341 
GAO Report 
Not Aware 2.6 (2.27) 3.6 (2.27) 4.1 (2.03) 4.3 (2.34) 4.9 (2.23) 5.7 (2.79) 6.6 (2.03) 7.5 (2.00) 7.8 (2.42) 8.0 (1.83) 
Aware of Report/Findings 2.8 (2.37) 3.2 (2.29) 3.9 (2.04) 4.3 (2.22) 5.5 (2.44) 5.8 (2.68) 6.3 (2.41) 7.6 (1.88) 8.0 (2.11) 7.6 (2.08) 
 p-value 0.1634 0.1012 0.5617 0.8045 0.0363 0.6840 0.4830 0.9798 0.9286 0.1978 
DTC Sale  
No DTC Sale 2.2 (1.79) 3.2 (1.99) 4.1 (2.11) 4.0 (2.29) 5.3 (2.31) 6.0 (2.66) 6.8 (2.09) 7.3 (1.89) 8.0 (2.08) 7.9 (1.86) 
DTC Sale OK 3.2 (2.80) 3.7 (2.50) 4.2 (1.83) 4.6 (2.43) 5.3 (2.47) 5.4 (2.98) 5.7 (2.25) 7.7 (2.07) 7.5 (2.61) 7.7 (1.93) 
Don't Know 2.8 (2.32) 3.7 (2.50) 4.0 (2.10) 4.3 (2.21) 4.4 (2.03) 5.6 (2.68) 6.5 (2.03) 7.7 (1.97) 7.9 (2.47) 8.0 (1.94) 
 p-value 0.0599 0.5784 0.8605 0.1836 0.0070 0.3682 0.0016 0.1423 0.5190 0.7018 
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Topics Covered by Attributes       
Mean (SD)  
Demographic 
Characteristics 
Clinical 
Validity 
Clinical  
Utility 
Findings/ 
Quality of 
Research 
Analytic  
Validity 
General 
Info  
about Test 
Conditions 
Cost/ 
Purchase 
Info 
Supplement, 
Diet, 
Lifestyle 
Advice 
Social 
Implications 
Testing 
Procedures 
Vendor/Lab 
Characteristics 
DTC Marketing 
No DTC Marketing 2.3 (1.89) 3.5 (2.38) 4.1 (2.17) 3.9 (2.19) 5.5 (2.35) 6.0 (2.59) 6.8 (2.16) 7.4 (1.97) 7.9 (2.07) 7.7 (1.91) 
DTC Marketing OK 3.0 (2.62) 3.7 (2.29) 4.3 (1.80) 4.9 (2.59) 5.0 (2.39) 5.3 (3.01) 5.7 (2.2) 7.6 (2.11) 7.5 (2.71) 8.0 (1.84) 
Don't Know 2.6 (2.19) 3.4 (2.18) 3.9 (2.08) 4.1 (2.08) 4.5 (2.05) 5.9 (2.62) 6.7 (1.95) 7.6 (1.84) 8.2 (2.25) 8.0 (1.95) 
 p-value 0.2257 0.5378 0.3512 0.0210 0.0117 0.2187 0.0024 0.6308 0.2108 0.4377 
 
a
 Includes 289 respondents completing rank question   
b
 p-values from Kruskal-Wallis Equality-of-Populations Rank Test excluding observations with missing values in characteristic. 
    
 
 
 
 
 
Appendix 8: Results from Content Analysis of Responses to Open Ended Questions in Survey 
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Appendix 8 Table 1.  Attributes of nutrigenomic services important to share with consumers 
regarding nutrigenomic services reported by respondents in open-ended comment box, August 
2007 
 
Topics 
Attributes  
Mentions 
N a 
Findings and Quality of Nutrigenomic Research 22 
Research design (i.e., duration of study, measurement of diet, population versus individual units 
of analysis, use of clinical trials) 5 
Limitations in science and research findings  5 
Agreement among researchers and other professionals on use of tests 4 
Evidence to support personalized recommendations 3 
Conflicts of interest in research 1 
Opinion: Science and research findings evolve overtime 4 
Clinical Validity and Utility of Nutrigenomic Tests 18 
Variables used to determine validity/utility (i.e., race, range of lifestyle factors, genetic vs. 
lifestyle factors) 4 
Added benefit of test information 2 
Purpose of test (i.e., diagnostic, screening) 2 
Additional measures of test validity (i.e., positive predictive value, sensitivity) 1 
Conditions the test does not focus on that are associated with identified genes 1 
Association between utility of test and utility of supplements 1 
Opinion: Lack of validity and utility (i.e., uncertainty in test results and information, 
overestimating test benefits) 6 
Opinion: Early screening is effective but supplements are not 1 
Vendor Characteristics 16 
Government investigations, legal actions, or filed complaints against company or staff  5 
Does vendor sell both test and supplements 3 
Credentials of staff analyzing test, meaning of credentials 2 
Who holds interest in company (i.e., shareholders, investors) 1 
Opinion: Companies offering nutrigenomic services are profit driven 5 
Test Characteristics (New Topic Area) 16 
Purpose of test (i.e., for health, not for health, use of information) 3 
General quality of tests (i.e., “success and failure of test", customer satisfaction) 2 
How long the test has been in use 1 
Opinion: Test is a scam, worthless, overhyped, not mainstream 9 
Opinion: Nutrigenomic tests are unique relative to other genetic tests 1 
Presentation of Test Results and Other Information (New Topic Area) 12 
Format of test results (i.e., visual information, risk calculations) 1 
Resources for unbiased information about nutrigenomics 1 
Opinion: Nutrigenomics problematic term (i.e., oxymoron, misleading, not user friendly) 3 
Opinion: Public knowledge about genetics limited 2 
Opinion: Consumers can be overloaded with information 2 
Opinion: Present test results in lay-friendly language 1 
Opinion: All ten topics important 1 
Opinion: Survey information important to know but knowledge does not exist 1 
Test Procedures 11 
Who interprets test (i.e., type of provider, qualifications) 4 
Next steps after receiving test results 1 
 254 
Topics 
Attributes  
Mentions 
N a 
Opinion: Physicians not ideal to interpret test results, Interpretation of test results should be done 
by nutritionist  4 
Opinion: Know pros and cons prior to testing 1 
Opinion: DTC sale may lead to testing without medical exam, counseling 1 
Social Implications 9 
Family issues (i.e., family tree, involvement of family members in testing, disclosure of results,  4 
Privacy (i.e., protection and disclosure of data and specimens) 3 
Potential for discrimination 2 
Personalized Recommendations 7 
Supplement characteristics (i.e., health risks, ingredients, targeted genetic factor) 3 
Difference between "nutrigenomic" and generic supplements 2 
Supplement utility (i.e., ability to cure/ameliorate disease, opinion: ineffective for non-metabolic 
conditions) 2 
Regulation of Genetic Services (New Topic Area) 5 
Opinion: Lack of regulation for genetic tests (quality of tests, DTC marketing) 3 
Opinion: Lack of regulation supplements vs. prescription drugs 2 
Alternatives to Nutrigenomic Services (New Topic Area) 4 
Opinion: Nutrition consult or general knowledge more useful than nutrigenomic testing 3 
Opinion: Other genetic tests better for determining disease risk than nutrigenomic testing 1 
Total Issues 120 
 
a
 Total number of respondents mentioning topic or attribute in open ended comment. 
 
 
